var title_f5_26_5536="Carpometacarpal arthrocentesis";
var content_f5_26_5536=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F52531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F52531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 507px\">",
"   <div class=\"ttl\">",
"    First carpometacarpal arthrocentesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 487px; height: 215px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The thumb is flexed across the palm toward the tip of the fifth finger. The needle is inserted at the base of the metacarpal bone away from the border of the snuff box. It is then directed toward the proximal end of the fourth metacarpal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from Owen, DS. Aspiration and injection of joints in soft tissue. In: Textbook of Rheumatology, 4th edition, Kelley, WN, Harris, ED Jr, Ruddy, S, et al (Eds), WB Saunders, Philadelphia 1993. p.545.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_26_5536=[""].join("\n");
var outline_f5_26_5536=null;
var title_f5_26_5537="Patient information: Complete blood count (CBC) (The Basics)";
var content_f5_26_5537=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Complete blood count (CBC) (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H87802901\">",
"      <span class=\"h1\">",
"       What is a complete blood count?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A complete blood count (also called a &ldquo;CBC&rdquo;) is a test that gives information about the 3 main types of cells in the blood. The cells include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Red blood cells &ndash; These cells carry oxygen to your body.",
"       </li>",
"       <li>",
"        White blood cells &ndash; These cells fight infections. There are 5 main types of white blood cells. Each type works in a different way.",
"       </li>",
"       <li>",
"        Platelets &ndash; Platelets are actually pieces of cells, not whole cells. They help clots form so that you stop bleeding after you are injured.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      A CBC measures the number of each of the 3 types of cells in your blood and shows if your levels are low, normal, or high.",
"     </p>",
"     <p>",
"      The test usually also measures:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        How much space the red blood cells take up in your blood, called the &ldquo;hematocrit&rdquo;",
"       </li>",
"       <li>",
"        How much &ldquo;hemoglobin&rdquo; is in your blood &ndash; Hemoglobin is the protein that carries oxygen in your blood.",
"       </li>",
"       <li>",
"        Information about the size and shape of your red blood cells",
"       </li>",
"       <li>",
"        If your platelets are smaller or larger than normal",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some CBC blood tests also include a &ldquo;white blood cell differential.&rdquo; This tells you how many of each of the 5 different types of white blood cells you have. It also shows if you have any abnormal white blood cells.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H87802916\">",
"      <span class=\"h1\">",
"       Why might a doctor or nurse order a CBC?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A CBC is a routine test. Your doctor or nurse will likely order this test when you have a regular check-up.",
"     </p>",
"     <p>",
"      He or she might also order the test if you have symptoms such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You are very tired and weak",
"       </li>",
"       <li>",
"        You bleed more than normal from the skin, nose, or gums",
"       </li>",
"       <li>",
"        You bruise more than usual",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You might also get a CBC if the doctor thinks you have an infection.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H87802933\">",
"      <span class=\"h1\">",
"       What can a CBC show?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The results of the test can show if you have different health conditions. Examples include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Anemia &ndash; This is the medical term for too few red blood cells.",
"       </li>",
"       <li>",
"        Polycythemia &ndash; This is the medical term for too many red blood cells.",
"       </li>",
"       <li>",
"        An infection, which causes your white blood cell level to rise",
"       </li>",
"       <li>",
"        Bleeding disorders &ndash; When you get hurt, your blood forms a clump of cells (called a &ldquo;clot&rdquo;) to stop the bleeding. If your blood makes too many or too few clots, you have a bleeding disorder.",
"       </li>",
"       <li>",
"        Problems with the body&rsquo;s infection-fighting system, called the &ldquo;immune system&rdquo;",
"       </li>",
"       <li>",
"        Conditions that affect your &ldquo;bone marrow&rdquo; &ndash; The bone marrow is the space in middle of your bones that makes all three types of blood cells.",
"       </li>",
"      </ul>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?5/26/5537?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86219 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-EE7AE732F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_26_5537=[""].join("\n");
var outline_f5_26_5537=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87802901\">",
"      What is a complete blood count?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87802916\">",
"      Why might a doctor or nurse order a CBC?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87802933\">",
"      What can a CBC show?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_26_5538="LS 55 yrs";
var content_f5_26_5538=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54149&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54149&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Severe lichen sclerosus (LS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 263px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Long-standing vulvar LS in a 55-year-old lady with severe pruritus for eight years. She woke up most nights scratching. Clitoris is almost buried. The inner labia minora and vulvar trigone are thick, firm and white with two biopsy sites visible on the left side.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: F William Danby, MD, FRCPC, FAAD&nbsp;and Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_26_5538=[""].join("\n");
var outline_f5_26_5538=null;
var title_f5_26_5539="M mode left ventricle";
var content_f5_26_5539=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left ventricle on M-mode echocardiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 412px; height: 211px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The M-mode echocardiogram shows the posterior wall and interventricular septum of the left ventricle (LV) in systole and diastole. The LV pressure tracing (red arrow) is superimposed. LV size is measured in end diastole (LVd) and end systole (LVs).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_26_5539=[""].join("\n");
var outline_f5_26_5539=null;
var title_f5_26_5540="Intradermal nevus";
var content_f5_26_5540=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intradermal nevus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Soft intradermal nevus that is pink in color. This lesion is symmetric with a regular outline and uniform pigmentation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_26_5540=[""].join("\n");
var outline_f5_26_5540=null;
var title_f5_26_5541="Sq cell ca lung CXR";
var content_f5_26_5541=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64310%7EPULM%2F52600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64310%7EPULM%2F52600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Squamous cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 379px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF7AYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDw8eENQAyIFZfUODSp4ZvFPMIH/AhXeW1lIFwm4D2q7BZznBIz9aAOBh8M3R6qoH1q9B4WnIB+SvQbfTt/DLg1dj0luy5oA4CHwtOMZC1bTw1MoyVWu7XTZQBxg1ILN1xvHH0oA4BtDkH3oCR7Con0LdnYGQ+hFeki356cVMtsjDBQflQB5NLpcsXWM49ajW0x25r12TR4JOCu0ms+58MK2Sq59xQB5xHac9Kv2enZxJIDs7D1rqR4ZkVi55Qfwngmpo9Ll3APGR6ccCgDIt7VnYfLgdhW1DHFarlyC3pUjxrbrheuOW/wrLubpV6cnsTQBdkvJG4RSo9elQPOwyXlxjrWYbt2Y1Q1C4fIUE0Aas91v53kjsKIL24jcGGQr6jNYSzsBy2SKSO7YyHPT19KAO/07WXIxOMn1robK6huMYIz6GvOrC4DqA3J966DTpGV1x+FAHfWmAykcjuK0AQFBAArA0m+BIV+tbp2uoKn8KAOf1Y4nb61TW5SMhjww6Crep28jTMVIIPas57GThjtAJx1zQBqaPKZLg85roQcgZGaw9Gt1iYDOT1JrbLBVwuaAK12QoYA4Oe1ZlyypGXdsAdTUmoXYidiec1yWtaiW4LE+goAfquuwW+4AFvSsKbXnOChxn0rKv3G4s53N6HtWPNc4bg4oA6Y6xcg5EpANWLfWJScSNn3Fcc92W4yKYt68ZyCcUAdz/aCuxEi4z3FLIiXEfHPcH0rmrXURPF+8AYirMNy0bAxOcehPFAFiaBlLKRn1FZVzYAZeMfL3X0roI7mO5AEg2SCmy2xBDJ1/Q0Acm9sPSofsoLANwM8mulubMOC8QwR95f8KpNb+1AGXd6YEXfGCVHXPb3qn9n9q6exwpEcnToCf5H2qS80VtnnWsbNHn5l7of8KAOVEBpfs+eMV0EWlTSHAjxV6Dw/I3LKxPsKAOPazB7VVl0/OeP0r0QeHpB0h/Okbw/P08taAPL5tLJz8tZ1xpZ5+WvWJvDs5H+rWqFx4cuOf3BP0oA8juNOZc8VnzWZXtXq934enA5gf8qxrvw7Mc4hYfUUAebPGVPIqOu0uvD8g+8mPwqgfDsjElWAHvQB9BpKh4igGPU1cjOR80K/hWomnhRgL+lPFmB2oAzkVc/cK/TmrcYwvyscVbS3x2qX7NlcgUAVlm2D5mB/CkN3A330P4VI8GOoqM2248DigB0RtJDgOVPuKvw2CFQ4Ib0qtBZLtLsMIv60SStG2EJB/kPSgCaSA7uB0qSK3bPJ+XvSW9yXwsg/EVpIquAIzkUAVTCkpAZAewxVLUbdIYysJDSHse1at1ItpEecuelctqF5tctIcsf4R/WgDE1BHLHzFKgdWPSsK6ES5K5c+vaukmvGmBWQKyehrKubSCVj5ZMbenagDnJJpMHGFHsKxNRml+0EliRiuruLOWMHKbl/vKOKwdRsnds8DigDEe7kQcMaW31J1YBgG55qZ9NJyWcY9qrfYwucA59aAOl0q6Wf7p+b0rp9PuHjcK3IFef6ZujbIJzmuy0m7WTCSnD+tAHc6ZIJCpHWussjuRQ3pXF6ZgDKnn0rqLaUiPBPIFAFO+yJmCnjJpsn+p2Y5AzTZ5VZ+vPenllyxz2oAt6TgyAdsZq/cviMk1QsCUjJFOuJCYWGetAHP6xPtdj2ri9Tu23NXW60o8hnc9ulcLqUwG4nH0FAGRdTtI53HFZV1cRofvZz6VJfmSaQnov1xWe0CMFU8c0ANa+w3A/WpBfZHKgiqM1riQkPxRHDJ5Z43HqMUAbem3qFyroce1a8Dq/+rbPsa5qwUruZgQavxElhsBz7UAdHDOQdr9q29OuFcbWOQemeorn9OS4cL5ibk9W611Om6PvZZIyW9vSgCc2bs26MZJ7ikOhyTfOikHuo/nXa6PawmJY5sbh0rVECRY2oARQBwNt4YYgFlAHqa6LT9LjhiGTl0GD7itmSHIyo/Co4omEg/WgCk9laE/LGFb1AqGS2aLqoK9mA4rVa2JzjinxNFGNs8i4NAGIYmPRf0pht5SM7f0rbuEihTzEDyR+qjpVQ6io4SAgUAZclo+OV/Sqktu68gHHpits3rt91D+VNNy38Uan8KAOalyv3lP41l3YJJwi8+1dpI0Eg/eQjPtWfdWFlICVcofpQB55fWvmAgr+FZY0rOcdM16Bc6TATlbpW9jxUUelRBeVzz60AelzacuMxk/Q1Se2IJ46V1ZtXU/OMVFLZxSnLff8AUd6AOZitWkcKo+vtWpDbhRtwCOnStCOycnCIAvtVtbIouZMKPfrQBzl3puRvQZ/2RVdbIDG9lX1FdNMFUFVGaxruFhKc9DQBn3QVYvl+4vT3NYzL8xJyT3rauhubA+6vArPkjJbAGSaAG2sZY8dTV7zBbISuN3eiNFhQjI4HzH0rm9b1MMSkR+X19aADV9cAYr1Y9W9K5+W5WQko4Y96o38jSv8AKDiqW9IwTnLjvQBsxo7ZJ+VfU0SGNPVvesqPUZuA/wAy1L9rh4y/J6igC8k5D4U5U1n6nbQXKsQDE+e3Sl+1rkbVJ5ps9ySCNnXvQBz11YzQtjG5PVeaqiLK8jvWs1yY5DkYqxC1rcqBKoU56jigDMt7cHllq/bQMsikdK0fsECuDHJwB3HWp4rTDffHWgDX0iRyEPp+tdfaTCWM/LziubsLYoq45HqK37JMKSO60AUmTMpKtg+hqaO2n6HJX1qOYbZsY5rWh5iQc9KAEijMcJ3HB6VDcTCKMkgk471blUYRSPrVC/UskhIxgUActrd3JJlOMH2rj7+IhvmBxXWXkZkckdOua5zUUZnIVSQO+aAObuIyfbPQVRaIM+Ohrelt5dw3RnAHrVV7WUvlYz+JoAxGhPmHI4q7a264PFXo7RQ+JXUd8DmtfT0s0UAxM59TQBBYWKMi/uQ5PqK2rXREUhjsi9qsQzoRtjKr7AYqdVYkbifxoAkhhgt8fJvPqelaEF04YeX8mPSqkbAAA8ilDKMkMF+tAHSWF1uYc7ZP5101pMLmMBuH9a82GpxxOAMs1bOl6y8zbHYIR0I/rQB2jlYs7ziqc92EP7tfxNRwyi5j+b/WDrUMy9QRzQATXMjnJbANVihc9ad/AQe3NOjGU6cmgCeyuGtzgkuvcVotZx3Kebb5OeSoFZscZLDFdBZH7KB5Qxnr70AZMmnkLndx6Yqm1upONwrtJLdLmHzYR8/8S1gXln8xaMYPdaAMWS1PbH51WmtwOrDFaUkbKcEEGq7wlqAMea3TspP1pkdsSvp7CtkWu7salS0+XgZoA9Gwx68j3pVtBIckbR61eVFVuBn61HcMeg6UAQSusSbYQN3rVIoXH7xgCf7xpbh/L4GC38qqMS5+Ynd2NABcDacVQufuZ9OlWHLDg9qqzcjBoAzHjJBphh8sg4/eN0HpWksYALEcD9TWTrdz9ltyF/1sn6CgDF1/UAimCI/KPvH1NcnPljuk4HYVpXEvUvyw/Ssi6ZnJwcDGSfSgCpeSfJtTAHoKw7mZICTIct2QVZv70IjLD34Lnr+FcvdTEk5PzZ6+tAF651GRyQp2r6Cq5uDtByc1mTS5OBk1LAjlPnO0e9AGtBqTqVDEMtakN7HOQuSprn4I4gQT831rRgmAcDAxQBpXVnJIm8Lx61DDE4AG0nFPt7mZWIDcHsatJPGSQ+Ub1HTNAD7NJM8EgDmtezUsfnHfrUFkpPzcEEcEdK27CFWIBwRmgDSs8RW+CB83ArVsyFjfBOMVkxjNyMj5R2rZiTMLeXkfWgCsyfvAxHOa17RNy4PUYNZpRwc4yK1bAgkDHJGKAEu0GBjrWdfc27r/AHhite6iO2sPWCY4fmO0GgDlpXXynj7jge9czfFycoNpzzXRSoI7gPnKE81T1G1Cu+BjuKAOQnaUSEktUfzFS24nB9a3Lq3QoD/KoFhjjjyqDB9TQBkqCzgnJrVswc4x1p+y1IUMOvUKaS9k2Lstn8vjvQBbJSFA7yKCfeom1lIeI2L+1c5fNKuC+WPqDmqJuW34zxQB2Q1vzQVOIz7c0CdmG7cWB9645bpjke1XbK9eNcKQVPJBoA6yKYOACM/zq5auyZIORnrWFaTrOv7o4fupratpAFCHr3oA67RNQZtqs3zjofX2rpXAmjEi/eHUV51AzQsCh46/Su50S7Fzbgg/OPvCgBAnzc96sQx/d461M8Q3Bl+6f0qRExtPoaAJIYxuXjvWvGuVqlEnINaEYyFoAfCzRsCpxU1xBHd8rhJh+RoQwrwxOT+QpQpV/YUAZTW7byrqDjjkUw2KMDhcGt7yldgzjII604WqjlOaAOdNlt6ggUqWhx9010wgVBlhn61XZ0ViB+lAG2R+7FV7s7YMj73arTD5Bj0qtdfcx7UAZLrnk1Ft5FWWWmMOKAK0y/NntVNlLN7k1fmHHPpVdV4ZvwoAgcDOP4Vri/ENxmd2JGeg9hXX6nILeyZj95uBXnuqyrlpJDiNf1PpQBjXMqrukkOE/nXPalfNLwvyoOgFS6rdmaQk8AfdUdAKyJWMmQoyaAKNzISxz1qlNas22R/lU/nWnJHHHyeZPWoZWBicMefWgDJJVPlVcH171HJIT9B0pLxliJHf+dUDcsc4wCKANu0UyIO2OuavIY0HLZNc3YSus5LsSDxgmt1FLxkqABn71AGlBMjNtVue59KuxeU/CFT6+tYqShVKqQPWnQkhxgnrQB1tg7W7fKPlPUHpW/aTKSChGPSuZslDBSCckcjNblh5SkfKQ3rQB0mnxbmBbknnFbSKVUYHesnSjuA9q6GIhUwRk0ANWPLYwM/StGwhO4HaufWoIo8tn1rVtIwAMdcUAVLqPJyw/KuY10ZU4HA9a6+6TaAcVzGtqm1gOp9aAOQuYArEL930rPu5NyLwfStW6kwvbNYdzN1QkfhQBm6lmM7UAJ7n0rHuBIwzuJrRknO5/kBz3NZ97M+0dFXPYUAEUZ8rJJGP51FO5zjPJqBrt1XluKjlvTjJxt9cUAR3spIGMelZ0zIxww59afd3sT5AOxvQ9qpghyMnNAEwjdY9y/MOlLDN8wBB47U61fD4z8uOBVgWiSOXJ2P7d6AL2nyEOHBII6GuntJxMQr4Wbt6GuRjJiO1hj2rTspCTyTQB2VqxDYPWt3Q7j7Ldowz5Z4YVzOmXKzKEkOJAOGPetywyrANQB6GiKenKNyDUixYBBHINVtIfzrBOeU4rUCZXPqOaAGRrxVhDgcdajjHFSovFADuD1qxbHeCjde3vUapUsK7ZVPvQBoIh8gY7GljG0+1WETER+tQMOaAI79jgBOM1RjX5auSjPWolTigDdK8+1U7zjIq9Hyik+lZt0++U46CgCsVpjrxUrGmMf1oArXApnl/IvoOTUkmS340XTeXEfXFAHN+I33kLnCAZJ9K8z8QXBkkO3hF4A/rXceLLnbGIlPJ5b/CvPL4/MS4/CgDAmjLks/C1Vd9o2qoAq9eMc4Wsm8l8lQSev60AMuCuGzw3v0rKmmIBUH8abcXZkyDjA6VTaVt49D0oAiu/nUnuKzhuL4A5Naxt2dyG+VaidVj/wBWuMdTQAlnbMTulwuO1b8ckSpjaW47msKGUl+31q4NzH2xQBsQmKSHckY4OMVZRIuu3pWPFMYnAUnFakBMnI6HtQB0emgNg4xXQW1uHcfLmsTRlOATjI7V1FkmHDN92gDX0eAKeM4z3raB+bHpVLTf5CrqrnkevNAF21+ZwuDmtq3TC5/CsW03CZTW/AD5IyKAK12uVxXIa9hAc11tyTyMVy/iC1aWJmz+FAHneoSztv2g9e3pWHM0m4gqdwPQ11F6VjDdVC9frXOSyYcsPmPvQBi3skkLMG4B5FULiQyRAE/N3NaNxIrM3mAdehquzw8HyhjvQBmuha3eQnletY013IeFBAxW9eS2z7kiRkB7g1gTW7+YQrBhQBTlcyYLfeFKkjoMDI9aVYyu4yggKOPrUe8P7t6UAa2nsJG56+tapkDlVBPHSuehlKYA/GtG1uQHGT+NAG0gWRAjgnHQ1NHG0Tgj7pqtbyb+e1aMcgUBXAI9KALtoWyBnvXX6U/2iMKf9avP+8K4yIMhDA5T+VdBpc5RlZTyOaAPS/DMnWNhwRXTRp8rKfSuN0CfzCsqfiB2NdrA/mRq49MGgCFBzjFTxrnqKi5EhFWIjyaAJFWpI1w4+tItSx/eHtQBqMu2ID1qBh7Vam/1aHtiqpOaAIXTimhD6CpiMCoieaANPfi3GO1ZhPWrcJzbNn1qo3FADG71Ge9PbrTG6GgBigZ3EdKp6rN5UBdu3T61efhVXueawvEEgxtz8qj8zQBx2sZkVnbls5APeuL1AlycDiuv1Fy5IBrkNbkEGQn3j19qAMHUJkiUr1aucvpS5yW3D0q/fOeSx5NZTQNKWJ4j7tQBTkHmAbF/+tUkSLHjJBJ7+lTybEj2xjj19apS5Uhs0AWZXDklgQcYqq8fJ7j1pHmBGCQSKqzzPIoVumelAEheGI5U7mHYdKspeDyx8ueKywoyMHir9vCdrE9COKALUN2j25bbhlOTWjp+pxI4VkbBrBgykrKeQeKsxoYuMZPXNAHouh3UUlwyowbIB69K66052jHNeVeHWIuTgkV6Po8jhl3kmgDsbAYTpy3Fa0KEBvTFZthgqtagYnAHSgCxaMQ4ytbgb5RxWNZjLj0FbLDgfSgCpcA8n1rIvo9wOR1FbzgbeayNQwFNAHn/AIjslkicr8retcE8gWRo2GCDivTddIKsFry7xKTbzeYpAJPSgCrcxDY5bk5/Ksi8n+QIoJWklu55YpA0hwPSsqSRyv3zuFAE0oYgMoJHtUMgMY9X71FHNKvG7INPS43ygSruGeooAguc7QmM5PNRfZBgvHw3pV292NKDGc8U04ChT1PWgDOXcD8wIPvVmJ/lxjirDskihWUe3FVnt3ibdnKetAGjZ3LRMG6j0rftXWbkfe6/WuVhfcRWxYMyyggkDHWgDpLU4GD0JrXtF2KCo4Pb0rJspFkQD+L0rYs2IYelAHX+GLjyZcn7hGCK9C0thgoTkHkV5jp5KIGXgHkj0rvfDtx5sSgn5k/lQBtTLiTNPi606Qbl3elNj4OKALKLmpoly2KiQ4xVm2GZh6UAX9wK4xnFQnaTTHY7qFYE9aAHOvy1Vd1RiDjNXJm8uMnt2rKYEsSeSaANOE/uGFVj0qeI/un+lVyeKAGNTVG5sUrUR9CaAGnmQk9q4/W598rgHvXXXDeXbyt3Arg9YlEMbOfvt90f1oAwNVuBCrKv38flXG6jIJCd2S9bV9MZJGHVjWJcoIySTlvWgDFuLNWJZzz/AHazLhWb5QQAK25QWJJNYmoSqwITqP4hQBQuiIxwKyJpyxx+lWpmfd833apSBWbHQ9vegCHPJx171Mr+YNj8HsaattIx+7j3qxDAof5juoAggRw4AUnmtm3t5WQBFJ9c0yD5JNpGBjrWha7peCTtoAqLZSB9zMg9BmhoWaQZYe+KsylAWTPzCkgXMg6HNAGp4fsz5pbqK9H0e3+RGGc+9cv4btNsSsR9413+iwdM9O1AGvZxMsAyOc1qQLwM0xIiEXA6VcWL5QR0oAlth8wxWsQOPpVGzjw1aJXigCGReDisjUFyhA61tMvFZl5FknmgDjtUtwY2JYA968s8aQrjr3r2HWFVYmPavIPFkonuzHHjap5NAHHrBKcmPByOaqvDKufk784rVHyMVHHamIxDk9hQBjSJhRUEY/eNgH1rZuArEDCnJ61SeAB9kZy2eaAKk24KJOhHSoTdlhllG7PWrk+Il/fDaO4NUbh4Cv7sd6AJ0cMcsc1bgYHC7SynrxWVFMsbcLk+9attd/d+VVbqAKAJxbRqd6DA/u1JC534IIUGkQeYxkbqatbVlADDB9R2oAvWMhVgQTmut0pluAOAGHJHrXG20MiyAdvUdK6GxlCMoBxjuKAOwtGKuMiuq0GXybhW/gPFcjpsgnj9HXqK6LSZMOFNAHoMfp2IpjLtPPUGi1O63ifvtqWUZIPYigB6GrdrnJPtVKHpir0Pyx/WgBz/AHqcgqLOTT84FAEM1wBIEb7gpoj3fNGQVPeq0xySahSVkGFYgZoA2YzhG+lV2GDUqnETVGeVz6cUARPTofuE1HIalX5Ysd6AKt9zbsD0xk15trcpnmfH/wCoV6BrUhSERDq45rzrVx5Rdf1oA5u8YRZCDr3NYd1IFBeT7nrWve7QDJKSEHpXLapKZTjdtQcAdqAKd/d+YMRnCe1ZM7ZBx1qecMoyvI9qhihMnzSfKPSgCqEeThVz6042SbdwAMg7VecKq/J071B1IIJz60AUgTk7u3enCPcufQ9qmlkhBzgyP7dBVRpXZ/vhV9BQBaRVKHDgkVPYuEYruOSO1RQ2DbWljO5SMmp9OUK5Min8KAFvhGtxHjILDn3qWB4Y2GD0PU1O8S3e3efmU4FQ6vCN6FE2gY3e9AHfeHBvtkxj8K7nR1O5elec+GXIgj56ivQtEkZdpYcUAdVCAWUZ4FXU4U8Cs2zkJbBFaSEHAA4oAu2/QfIauH7vSqqcACpy3HWgBrsQORWXfnrzWmTnINZWqZVSR0oA4rxdcm3sZGHB968iml8yRi3VjmvSviBOx05li5YmvIbmOd5MHIOeKACZohNy34VC/wAmWVl5pjWUgfL9RzTL1WKbcc44oAbF+9k9KekXl7mwQc9ah0yynWVnbO3HFW724+zKBKu4D070AZ16RMdrjpyayp7ViuYwTz0rYQRzRSOj891PWomc8CMYx2PWgDHRGGcjketWISY/mBy1XHgWXJY7XHpVcxtH8rLuJoAt2twdw3mtu1iMwyhB96w7WHLDzFwta1rP5TAJwvpQBu2yhU2nGD1NTrGUYEH5fWq8EiSxgxnkdRVyKVVADDd/WgDX0258t1ZDyK7LTHEoSaM8HqPQ1wMCfOGQ/L6eldV4eufJlCv9x+G/xoA9V0dvMsVHcdKuOP3YPpWbop8tAucg/rWtIvyE9jQBDF1q4D8vtVRBgirIPFADh1pJWxG35UL1qK6bgL+JoAqzNxVYNU03IqsENAG5n90aYpGDmlz+6aoS3FAABmQCpAcsRTIeWz7VJGMNu7DmgDA8QyhZm+mK4vU085WZztVO/wDSum1pjNO7Dua4rXLv/lkhwg6+5oA4/WboyyldpCr91fSucuHbcVALE9q6W9i89iVHzDqay5YPJUkc++KAMlLfZ88vzD+76VFPiVvl61akBkkwAcfpWfezCIkQ4Zh37D6UARF/LLbuD6etVLmR5cYAVT1AphkJ3PITuPc1CXGeW4NADW8xDz909RUgiL8pkqf0qxBAJQBn5PU9q3LTTIY7cliSOuT0oAisD5dq0BQncODUun27kkFCCOxqxEN0qeX9zGBjpVyO1lcuyqcjvQA22sSxYsFH0pl/pxaDCMcmtKwiwxWQ4PXBrRjgVnUBcg0AM8NWjCCFXBBHHSvRLC12xKM4qjo+nBY0JUACt+FAAdoyBQBdtYiFyK1bOPOM1UtE3DOMVr2sO0fWgBcYNNdsNVgxgnrxUMi+pFADT0zWbqK5U56YrRQkcHpVa9jLKSKAPNfFkAe3cEd+K88urMbsuCPpXq/iG2zGcnHNcRqVoqk459aAOWNjnnqDTxYgjMkXA9RW7bGPbtk47DioZFkPBOUBoAwJ/LjBCjFYurWxdHZug5FdZe28ZQkrnPeqFxpxuLaRQSqKuTQBwCqw3kttIPFWoJd5Cy5443DrV6exEHDANk9faof3SFtqk0ASiABQQcj1FSxquMOARVRJpEYlRjPr3q/DJFOgJwp9PegCvJAw5iOU9B2pUfGB6dauqVTmPg+9RzrHKC0YCvnoO9ACQXLQsCh5HSt7T5BdjK8SDqvr7iuZViCQUAOehrQsZXSRWQ7TmgDsLLKkA8Y9a3bNWEgdPun9KwtMmF0mT/rx1X19xXSaHkuCwyooA9I0KTfZx85eMAH6V0X3oTiuP0SXyZ0B+4/FdhHwq0AQ4qVTTXGGIpFOKAJxwKpytlianLVVkoAibnrTRSngU3NAGjn5GAqHPahX5pv/AC0x2FAFqHoadMdkbDvii1HJPYVFcnjnp1oA4zXZfs6OAfmf9K4W+Bmc7Onc113iPM1zIOijv6CuQvH8r5VHHpQBm3GIxtHA/nWZcKCd7cR9ya055EEZd8bR/nFc/f3plbDcRj7qDtQBnalL5xMcKlI/ryfrWRIEjBBOT2q/dgs4EXU+lRCzVfmc7moApm1E6hlYAD7wNRpBHF/CC3vV5mCE7fWo9oZiVH1oASLCKWbnHOK1NKu5XbY64hbjJ7VjT3UcOAo3yeg6Cmw3U08iqx7547UAddctDbxoEI3Z5Ap8V+w4ycY6CqFqQyj5QT/earcDCQsGUFhQBaglXzt7KSO9bulSRvOigHIPesm2iRcd89q29ItSbkEDFAHc6agKZzWnCmOnWqWnQYhyeta1nGWYBeaANPTotygEHmtiOMKuBUFjFsUA9au7QF96AIdoyagkiBbvVnHNMYckUAVNigdzUNxwpIq6UBFVL5f3fFAHG+IIw0bY61xl8FC4brXca/F+5bdmvOdXmMbkAnj1oAoXJi835clvShXX5Vcgk1RF0Vbc3LdOlNVmZyTxmgDZ+zRXDARKS/cdqqa+BYWqhfmZuCB6VNBc/YbclQTIay7y5edWkuhuA546igDGkEbjcwBJNZl7ZnBMeAeoWtUtbtGxi654Ge1ZM10sjFVJz3oAzXt5GbByD/KkSPy2G1sDHFTyuG9c+oNZ8pZZQWbI7EUAX7eckYkPHQGrSxsMEdPWsVJCBtXJOetaWnTupIm5iPWgC8qCX5SPm9R1qZIWgxvGT2qxGY0VWhw4PRqt267/ALwBB9KAJdKd1mV1bDDvXoGlus0YkjAB/iUfzrhoofLO5BkfyrodFvPJmXGcdGHrQB6HpjbgqnqOQfSu2t3L20bd8c1wWnsAUdTlTzXb6W/mWOe6mgC1JyAcdRUJ4IqY8x/Q1A9ACM2AagZs0TNxUQNADiaZ3oJ5pufegCVWz0qdOSDVOM4Qepq7bjJAPrQBdiG1APXmqeqMUgwPvNxVw/e/SqGsnaRnsOKAON8QAKnH4/WuMvVUbnf7ortNQ/eM27la4XxDOASq8KOnvQBzGqXRaVj/AAjoPSsvJuMhARnqT2rQlgaXLuMJ1+tU7liRtUBR7cUAIgS2U7QC3r1Jqs75k3vj6CmM23LM2fU+lZ9xdFhthGB69zQBPcCJSSHyTztzUEju8ZxhU74qqqMxwcitIIiWu0kF8dPSgDOFp5g3471oWtksQ3bsn0qCBm3jPAPFaFtbTHLIpYUAMgmkacAkgdhXUaWqMrK6DkZBrGsrNzIPOTpzXY6NZQykk56ZGaAG21rlg2OCeldNo9riRfl4osrQKRtUNmur0WxZ2BKAD1oAs2ls3lqqg81t2Nr5QyfvVNBbrGoAHPrVqNfagCaFcCpsU2IDFSgUAQkc0wjmpyBnrTCBnrQBDioZ49w5q3getMkAIPNAHLazZeYrkeleZeJLEqSVA6+lev36khq4HxDHmOQlQTQB5bcxOjkAflT7aRN6iUEL6+9bF1b7mJVQSKz9QA8tIwvPc0AEj7gSqnnv1rKv/N24UEitaBwIwgPNF5IEg37cnpQByEkTI6swOPUetZV0DbysHB55zWvdTSl2B5Ge1Zl2gJO5t+entQBWX5lBBGPWpswJ6OcenFVTviBCn5T1HrTkjLqdg6daAHsg/wCWYGD+lRMGyCSSPaphGVxjPvUwhGA3f09aAJtNmMbYHzA9VNdDbkFA8RyD+Y+tc2jrnGMe3etKyuHhIMYG08MD3oA6W1fHBPXqKuxKEYOvCn9KyopFKqyHIP5j2rVsX5+Y7hQB2/he58xBA591r0PQCfJkQ15RpRNvOjr93OQa9S0OQGMSD7rgUAa+MKwqrNwpq62NoaqMzAg0AUnbIPNQh8GllPJFVnbHSgC0WyKbuBqFJMijdQBZQ5YelaFn98Vm27blU1p2f3xQBcUbpKyPED5lKCtqLrnvWVrEKlnmLYwOaAOI1qYQRFFPzEc1xd/AJhvl4UdB3NdRqvzyvJITjqBXN3hD53Z+tAHM30jElew/Ksm4J2lmwE/U/St7UViRNzg57DP3q5W+kkeRi+eOg7CgDPvZC7kfdUHhR2qoztGcqR7VLMhbrUPl5bauS1AD4pdrFnOTjmrFoC6byxGTznvSR2YXDSNlvQVct4VLKqgnnpQBoWVirupxkDua6yzt0CBCBkis/SrZy4BArooo0STk5PoKACCyG0bkBPsK1tJ0/wAuZOMAnGKLSN5FAQBa6fQ9PLMHkHyr+tAFqw0lI5d+Pl6101jCBgKMAVUA54HStWzTag460AWFTinqlKtSAUACpxUm0dKEqTFAEQUYOc0xlHTFT4qMjmgCPA9Ka4HpUuKY44oAyb9BtbrXI6rbrJG47812N2CciuW1EhfMJ6CgDzfVSLeRwNu7FYtywlhGDmXqa6DxBp3mh5UHzda4a5Z4pySWB9KALKsWLgZ8wdqejGaIRsDj0qjb3Ui3Eckg3ITg+orWuZU88eQw2Ec+tAHP6taHbiM8jmsBg0Y+cbsHmupv42Y7l5x3qqtotwSjLgN1IFAHO5RlJ255zio8uGBjHy54FaeoWIs3IX5k/WsyZijfL909qALMbh87sCT07GnRklsuMY9e9UY9zseCMcmrK3LTKFmwMfdNAFhlSQjs3qKZ5jRsQc5ojGDz+lWgsZwGyc9/SgC5pM5jfd1U/eX1rqrNQNrRnKMMiuSgjMY38kZ4966LRroI4jkHyHr7e9AHZaXyoV+h/SvRfDBIsvLJyynI+lee6XD8wOeP5133h58SKvYjFAHUJyjD2qhN0q+vyiqdwMM1AGVcnD5qu3PUirF33xVKVscigCNHKuwz0NSh/SqLyYlPNSh+OKAL9g/AGa27VsMPWsCwPyitq05kTHrQBqDjaKyddYKnPQ84rW+9Jiue8TSEyEA8KMUAcLrf+vY5+U1zuoSrCm5sMT91fX610+psgjJbBb+EHvXA6luErs7FjnmgDMvpGkkLP1NZ0sbOrKoBJ9qvzO+OQGHbNRwxPvDkEY5xQBgSWkrNnBAHGaBBs4RD7n1rrB5dyu2VQpHcCtTQPBmqa7Js0y1eVc4aQcIv1Y8CgDhYoiM7uAa6LR/DOuXZB0/Rr6dO8iwNtH/AsYFfUfhKy0XS9BjlEWjRz2iBLu4tEQKJFAySwA55z+NebfEbxvc+IPN03SZJLbTejsOHuB7+i+3fv6UAeb6ckgmaKUgFCVIVgRke44P4Vs20HzZJqvY6aeNpIPU10djppkQZBzQBd0O3Esqp1HeuyhjVECr0FZmlWa20fGNx6mtWMHHFAFm3QtIFrYRcACqthCQu9uvQVoKooAQU9TxzShaeo55oAcgwc089KVFzT9uKAI6Yw5qbAzwRTSBnrQBDimPkipyBnrTGUetAGVegjO2uR1UEM4rtrscVy+qw7piCOtAHG3YyDwK43XdN8x2kVRnviu/vrVhkAZFY11AGUqwxQB5mY1ilUMGPOatOgblThvWtfXNO5DRpgryaxxOm1UJAJ4OTQBWt53DSxSDLdj60gDRhgTjnkGoNQ3R3AwNp9aqTXjqhEn3x0NABqjldsmN8fdazJ1hdN+SHPRauRXqyYEi/L0Oar3dum8yRHK+npQBi3Ltnbkj9M0kRkbhsgVqT2qSR7jyQM5rPMYXoSPSgC5aymP5JCSp6H0rUgQkgYyD3rItlDMFY5PvWraOy4jb/AFf6igDVhjAXGcp6GrkEZQqVBK/yqCCFto3AlTyD61rWKAkAjgfrQB1/hqXzIAjckdPpXaaRJtuIh3BFefaYWtZ1cfd7V3emYYxyqeODQB3MvDexqtdfez6irAO+NT3xVe8PAPtQBjXfGTWcz84NaN30NYk8m05oAqvIPtboTyBU8cmFrF8//idOM8MlXxIaANrTpNwArfsOZB7CuW0lzkCur0sZdj2AoA1Yeoz9a5PV3DPMznjJrqY2+Vj6CuG1ybdMyA8A/maAOS1WV5XZz+XpXO3sZuMoB856V02oR75AU6ms24RIwcjDHqR3oA5R7d7RyHG5j+Qqu8hHPGK6GeFZB8xyv6is26sosYVyrejUAU9N1JbK/gnntYbmONwzQSZCuM8g49a1vE/j/W9WgFrvis9NX5VsrJfKiA9CByfxrD+yIrt5sg46Edqdb6dGzEmTIoAfpeqX4he2+0zLbSOHeLcdpIzg4/E11VlbXUxD7cx4+961k6dZQrIAE69zXW2LSPAIIEIUd6AH2yGFTkbm9BXTaVE+xXlxz29BVXTrEIoLfM1a8OVT3oA0LdVIHFX4I9xAArMtiwwSa3bUhV9SaALsCYUDsKnVahiJIqdaAHqtO20CpB0oAAvHPFOwMdaRT1paAEwKa4FOxzTWHNADQo7nikZQf8Kdg4pM0AVLlflzisDUYgz9Oa6Wfoaxb5Vzkj8aAOau4SCcise5tgxJIrqJtjcN371nXduD9w5HtQByN9p5IYr8xI6V514r0loP30YI5yRXsEkWX2kVheJNOSVeV7c0AeOSXLPCvmHLDjNQ3AYqzRoMYBrW1nSJLV32gtG3K4FZEchRTE3HY0AZEsjMSuTjNWrScfcf9aJYR5h9O9U5EKEsuW5oA1P9WuTyh6Gofs6SHttNSWk3m23lspK+vvUlvbvBICf9X3zQBV8l0bCYEfqKtwR7sckvU+1EcsAWQ96m2EDfD09O9AF3TJGQeXJny+wPY10lou3HOQa5a3bBAfPr710GlXCkiJsY/hJP6UAdDa5YAEcGuv8ADEm7Nux5U5B9a4+33cAHiuo0A7bqJl6g0AekQH5APQVFfcYA9KfGe46VHf8A3VP4UAYt4etcpqF0qFhnJya6TVpfKtpX7gcV51c3DMW3HnJoAjjusapE7HqcGuhDda4e6n2ShgeQc11kE4khRxzuANAG7pJ5Fdnpvyxn1IzXF6PzIijvXZ2Jy5A9KALjuIrdz3I4ridQiMkxI/Oup1CY7zEOwrmrxwFYDr3oAxLuNQpTr6msK4TYTvJb0NbtySTxWNqOAp5ye/tQBjXIKg7CN3pWTIjMTvIH1brV64i3tuyR6VFHArsFaPP+0TQBUW280Er+dSR27KdqHLd+KvFooisSgknstb+iadDIDL5TM/cntQBDounH5TKDk11MMAiUBVx702GNFIKj2q2hJHHI7UAT20ZABzV7cFICjJxVGOQqApXLVp2luX+ZgRQBPZxk4Zufatu1Qk5NV7S34BIwK0okC9OlAEyDip0FRovpUyigBy4p2PSgCnAUAKozmlIoAwKQ0AJSE07FNIoASkK4p2DijFAEEy9fesi+GFNbUgz9Kx70ZagDGmXHTFZ0wZWJU4rZmXPas+5QY+tAGY0qF18wYb1HeotXtxJFvC54qaaDcwxSXEjJAVbpigDgtV08PGwI3DqPavPdW05t7lV2uPSvWtQiJU89ehri9Wtd7McdOtAHniOY5iky5B7mpp40h4EYIbnOc4qbUbbdIQcZ7GoVfYwjk5UjANAEiwTACRDtiHPApjzOVyc7e4pJ7ueELEJCYx0p1ncq7hCAAw60AWoCskZAxyMj0NTQMAQCu2qYUW8m9DlCeQBVmTAxLG3yN2oAv+Wsq7o/vjr71PZkBue3aqVm7hgQcZrWiiSTBQ4egDpdHlFxFz99etddoK4nBP8ADzXA6XO0U68YIOCK9C0vCwKw/iGaAO405/MtgfTinXfMTe1VPD0m+KZfxFWZTkSD2NAHJ+IpP3Owd+tef3vVh712+ttvdq4i/OGegDn71/mYGtjRdQB09AW5X5awtRcAmsiK/MG5BnGc0Ae6aGP3m7+6K63SmyWbsBXKaV8ts7dycV0unvstGb1oAbdSDzmY9TXPXLgyEkZ7Vp3DkzEnpWDqk6xuwDAEmgCtesiKSW69qyJ3iA5BbPTFPMwLHkkA9TTGKlsuo2+1AFGVEkOdhUj0qnIqq21UZmPYVsKZ5jsgUAE9hzWxp2kyybQcM3cle1AHN6bpRldTkqP4j/QV2NhbGKArGuxe+eprVtNFZQFSNQO5NakOjL/Hk0Ac0UCkkDPuKdBHLKdqKSc+ldlFpUOMGMEVdhsI4/uIB9BQBz1hpbABnXLd63La0C4zya0I7fA6VOsIAoAqJHgYqdExU3lY5qRY/WgBsa1MBilAwKcKAEpaMUYoAUDPSkYGndBTSeKAE5ppB9acKGPNADRnNKc0Ke9LnNAETg45rLvgPStdxxWXeDk0AZUg4NUp1yK0JOD04qpcLxxzmgDOZDu96q3kW6E+taDjGcdaqXIzGc0Ac3Op3EdfauS1mEx7iO9dbfKyvuXjnisHWgsikEc9aAPO9YTksBWNO26NVI5x1rotXj2ShGzsbpWBcp1BHHrQBACJISp5I4BqsGEeM/lVlFKsGU5A7U+9tlaATR8g/pQAWko2bC2fY1dtXH3GA2nrmsRBtYGtRCGRXU5PQigDWjXpt6dK07MEYyOlZtmxVPMI3Y6r6ituy2yDcgxnt6UAalnBvYSg4YdRXXaNcbkEZ78g1zFgDGcHpWtZsYZ1K8LmgD0Pw2xWRge4xV+f5Wb6Vl6NICyOOhFad32b1oA4vVRy1cVqfErV2+rD5m+priNW/wBc1AHK6i2CfTNc3cHMrV0Wpj5TXNzEeYaAPoy1+W0iUdyTWvd3AtLa3ToWrMtEy0C9lUE1H4knH2lFz9zFAD7mY4Zyc4Nctq7PLdZ5BbmtF5/Mk2bsjqatm1WYJ5cQJHGetAHNRQSzNtjRio6mtvTdDeUjzwT6KK6jT9M2quR+GK6Gy0wAAkAD1oA57T9CC/KsYx64rorTS0jUBV6VrwwpGMKKl2gUAU4rVV7VOIVGOKnC8U4LQBCseO1SKvtUoX2pwWgBir3pwFPA/OlxQA0LS4p2KKAG9KM0pFJigAyacD602g9OKAFNJ1FOA4GetBoAZ0pDzS4ooATtRTgKCAKAGOeKy75sda05On0rK1H1oAoyYYEg8+lVpSBwDT2fB681Xkbc3oKAIZRjp3qpKPlK1cf72Kq3CgksPyoA5vUl2sc/hXLayGKFl65rsNQYMx3jgVymsxnyHZR3oA4jxCN1ujZwynmsKXEke+Pt1Fb2sqXt5M9QOlczbzbQQ3Q9fpQBHzgkdfSrcLKLVgvJ70hSNBu3fe6D2ohVFQ4U7SeaAK1xbgDcnT09KLUkMEI6VpQ20jsGUZ/kamWwRVLngjnHpQBJYoVbcOV7g1sWreS/T5G6gdqybU7SUbO01pRZPy9x+tAHRW5ygI/CtW1l6Bsex9657TZ8gRuwBHStaJ8sCOCKAO68MS7o3jY/MvIropW3wj25rjvDkwSdWPTG011SPyV7ZxQBzGrnLP8AWuI1YfvTXbarje49643VB+8NAHH6p91q5ad/3prqdY4Un61yFyf3p5oA+n7IY2k98AVh+Ipf307+lbkTbNg7gVy+uRvdXogjz8zZY+1AFTRVmvZwseSOpPpXpOk2KxxKqrk9C1ZHh3TktbdUReT1rsbCMIgoAms7VYxlh81aCDiol9e9TL0oAeKUCkHNPUUAOA5pwFKopwGaAEApwFKBS4oAQClpaKAEopaMUANIpMU/FJigBppVGaQ0ooAcRSEcUuCRRigBnakPWndD0pCOaAEpaMUYoAYRWTqnyitZqx9W+7QBjSPnOars3PWlmOM81XLfMKAHyvt5J5qCRvkpsz/MTVRpi7MKAK2pLkcDk1ymqMVyhHy9TXV3DqVYE4OK5jUow+Se/WgDidRjP7zgYPeuQkgJkdc7Tniu71SIKhHUE81yN5FtuGPRfWgCmYjsGXG4dqvWywpEpzuY9QaoTtltxPPTNS8KFZDwRQBsrJvgHl5QrSQuc4bn1qlZzgAgtwe3vV5cEhhwf50AP2KGznj+VWoMxPtkIAxkVACNyk4wBk1HM5kIbPyjpQBfyScq1bum3HnRjJ+YcGuZhl+RTnnoa0LC4EU6sp4PDCgDvNLm2R59TXX203mRJIOQQK88+0iOMbTxXY+H5vN0bceqNigCvrHE8ue5yK4vVuX9q7PWOdjeq1xerfeNAHH6yy7GDfnXE3coE7DNdfrr8NXB3b/v25oA+sAxLv7Cq9pZBrySRh8zHNWLQj52PIq5Dww7ZFAGlYxhSvTNbcPAHpWVaDCj3rShOABQBejPFTKePaqitVhDQBOtSrUK1MnoKAJFFSCmrThQAopaSlFAC4pcUCloATFGKWigBtGKdRQBHtpQtONA6UAA6UHvSmk7UAMJpuTTzTaAAU7jFJjBpaAIyKy9WgLj5TzWuRxVK9AKigDj7mGUE4Qn6VUMcxPCNx14ropk7ioCMcUAc88M5ztQ496rmxnJzwtdMI89qY0IAJNAHM/2U8gO9zu9qadBiP3gW+tbksio/TpVf7QXZsDFAHN3nh61fd+7Tn2rCuPCluzfNEjDtxXcTnzOgximLbM2D1BoA8/l8H2TD5rZPyqrL4OsmwPJ2/Q4r0p7XOQRiq7Ww7rQB5bdeCEz+4lkX681X/4Re9txlZElx0HSvWGtg6njHtVSSxBPIoA8hurG8iyZrd1A7AZFVomC53dPSvX5LTK8qD9a57V/D1tchmRPLk9QMUAcE5CHC5455qWCYqc4z6U7U9NurKQiVS0fZwKo+aEG5SDigDqrC5M1uRnLL6133guQvpd1GTzw1eVaPcbbpRn5X4Nel+C5dtzLH0UpQBo6rg20ZzyCRXF6wcbq7TVBi3cf3WzXD64+FNAHCa8/LVwt43+kNzXZa6/LVwt6/wDpDYoA+uYmxbx/7TZrTtxkrWPG2UgXPRK2rMfu6ANe26VejbAFZ1sauRnJFAF1KspVSM1aSgCdD2qdOOO9QRip1oAmXpThUYNPWgB4pwpopwoAcKWkApRQAUuKKDQAlGKWkNACGgHnFJQB3oAeRnpSEcUL1paAG4603HNSHpTaAG45pduKWkoAQjrVO8XMf0q4aq3Q+XIoAynj5qu0RB9qvkZ5o8vIoAorHg4xUciEZyOK0jEFFU7mJmBwefWgDBvVRAfWsyRvlBB5rTv4mJwapG3J69KACFAwUnvWjbRgDmqkSbSAa0IflIz0oASWDjIFUpoOelbioHT3qCeAdcUAYnlcGo3j6GtF4sZqNosigDKeLJxVWe2znIrZeL86asGev4UAcnqGnqyFXTcp9a858R6G1hK81uuYZOWX0+le1XFpkc1gazpyyQspXIoA8dsyVfg9DkGvU/B8mZopP7y81wOraYbK63IP3THkeldl4LfNt7xnFAHUavzHJ7jNefa83B+td9qhzals9jXnOutkHmgDhdcblq4S8fE7V2muNy3NcJeN+/agD68tyWkCDqFGK6C24Ciues/+PkP6KK6C1PIoA0UO3j1q7bngVnKdzZHar9uelAF+PtVyEZqlDzVyPtQBZXrUg6VGpp45oAmWpAKYtPFADxThTRT14oAUU6kFLQAUlLRQAlIaU0hoAb2pKcaVaAAA4oHWn4pDQAjU004sPTmk60ANxxSc+lSACgrmgCLNRXAylWCKjkXIIoAzghJqYIAvAqbYFppHNAETLntUMkWQatkZpCvGO9AGBfWuVzjFZjwEkgCuplTIIqpLbqTnHNAGFHbkDLdTViOHitH7P7VIkAWgCCJCqAUSLVgimsvFAGbLHzwKhaH0rTMeaiaLBoAzTD7UhjwOlaBjFMZO1AFF4tyYNZt5bgqeM1tsoWqk6ZFAHnWvaWCXBGQ3NU/CsbQTXEL9T0rtdWthJCxA5HNc9FbmG9gYD7xwfxoAvakw+wSn0Feca4eWr0PVTi2kTuRXm+utnNAHBa82Nxrg7lsztXa+InwHrgp2zK1AH2ZacIreorctmxED3xisO1/49YfatWJuFX8aANS3PStC34rNtzWlbjcc+lAGjD0FXEqnD2q1GcCgCwDUq1XSp1NAFhakWolqVaAHinCminUAOzRSCloAWjtSUUAHakNLR2oAaaUDkE0UlADyaRqDRjigCOlFO25oA5oAUUue1FIKAENMPNPPem0ARt1qMipW600jFADKKdjikxmgCGQZ6CozFVnbzSEUAViuKYRVhh1qFyB1oAhK+lMK5qQnPAoxQBCV9aaUyKsEcU0jFAFRlxUbirci55HWq7igCnIMA1WkHFXZRVN+tAGbcpuJGOtc/PGftcQ9HrppxgE1i3C7Z93qelAGNqb7p5h2AIFeda6etd/enMkh+tee68etAHnXiVsI1cLKfnNdj4nfqK4uVvnNAH2nZ84j9uK0YjmXPpxWbZ/8fK1fh/17DtmgDYt+ea1rUcCsi17fWtiDoKALqDGPSp1NQJ0qaPqBQBYSp1NQJUyf1oAsp0qQVCnSpVoAkBpaaOtOFADu9KKaOlKKAHUUlLQAUlHakPSgApV96SnDvQAoxQaQH5hSnrQAvam96ceopKAFAoxSClFACHrTO9PxTT3oAY3rUfU1KabQA3FGMU6kNADDTSyg9aJOv41Wb7woAmbkVXdc1MOlNboaAIAvpQRTxTH+9QAnegjNDUq9BQAxhVaQcmrT1WkoAqSjg1Rl61fkqjNQBWucbfrWJfffQ+/NbE33BWNe/db6UAc1fN8srdgDXnmuv8pPeu+1I4t5iPSvO/EBPlvQB5n4kfMjCuPlbMhrqNf/ANa1cq/3j9aAP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph in a 51-year-old man shows a right lower lobe mass and collapse of the right lower lobe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Squamous cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 270px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEOAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5amlk85/3j/eP8VM82T/no/50Tf66T/eNMoAf5sn/AD0f86PNk/56P+dMooAf5sn/AD0f86PNk/56P+dMooAf5sn/AD0f86PNk/56P+dMooAf5sn/AD0f86PNk/56P+dMooAf5sn/AD0f86PNk/56P+dKkTv0HHqamS3A+8c/SgCDzZP77/makUTt/Gw+rVqaXpV3qV0ttplpNczt0jhQs36V3enfC+6iQzeI9RtdKjUAmIHzpv8AvlTgH6mgDzVY5O8j/nViCGWRgkQkd/Rcsa9ctdK8H6Y6iDTbjUWz/rr6QhR/wBcD881t2/iS9gh2aTbWVikf3Rb26rkeucUAeR2nhXxJdgNbaRqcinuIHA/MitKP4eeMJNoGlXClugeVF/m1dxfeItav1LS3N0QOcBiA34VQS9aQkXUswOOMMS2aAOZf4c+MFJB0yYkdhMh/9mrPu/CHia0z5+k6goHUiNmH5iu6U6pMxZHmIxwfmAFXbO61u1mWTzrtFII+VjigDx+eC7gYrOs0bejgg/rUDGTuzfma90ttU1m4DpLHBqMGMYuo1cr+Yqte6Pol7bf6Z4ZltZ8/NJZyFfxwcigDxEtJ/fb8zTCZR/G//fVeoX3gTS7gn+ytVMLnpFfRlDn03Dj9Kwbr4f6/GC0NibqMHG62dZR+QOaAOODS/wB9vzoLyn+NvzNbE/h/U7dts2n3aH0MLf4VCukXjNhbS4J9BE3+FAGcHkA++3504M+Pvt+dblv4V1q4IEOlXrZ/6YkD9a39M+G+q3LD7ZPZ2KYyQ8od8f7q5oA4TdJ/eb86khWeaRY4BLJIx4RAST9AK9S07wfoFoy74NS1q4HUAeTDn8Pm/WugifUNPtzDpGk2+lR5wHt4cOR7ucn9aAPOtJ+H3ifUESWS1Njbt/y1vJPK49dp+b9K2Y/Ael2gH9reKASPvLZws36sR/Ku10jQ9X1KfzJpJOn3pSeSfrWoPAU8hBe5gXJ6hdxx+NAHBW2heDYVHmnWrticAmVYwfyFaGn6T4FMjre6fqartJQrdscntXXXHw9uHk3xanEjYwF8rpVZ/AOoxlmivIHlPrxxQByh0DwZPHu8rWLYHOCk4fH5iqsvgfw3dHFj4ivYHPQXMG4A+5U11Vx4T1iGLYbGKVPUcnFZ62q6e7C4sZBkc7gQBQByF98MdVZmGl39jqeO0M+1vybFcdrHh7VdKk2ahaXds3QeYrAH6HvXqzFXO+GZF/2hxn29q0LXVdQgheO6nW4tjjMcwEiY+hoA8CeOdScSMfxxULPMv3mcfia90uNG8HeIQ6sG0a9xxJCN0LN7qeR+BrjPFXw91bQ4/P8ALW7sCMrc2/zpj37r+NAHnnmyf89H/OjzZP8Ano/51cltQOqlT7VWeB16fMPagBnmyf8APR/zo82T/no/5008detJQA/zZP8Ano/50ebJ/wA9H/OmUUAP82T/AJ6P+dHmyf8APR/zplFAD/Nk/wCej/nV+xkkMJ/eP97+8azav2H+pP8Avf4UAU5v9dJ/vGmU+b/XSf7xplABRRRQAUUUUAFLT442fpwPWrMcSp7n1NAFeOFm68D3qykKL2yfU0+uv8H+CLzXYDqF5ILDRUOHu5BkyEfwxr/Ee3oO/pQBzml6bearex2mm2st1cyfdjiUsT/gPc8V6NYfD/TtEAfxfdNLebQw02zfp7SSdvov511eiajpegD7FoUBsLJxiWdvmnlPq7ensOBWXqNvctcFrk4jzlXPV8980AXW12SDTPsWi21tpFoP4IF2k+7Hq31NYkjl41feblidp3HAJq1YaPd6vOlpbxMxB5YdAPc16To3gzTtOCtdj7VMB8390fhQB5zp2k6rdz7Le03L904Xg/jXRWPgPVLnab+5jt1H8Kda9CnuHgURwW7ADgADA+tNnu1gtxLezRwpjJLNjFAHNWHgSwtXBurm4uR2TOBW3baZpNq22CziRiMZZf6mobLW7HUfN/sy7hnaL7xWRfl/Wo3kubwq8Cwy7WyQkymgDTVogfLEaBQOoxioZ72Hy/kEZKnBGRxWRdLeW5d202coeSyjOPrWWuoSPcMNiMgIUp5eCPegDrbCGO+vVtbW3tzMx5yBxXbp4EEkQCX0SsRyBHkfzrhtFvI7SZJWCxTbfvDg59Oa6u0v5mUMs7ENyCDyKAMzWPh01/dtatZwyNGoYzD5AQfQ+vtXOaj8Kby2JaxhvI5M/ejfcD+Rr0jTtYura6gLSyzRE7GQnOav6rqt3Y3YZpmCMN4j29B6GgDw6/8ACXibTSWha9lcdAA1Y8tj4qOBJb6iZGIzwwr2fV/H+o2EDMkUUjYyAF6ViH4neI93NnakeqIT/WgDiLPwP4l1dFIiulXGP3gOSf8ACus8O/CK9tbjz5URHxg73wPyGa3E8ca9NEDNtgJGdoi5/WtzwxqGr6lcGK7nl6gh8YDDGeKAOW1DRn0DU47e8jjht3QskifdfHUfWsKXXAWH2a3MkSkgsSMivRfi5cRQ+G4UuNvnl8offGDXkmmXzx2MtwV3Qx8ABeSfegDagvLl1Dv5Ua54HXNW1u4TIFaeMFeoz0rjJfFHh/TorlvE1xI8jxkQwW0mWRvU4rzTVfG+lyahNNbWd2YmACqZsfnQB7yL20nkxFc5OcBVOSatOBGm8K6J/e25zXzxJ8WNZht/I0u3srFAMBki3P8A99NmuX1Xxfr2qk/btVu5VP8ACZSF/IcUAfWFrqWnTttjvovOBwV8wA5+lWpITIuZovMQ9mUEGviszSFtxdt3rmt7Q/GviLRJEbT9WulRekcjmRCPTa2RQB9Kat4Y0rUcmONbWYHIdOmfcVxGteGr3R8zvCJ4c5M0IySP9oVQ8P8Axms7rbD4p0zy26fabPOPxQ8/ka9T0vUbDUtN+3aJfx31qRyqnO32YdQfY0AePFYVbfDbxu33gw7n3FS6drGo2Mm+J3jXoV7OPQg9q9K1HwzYXZNxZBLe5GSU/hY/SuG1OwmtrnbeI0Ev8LDlcUAZ+qaBoviqItbxxaTrJ4CjiCdvp/AT7cV5br2h32i3slrf27wyp1Vh29R6j3FeseTEJhKo84AY8xDgg/SrU02nataro/iJmZFO23vMfvICenPdfUUAeDOgYfMBVaSHB+U11/jDwvd+HdSe2ulBGN8ci8pKnZlPpXNMDQBnkEHBGKSrjqMfMM1A0XdfyoAiopSMHmkoAKv2H+pP+9/hVCr9h/qT/vf4UAU5v9dJ/vGmU+b/AF0n+8aZQAUUU5VLdOnrQAgBJwKnjiHVgT/KnxxgDjNTAUANHTp+VOAyaeiFjXpngjwjBZ2kWu+IoVeNvmsrCTj7QezuP7noP4vp1AKfgrwZB9jTW/E6OLE/Na2IO2S7PYnusfv37cdej1K+vNVvI4iDHbxkJHFENscCjooA4AFS3N1ea3dyNczATk7gccYHRR6YroNF0i4vraQl2jjxs3/3j7UAYP2EQgJMouLphgAnt/Wup07w7f6uLb+1sRwxLhY4x87D3rvfBHw7EYW+uyAoHNxKOT/uitXx/wCJPDvw/sAJ8G7lUlIR80r+/sKAMG0sE020MVrEsSDkjgfiTXFeKPiPouiDbbztqd6uR5UT7Yl/3m7n6V5l4++I+o+IpJIYWa0049IEPL+7kdfp0rzyWQsTk0Ad9q3xY8S3TuLW6SzjY/dhQfzOTXI6v4i1XV3D6lfT3BHTe3A/DpWVSGgBwkYHIYgnjg05J5EOUkdT/ssRUVFAGxZeKNdsWzaaxfxHp8s7fyzWxYfEbxJa3cNxLfC7aJgwW5jDA47Hoa4/FKFxQB7HcfG2TUtRa81bQbd3KhdsEhVVI7gEV2/gD4y+FTby2/iBLm0lJ/dPs3Ig9yK+ZwtTW1pLcyrHBGzuegFAH2XoXj3Qp9UgnluVOnhuHX17cd66u88beGJ/Nl8u4uyePuEA+wzXyb4G01LDLzSl5JAAUB+RD7ep969Y8P6RqOoShRuSIn/JoA9Hn8Y6Mm4WuhwkgZzLjp9Kqn4ivCTHbaXYxjqSFpIPAN2sRZJfmI5JOSawNd0C408D7RFvU8EqMEY70AR6h8bb7T76aG70qweGHlpDleO1Z5/acsIm2/2D07pJx+WK8Q+J9rLb+I5S0heOVAyH29PwrhHByaAPWfHfxm1DxNqLXAhEcI4iiLEqg+lcPdeNNcnSWMX8kUUnDpH8oI9K5ukoAkklaRiXYk0zNJQKAFpMgd6WkNACiikApaAFFaWh61qOhXy3mk3ctrOOCyHhh6MOhHsazKcKAPp74R/ErRPE93DpvihIrDVW+WOUHbFMfbP3T7H8PSvTNe8HRyu8O1ZgfmSOQc4/2TXwupxXu/wf+NUunJFoHjeeW60c4WG+JJmsz2JPVl/Ue4oA3fEXhqfTnZ7SJweSYgvIrlLyE6hCTtCXicbB1YV9MqkepvBbagY54pkD2WqQ4KyqRxkjivMPiD4Pktrwm3XybyP5lZBhZR7UAeeWjL4hsT4f10Mu0f6JdMMtA/of9k9xXkfiLSLjSNRntLuIxzQuUdT6/wCFes3UbQNO0yuJQMsucc+tVdXsF8Y+Hi6JnXtPTB9bmEfzZf5UAeLyKOTUZx2PNXbqExOQaqMuO9AETKGHNROhX3FTgZooAq1fsP8AUn/e/wAKrSR91/KrNh/qW/3qAKc3+uk/3jTKfN/rpP8AeNCJu5PSgBY03HngVYRBjANNX0HFTKMD1oAAMCnqMmmjk113gDwt/wAJBeyz3jtb6NZgPdz9PpGv+036DmgDZ+HXheF4R4g12MHSoX2wwOcfa5B2/wBwdz36etdtfwT6pfx3+oSHyZD8ka9PYD0FRyXcerLEjwrb6Za4jtoU6BR0UD+tdr4b0jzSt5qKcgARRdlHrQBV07wurK014pROgiTv+NetaD4ZtNG0uO+1OINIqjyrX+FT2BHc1X8KackksuqX5UWFpllB6Fh/h/On33iuCz0fUfFeubk0u0ytrbnrK/QAepJ/zxQBk+PfHbeCdIOp60yS6vcgjTdMBwsY/vv7D/6wr5C8VeIb/X9WuNR1W4a4vJ23O7fyA7AelXvHviy/8V+ILrVtUk3TzH5UH3YkH3UX2H/165GRySTQA2RiTmo6caM0ANooooAMUYpaUCgAVSTUgjYkADk8D3p8QrvPhd4YbWtYF5NGWs7RgT6M/UD8OtAFLQPh7q2oqJZ4zbxZxtYfOfw7V3tl8NLt44oLaWOzjx1xlifc969dsbTcm51QFeCBxx61JbwM94q/wZ4oA4bwv8OLuC6aDVVR40cNE6Nw1e0+GdJFvAyphiOopdKia7Nu0ABjibD5HQ11tvBHApCAAk5NADUjZY1XH41meIdOF1ZsuxSccZrcoIBHNAHyn8TfDK3dlJCY8XSMWhcj9Pxr5/1C0ktp3imQpIhwVPUGvvvxj4SXU0ea0A83HzL6/SvnT4ieDYpDLmDbeDgPjp7H1FAHgJU001q6pps9lO0c6FSO/Y1mkc0AMxQBTqKAEpKdikoASilpaAEpRRRQAtOU4NNooA9x/Z++Jx0W8j8LeI7gnw/etsikdv8AjzlPQg9kJ4I7E59a+nJo01HzNC1Xi8jG62mP8Y7EGvz1U19X/A/xjJ438JDRruc/8JPoSCS0lY/NPAOAM9yOFP4H1oAk8YeGz58nmxhbmEkSLj7w7GvM7t7jQdQhurKMqqtuBHb2r6T1YJ4k8OJqsUe29tgUuIgOePvD8OtePeLrCXyhNAoe1P3kxnHvQB5d8QtEhurSHxHpkeyzvGImjH/LGbuPoeorzSRdpIIr3XTDGtxNpl9j+yL5PLcD+Eno49wea8p8XaJPomsXVlcr+8hbGR0YdmHsRzQBzhUelN6D7ufrUp44phHtxQBETk1esVUxMcD71VD7Air9hgwnB/i9fYUAZLrunf03HP51Io4wBTpQFlcD+8acnA6UAIoGKeKQHPHNXtH0y71fUoLDT4TNczNtVR+pJ7AdSaALnhbQbrxFq8VjZ4XPzyzN9yGMfedvYfqcCvW7yO2gtodF0YFdHtThWX79y5HzO3qSfyHFU7K0t9G0o6HozLLK5Bvb1R/r3/uj0Udh+Namh6f9t1KO2jBCqeW9qAOg8H6Ot1IGmjCQwn5VI6mvQra1e7uIbSLh5CFXjj/9VZ8Ua2sawwgbUx0rtfAVqJrya8YHbAu1T/tH/wCtQBa1vTmuorTw9p7GK0jAe6l9FHPJ9T1r5g+PHjxPEGsppGjuB4e0omK3VekzjhpPfuB7c969m/aF8cp4Z8NvpOmyBdY1hT5jo3MMPQn2J6D8a+PbuXJwKAK8zlmPNQnrSluaaaACk4zRmg0AIaKKX8KACnLTactAFmMfLX2L+zVoFnF8Mba6uYFkkupnlJcdBnAx+VfHafcP0r7u+ElodL+G3h+0dSHMClh7kZoA29c8M295aOLP/RpsZUjp9K8ll1KXTL+W0vwySwucsOAR0BFe43E5W3O4Hdjt2r55+Omrra3dstrBunLlXZeoFAHofhvxPFE01skyFRy7A8lvWvRLW7Sa3jlVs7gCD618saH4e8RfaHubNAbZz5m7f2IzXsPgk6ra2xguZhJFt4Rjhh9PagD1JTkZFLWXpN6HzFI4DjoD1rUzQAVynjXwtb6xavNGgW5UdQOorq6KAPkjxv4Zjh81ZYd2wHAI4ryjxPpVpaLE1nE6qRhixz81fT/xiihsHYLtJlbIHoev5V4Pq+n+dZ3CMd0jL5i8d6APLmXnFNFWLqPZIfSoKAExmkpT9aKACiiigAoxRRQAc0tJR+NADhW54N8R33hTxJY61pb7bq1fcAejr0ZD7EZFYQoU4oA/QrwZqen63YWniHRv+Qfq8YaWP+5J0YH3ByDXHeItLFpq97YFC0Lcx5/unkV4d+zn8SJfC2ttod/JnR9SbADf8sZ+gYf73AP4V9EeK54r+9t54iGPlhT68etAHiPijRJLQPGkig5LK3oe1Y3iqzj8T+FmuY1LatpKBZiBzLB/Uqf0zXqfiTTxdWUxQZkUYB9K88028bTNSS6SACYOYrmI9GQ8Hj3FAHhdxEY3Iquc13vxN8M/2Drrpb/NYzr59q/rG3b6g8VwjDBoAjIb14q5YcQtyPvf4VTIz3q7YAeScD+L/CgCjLzO/wDvGnE8UkoPnSf7x/nQF+tADlz/APqr2HQNOi8KeHZraQBfEF9Grzyd7eI9IvYnqfc47VyPwu0iG81uXUtQjDadpSfaZQRxJJ/yzT8Tz9FNdbdObuZryQs8sr72B75NAEtopijEECMpbq3dq9O8Jab9gshJKqiWRemOVFc9o0NxrGrWc1xbLbW0EYO1Rw3vXcsP342kAAc+9ADpiqKSM5I6962bLWjp2gtGJBDEhM0zd9oH/wBauelkwxY+mTkcVyXxM1ltO8ETrHIVmvnEC89urfp/OgDxv4geJrjxN4kvdUuWJMzYjUn7kY4Ufl/OuRdiSSaluXLPVcmgAzk0fhSCkNABmlz+dJSigAP0oH0paTmgANPX3phpy0AXrcjem77u4Z+ma/RDwyFbRrQKoEZiQp9MCvzut8bk3dMjP51+i3h0qmgacF5UwJj34oAbrEirCoJwrNt4+leA32j3PiPxTcpMGMay4Q4ya968TlIrAyFRuHIPoa5rwTYxCe6uVUAliVHc0AXvDHhSDSrMREknrgnrXRR2Nvgfu1OAe1TKCwDHipOAMZ6UAY+q6aFhea3JVwM8HnNVdD8Qbm8i/YKxwEPf8a3Xy7rjO3BrE8ReHk1G2Z7VvIvFGUYdCfQ0AdMORkdKZO5jhd1GSBnFeeeHfHkdtv0/XW2XMDbC3rVrxP8AELTLLTJGtnMkhGBj3oA5fxvaHxLcJBIMSl+3Yd68q8XJbaddTx2oykUJhGfXua7/AELxE90ZpoYXkuJCQCp6Z9657xJpumyajFPrs8YSNeYo/vOevOKAPm/UVxKQe1UeK7f4jm0m16aewt/ItnUFExj2riW60AN/CiiigAGKXg0ld94E8I2N/wCGda8S+IJmj02xHkW0KNta6uSMhfXaoIJx6+xoA4Gl4xVq9WMSERgAegqqaAE7UUUUAH60GkpTQA6NmRgyEq6nKkcYPavrLwxqralo2mX4cmK6gR+eobbyPzzXyWK+gfg1fG88Am3Dky2M7oBnkAncP/QjQB6kpBLBuhHI9a8+8b6cbbUIpwMRv8r4HUetdvazBogxGWxUGs2w1Cxmhkx0JWgDza7gh8VeHZ9FkDNrFnumsmJ++O6fiP1rxC9hMUrBhgg8g17ES1jqkMqEx3lq+QQeo7Vg/FfR42uotcso9tpqILOAOI5h99fx6j8aAPL2Aq3YDEJzj71VpFwSKtWKjyjnP3v6CgClIv798j+I0oGAc9qfKP3z/wC8a6f4c6Kms+JYvtQzp9mv2u6yMgovIT/gRwPzoA7nTtPGg+FNP0tl231yBfXisMEFh8iH6L+pNXRpk76M2oSMIowQirj7wzyal04TeI/EM9wwz5r/ADsew9B9K63xG1jGlhYTq6xE7VRf73agDQ8KCT+x4jcks2MK2OQvoa15MiL5T1HemwqsCLCMbQoAPtSs6mElxgdjQBSvp/3aJgnzOMjqK8i+NupK+q2enxMTHaQbiO25+f5AV7TDbpeFFA2sOM9vevmLxvetfeItSuGbduncA+wOB+goA5pzkmmU402gBPpSU44xSGgBM0uaKKAN/wAHWGjajq0MPiDVG061ZwpcRkg57luij3NaPj7wXeeEtXa0uCkkEi+bbXEZyk8Z6MprkFru/D3iyC78PxeGPFBdtNjfdZ3o+aSxY9sfxR+o7dqAOFKkGlGRW/4k0C60S+MF4oww3RSpykqHoynuKxmixQBJBksoX7xIAr9CfCMzXGnW0MoBe2jQEhu+0V+fNjC8t3BFGCXdwBj6198fDC4tbzQWuLZg7lgsh78DigDW8ZQmXQblh95FJFZnw9iLaMjSqVkXgj1FdLqlzbWWm3V1fuqWkEbSSs3QKBk15L4d8eRy60Hy0en3RAjIH3T/AA5+ooA9hxxtFMwD3471nR382wFoiyk4BXvUjX0K5Dq698Y7UAXeF9qZ1IA6etZH9vR+a4jhkc9sLWPr/i+a0s3FjYSzXJyFGCeffFAHl3xZuIYfG00MQAJUPJt6k4pvhrTLa/iJv/mONyr/AAgehrH1Twjq+q6t/aN60zTXTBmcnaBz0x6V6ZB4fWx0OS1s5Fa7CgvzyPpQBytzNZWQFrYSqhPAEYrJksog6LdwpkN1fOW/HvW7p3h/y7hhJF8w4/H3rSntC8q2jIJG6LkdPxoA8Y+M+jpaQ2d3HFGschKAp0HGcV4zKMMa9H+LOu3V5rsumsGjtrB2jWM/3/4mNecSHJOaAIzRQfrRQAlW/wC0Lv7HHaefJ9mjZmSLPyqT1IHvVXtntRQApYnrUltbz3UvlW0Mk0uM7I0LHHrgVHXUHxrqcWippWnR22nWewJKtpHsac4wWkbqxPfnFAHMOjRnDqQfemVNJI0jFnOSajPWgBvejqaXoaDQACvYv2fbpRcavYs20yLHKvuRkf4V48te0/swaKdY8d3ALMsNva+ZJjv8wwPzoA9itY3QMDHtHXn0p52h9vHPy59a67xrpUen2FvNF0DlGrjQ4znbjAyc0AeX+K4Ug1a53pjDZX3FR6bENe0jUNBfB+0J51qSfuzLyMfUZH410vjhYra+sr2SISRNkSKTwwFcSb02+qx3tl+6RZVdVHYjtQB5JqEJilYMpVgcEHsfSiy/1TcfxV1vxUsUtvFl80KkQ3BW6j47SDcf1JrlLIfum/3qAKswxK/+8a9U8O2L6L4Qt7ZFA1HVmW5lBGGWPpGp/Mt/wKuJ8OaSmseLLWybAgaUvMfSNcs36Aj8a9i8NQDWPENzqU6j7LEx8tMcADgD8BQB03hXSl0vTUEoCzuNzEDkVNqNstxLaXD7WCzDAxzmrl5O6WxaKIuSc7fUVV1ufy7S1aNhlpVA5xQBrtGpyOD3INFtp0mqX0NlbuQ7tuOPQdafHkkDPJHX0rqvh5bq2tTSleYYMA+mSKAOI8ceb4c0nUbiMsEigfa3oxGBXyjeMWJycn1r7b+L9rBqHwv8VyR7W8qMOpHUFWGa+JrtcUAZ5ppqRutMNAB2pMUtFACYoxS0UAFPUc00dakjHNAHu3wP1XR/E2mTeCvFdtDc5Qtp8sv3k/2VbqCO3t9KueGfg1LD4ovYtV0/+0LCNSYSHKg88Zx1NeHaZc3FnqFtcWLMt3FKrxFeu4Hiv0L8OuJtMs7mVVW4lhRnAOdrYGR+dAHy9rnhCXSNfEWlaKlkPLIYoCzHPoT0/Cux8A6jr/hOcRw2RfT7hMyRMfmDdmGe9e/tZW7XDTvCjSsNpYjJxVC+0CzvJI3K+WUJPycZNAHA6/qd34r0W50p4mSFh5cu4YZz6GqXhTwJPY2jJc/v1HCk8YA6fjXpFnoFva5LM0pLbjnjP1rXCrwAowPagDEspryxhSCWF5kUAK1X47pZ4yRbuWHYrir2MYxRjFAGVc6fNcSq+4QLtIKp3p9rpEEI5JJzuPbmtIjpmkx831oAq3OnW08WxowB2xXP65o/k7rkbhsX/WqefxFdUxCISSNoqm2pWxJRyG9R1/SgDya/1NoVlmSQrcIDuUd8V414++Il6sctraSvFdzAF5kbaY19B7mvW/HYt01qcxAiJYy5PTgDO2vlLV7h729nuJOWlcsfxNAGddXMtxKzyyM7sclmOST6k1XP1p7rg0wigC/a6tPbae9nFFa+W5yzmFTIf+Bdaz3Ys2Wxmp7G1nvr23tLWNpLi4kWKNB1ZmOAPzNW9d0S70TULiyv1VbmBykig5wRQBVv76e9naW4KGRjk7ECj8hwKrUEUflQAtBzS0lABg0YozijrQAlHaloNACpX0l+yIPIHjC+C5aK2iUH/vs4/QV82rX01+y7Hs8A+OrjODlFz9I2P9aAPa72c6n4Aknl++nzHPbDf4GuBRcFW5PHOa6zwncfbfhlfsxJ4cc9e1cuB8gXklRjNAGF4utludKT5N5SUMBjOfavM9atlt5bmLBVVbeAD19K9Z1e6jsbb7TJlkU9O+TxXnvjiFIbuC4AwZIwxHrQByHxOUzWGgXTD5nsjEx9SjkfyNcDZ58tv96vRvHSeb4K0KYc7Jp4SfyNedWv3G/3qAO1+HsTJD4i1Mn5o4ltozj+J2yf0X9a9f8AB1mthocOVOZfmb6mvMfBSRL4IvCCwmm1PB9wqLgfqa9jswn2CDaw2ooxn+VAE0mVTlirdsdxWJcqsmpafYcnyvm245HfNXtRuI7RGuJGOV+YL/QVjeCmuNR8QX2oXkRVWjAizwQKAO2ij+YdD2+tdf8AD0gTakQMFYhk/ia48EB88gdf/rV1Hw8lDa1qUGT89qG5+v8A9egDKhK6l8P/ABzbAu/+jSnDdc7WP9K+NLscCvtrwuiTab4wgjU4MLpnHX5HFfE94PlAoAzG60w09+tRnrQAtIaDSUALSim5pQeaAHCnrklQOSTgUwdDXpnwy8HJfWY1m9QSqWIgiI6YPLH+lAGj8F9G1DTvFkN3qWjh7dh5XmTqD5ZP8S+/vX1hpvhY2ESPYandK33wpIKEn2rxyA+WgOSGAGwE9D712Wj+NdXt0gtJEiljBClyDuH+NAHSar4k1jR7gJcWkdzGONycE1saN4p0/UgE8wQ3H8UbHv8AWsLWJlmtw90dzHkDpiuLvLO3kuW8rfG+c7ozzQB7eCCOORSLwDXjeheMdQgluYbK4W8+yttktmPzJXf+F/F1prY2MpguByyP29qAOm/lQPrQOaUCgAFIuMkYp1FAGbr0NxPYGO2+8TzjrisCy8MPC5kaZyzEHk5xXUTX9pC+yW5hRvRnANDX1mke97u3VP7xkAFAHM3vgqzvs/bGZi/JwK8X8afs6XEly914cv4wjsWa3lBwv0P9K+kbe4t7jJt7iKUf7Dhv5VPgigD84Nb0m50nUbmxv4miuYHKOjDBBFZbR819jftFeHNFn0ttX1DTy08af8fEPyv9Ce4+tfLs1zov2DyU0aUXWeLn7Yf1TbigDO8OXsmia7p+qwIsktnOk6o3QlTnBp/ijV5tb1e81C4H725laVvYk5xXR+AvAeo+O7ua20Fo0mh2l/POFUHPOR9PStXx78G/E/g20F3fxw3diTg3FoxdUP8AtAgEfXpQB5WfekIqzPAY2wwqAjmgBKSlozQAmKSlzRmgA4pDRmjNADlr6k/ZNC3fgzxlZc7mlQ8ehjI/pXy0pr6J/Y81IReJNf052CrcWaSjPqr4/k1AHuGk2J0j4cXsTk5bOM+5ArlgQFz68V3Pjq4jttJtbCHBaeXkey8k/niuMKKse3aflPAFAGB4nj87TPsqLl5ZAF9+a5z4h2J/s20nUAFBsb2reQ/a/Flxu/1NtEqgf7R71c12wW/0i4g27iVyMjvQB5Dr0K3PwwdkGWtL9XPsrqV/nivMbYYV/wDer1rToftGi+JNKI+Z7YyKP9uM7v6V5XCmA3H8VAHb+CZjJ4SvIdm4RamrEjqAyD/4k17Dbypcadb+X1AHIPJrwz4cTedJrmmhsPPD58X+9G2T/wCOsfyr2rwq4m0aE5DlRhqAOm8I6Ta614hjttRXdAIWYLn754rS174dLo8MupeHLmdkRcyWkh3fL/sn+lZOkzNY6nb3cRwYXDY9R3H5V6LdXUsGp2upWrGTT7tRvHUfSgDyzTLr7RC8gJYBiGJ610/gu5SHxlY4PE8EkJ/9CH8qqeKPDA0TU5tTsQx0y/bJQdYnP9DXKanez6Zf6dqFqW3W8qyYz94A8/pQB7TaW9po6alDIQj3RdxkfeGD/jXwNq6+XczR/wBx2X8jivsvxtraXIjurdgYZoVCH+7kZxXyl8TNFfSPEk6HPlXCi4Q44Ibr+uaAOIfrUdPcYJqM0ABpKKKACiiigB4NfRfw9dH+HujMqY2xspKnBJDEV85CvcPgrd+b4bOnOXjf7RI8W9SBICATsJ4JB6gdM0Ad9HGGO6T933xxzW/4ctZLrUoEVMjcDt9Pesw2sisOOQMKf61seCmnj1+y8ssMyBTzwR3oA6vxXbfZVjUnGRxXMJD5R89iAx9+tdt4/wCYrdQPmO45JxXBkFlwAQcZ69aAM8WNrB4ik1K0OyeYBZCD9/HeqltfTweJ2llZRv6qOARnrV5253jqOOB0qO5sbi8vXuItm2NR97rQB6BpHi1IFxdAsh+6c9PatyPxbpLJuafYOOo9a8XmE7yRrvJU8gj1qtb6pavqNxpFuwn1C3G8xsCFCnuTQB7fdeMtEto2ZrxWK/wqMnPpXM/2zq3i+4MekB7TTlba8x4JFeX6jqDS38VnpsSyStIEkmVfliFe+eHrOPTtJtbeFQAEBIxgk+tAGT/wgunyIftcssztxu3YrifiZ8IZdZ0F4dH1GdZEbzVikYlWIHSvYPvHJAxjP41IvBGMc0AfndcvrXh7Up7X7TeWN3AxR1SVkII+hrqvC/xm8b+HbmN11iW/twfmt7396rD0yeR9Qa7j9q7RorPxpY38KhTe2x347spxn8iK8Cm4NAH2z4I+Jvhb4p6PLo2oRrbX1xGY57GY/eyMZRu/8xXzX8T/AASPCHi640e1vEvFGGiUf6wKegYetec2tzNa3Mc9tK8U8bB0kRiGUjoQR0Nd58JZ/wC3Pi74dbX7pp/OvleSSZsmRwCVBJ9SAKAPaf2XbOfw7a6vcaxaS2xvGQRF0IbaoOePTmpfjt8YdIudDvPDnh6VriWY+Xc3IUhEUHlVz1J6eldn+0T4nbw14KSLT7lLbVbuURw7QN6xjO8j0GMDPvXxXqExdyC2fWgBl5cCRuOlUmbmlY5plAC0GkzSUALSUUUAJQTR3oxQAoNeg/Ba7vLDxc91ZPs8q3bzD6qSOPzrgUQmvZ/gvpKxaNcX0qZe7mCJn+4n/wBkT+VAHstvqE2oXcMty5Zo4icH1Jq0eWC5IXuRWPpWWvJgCMAAHsBWkjFT97k0AZmlwxR3mpyJzI0g3knO2tKNvMQZYENxXPJPFp2ramhfm6O8EngHFaeled9n/wBIwFB+X1NAHAQ24s/HskRHyT7kx6hhivIpoPIuriI9Y5WT8jiva9fBXxtYvEPnLqOnSvINZXGt6kP+nmT/ANCNAGR4V1gaF4pstRZQ0cM371T/ABRnKsP++Sa9/wBDuksdeubQsotpsSwuDwyMMgj25r5nlP75/wDeP869Z8B6qdc8OLZb8aro67oTnmWDPT6qePpigD2YubeQh2DRtwa7TwTfxzxy6Rdt+6mJaBv7rdwK878N6rHrOmYcAyLw6kdDWtbO0JXycrLGQysDyKAPU1tw9tPpF+CyyqdjkcH/AOvXkPi/RbmyBSePaYjgFhwwB6ivUPB/iW28RQSWdxIi6lbnLJnDED+ID+dcx8e7iS30rTduQjyMrOOMHAwKAMrRNFvtZ05giq0EQG1l9cV5V8edP2afpc7gGeJmgY4wdpGR+or6E+DcvmeB4pMZbzXDcelc3+0RolvqXw5vdSs7eOSW0Ku+ByFyMn6jNAHxVMuDUDda0LlR1qi1ADKSnUh5oASuv+FvgiX4geKE0W21KzsJDGZd9xklwOoRQPmbHOMjgHnisfwr4b1bxVrMOl6BZS3l5L0VBwo7sx6Ko9TxXqcmo+HPg4rwaC9t4h8ehSkupFd1rprEYKxA/fcdNx/TlaAPZ9K+C/w++HGh3GveKN2rfYY/NlnvgDECOywjgknACtu5IFfL/wARfHd/4w8WHVlJsoLfEen20J2i1iB+VVx0PckdT7YFb/xe+MGq/EWy0uymhFlZW0avPDG2VnuMYL/7o52jtk8mvL6AO1j+JPiUWLWr3+8H/lqUG8D0zXpP7PnxAnfxpaaZrsxnjuPlglb7ytj7p9a8CFXtLvJbC+t7y2crPbyLKjA9CDkUAfoB45VWFu+QQMiuKkAW5ZS/AHBp7eN9M1Xw7Y3V3eQ2/wBptRPHvbG7j5gPcGuOsvEVpqviC1s7DUIpFdPMZR1I6UAdPshifdwzN90etXLe3ECGWVSC/TOce4FEtpaafDFEvzP6nmrlld3t1aXNsgRUiYMA4zx60Acvd2c0MlwtvKIzKhMEhG4ISPQ+hrI06e10vyNPuLyG51V1zPPtClz1ycfoK6fxLe/Z7NEhUPdTYREVdxyeNwFO8L/Cmzt5hqXiK5f7RP8AMIBw30z2+goA5bU41Z4ZLHyo7hHDMRwGHrXuXh28jv8ASredJEkdVAbYc1jjRvDIiK/2bKsK8GXLcdvWs290a/8AD8f9p+E3N1ZgFpLb+Ijvgd6APQFAPPNSADGXwAK8+t/iZYx6PHe30DRBiVbnG1h1BrzT4p/G1o9Pa20QbZp1+Rz/AAD+8fU+lAHF/tN+JoNa8dra2kgeDTYfJLA8Fyct+XArxVZUjuEeSJZkU5MbEgN7HHNOvLt55XkkdndyWZickk9SapMaAHyuGbKoF9hWjoFql5eSK919maKCSdGzgs6jIUH1P9KyqX6cGgDS1XU7+7uC17fXN04G3fNIXbHpkms1jnvSGkxQAtFJiigBaKSloAKDiikAoAWlUZpMc1LEuTQBoaFpd1rGq2em6fE0t3dyrFEi9yTX1z4d8EHSBa6ZEhP2dREAT+Z/Hk15/wDsveH7awg1Xxzqq/urMfZLMEdZCBvI98EKPqa+kre4triz/tthsWOJnx7AZoA8atGMOo36kt8szKM+3GK6Lw/pdxrU/kxfKi482XqEHp9a5nwva3mvai8lvE7NNKzA9kBOSTXs+i2aWNuLSzCLbx/62YdWbvQBwnjnwJpdnaw3sMk32gMF+Zvv/hWTG6bOcAr1NbvivV11jUQIGJtLc7UPZz0Jrl9UljsbCe5YgBMgYoA4+9K3PjiB2bEcQLsSccKM/wBK8XuZxcXt1Nn/AFkzP+ZzXpl9ffZvDWsazMSJrgfY7fPct94j6DNeSQvkN9aAMSXPnP8A7xrR8O6vc6FrFtqNkwE8Dbgp+646FW9iMg1nzMDM+CPvH+dNB5oA+grK/to47XxBo+9NNveZIgf9U4+8p9wa9BtLhbuBZ4WDqwGD6188fC/xHBp99LpOsP8A8SXUcRyk/wDLCToso9MdD7fSvW/D893oGqvo+oKWi3YjYHgjsfpQBZ8Yrd6PcW2u6ZM9vcQyfM6HBx/hXQ694nXxl4Vt7a/2eZnfvA/ix1qS+t4r2zlt513RyAr+OK8ns3uNIv7rT5pGUI3yKepHrQB7l8BNWQ2+o6Mz5aEiWME5yvQ/0rsLO2t5rvVdGvDutr6N42jb3GD+hr578I+ID4e8c2Op8rCWEdyvqjcE/wBa+m5dPim1m11CIgjbu3A8Hjg/lQB8B+L9Gn0HxBqOk3SkTWczQn3APB/EYP41zUgwTX0P+1f4eSx8Y2WsQoFj1O3xJjvLHgE/ipX8q+fLgYegCtSE0ppO1AF7StY1HSGuG0q9uLRriJreUwSFC8ZxlTjscCqGT6CjP5UlADs0lFHagBRU8XeoB2qVOtAH0p8GND0zxF4H0l761EsljNKmWYkcsT0/GtnxDpkOn+JY4LW1jUjoyqAwFUf2ZZs+Fktl6yXzZ49hivQ/G9isXiW2cAeYRyw64+lAHGfEnTNXvPC6zaHNMmoQ4kURnDMo6gGtbwz/AGymh6bLrO/7VJCvnN0LHHU+9S+M9YGlaNdXUcMs7W8e4JGcH3pY/Eiat4Vs9QtY5FiaDI3LjNAG74N06K61a51y8TclqNsAPTd/jWyl2bu6YqWkkZyW3HIQdgvFVvCbbvAgEsZLh9xQNgnvjNSWd1Fb22+PZDHOcRAjMgz2+ooA0I7fVZNUkWG8X7HCQojYZVzjkVastQeZnkgtntn6fvFwh56Z/rVawhvJhNGtzI1mh2LGqbWORySe9STmVf3TqWMS7A2eG9eKAPOvjh4eim0CfVtKRVjEm29jQcBv74/Gvk3xBKZdRlGSVQ7Fz6Divu+xt4b/AEfUbOVneGeBkIdcYwP5ivh/xxpbaV4ivLZsld29T6g80AcqaZ3NSPwTTD1oASgmjvRQAZ4oyKKOKAAGiig0AGaWkooADSg02lHSgBy9auWULzypDCpeaRgiKOrMTgD86pr1r1X9nPw3/wAJH8UNM8xA9rp4N9MD/sfd/wDHitAH0ePDY8O+BvC/hODAZFElwfWTqx/76J/Kuu8R6bcTeExoti6x3F0oh3dNq9WP5cfjW3Pp8dxfpdTYLR/drwzx348vJviDF/Ysp8iwby1IPyt/ePvk0Aew+GvDVtoGjJYWZOWGZpj95z3rnfFevIIH0rR/lhX5ZZV7+qqe/ua4efx7rev30Vjby+TG4/e+WMcVrJAsaYQjavABoArRKVUfwop57VxmtTtrusf2RacI3G4Hv3Jq54u1xbWJrS2cvcuMEr2Nct4k1BfBnh0x7s+ItSj3Fs5a3iPf2J7UAcV8V9ct/wC0INH0359P05TErg8SSfxt/T8K4mzmUxsSp+961V1CXzZQc5xT7H/Un/eoAymbdLJnqGP86eOMEn9arSkidyP7xqRG3D3oAtIefavbvAmvf8JV4WGjXEpGvaYnmWkrHmeAdV92X+WPQ14eM1f0q/udOvYLuymeC5gcPHIvVWFAH1B4U1j+0bXypCq3CDDbuhxVfxj4fGoQC9t4QbuEc7TywrmtPuE1vQ4/Evh8+XdRnbqFmp4gk/vDvsbqPy7V3+g6xFq1nHNGV83bh0HHPegDxq8dwTE+VZT8v/16+mfgf4rTXfDEdhcOPt9ioTaTy0fY/h0rxzx94dKo1/YxnP3mjXtWV4F1C807U4bnTJ/KuojkADIYd1PtQB3P7T6yXvhm0eRCZbK6Lg/7DjB/UCvlS6++a+svHt+PEGnFpLfzIJhtuIxwUz3FfMfinR5NK1GSBssgOY3xw69jQBzzZpvPansKYR+dACEEmkw3rTscdaZg560AOwcdaXkUn5YpRQA5RzUq8c+lMUV0PgfRG1/xLZWPIhLb5mH8MY6/4fjQB9G/AO3fRPDunMY8s+Z5Gb+Hdz/LFdbdzS3fiS4u7gkpngeg7Cs+CR2jS0sIhBYx4BYdXq/bfv7vCgbM4Bxx+NABPAJ5nM8YYOM47AfSs/xHci20wW0KqFYjanT5R3AroVUJIzyEHAycVx+r/wDE31IiBlMxykaseM9qAPQ/CtuZ/B7qAwEhGCPYdataYiMxRwM5GN3Udvwp3wwvZLzwssF7B5N7ZyNb3EZ/vDofxFdINPt1IIjUMM/N3FAGPPqElrbx7X3O0gjCnnr2NS3m90jO0rMcZAbisnWPFGg2t7FbT3e6WNsho1yin3rorWG2u4FnhlFxDJ8ysrZGKAKul2siySuQCHByV9cV8ofHTSWN39vRDmJzDJxzjPBr7JghSBAkS7VHFfP3xP0+O/1/V4p8tpz/ACnb/ex/jQB8nzDBqA1q61ZtZXs9u+cxsVz6+9ZRoAQ0UUZoAKT8KWk5oA2bY6J/wjzCYXn9tfaODx5Pkbfz37s+2KyXxn5c4ptFACc0c+lLRQAc0UoGaljjJoAYgPpX0r+yPZNp9/f6ldAIt9F5MJbjKqck/if5V4P4a0O41vU47a2ieRQQZSo+6v8A9fpX0l4e06806OGUlbeOFRHHEvAUdh+FAHrHxK8TDR9EeG0kAvbkbVI/gU9W+vpXz20f2aFgG/evyzEckmtnxzrc0l4I/MaWY9fQfSpfCGhGeb7beKXiRfkVuhPrQBreFdNGn2QkmBN1KuTzyBUvirWV02xKxt/pDD5QO1X768SwtpJpSvyj7uK4myiTXrm51jVpTBotmu+Vm4BA6KPUmgCtYmDQtMl8Va/iSTcRaWp6yydvwFeKeJ9autY1K4vbyUyXE7Fmb+g9h0re+Ini2XxJqxmUGCyhHl2tuDxFH/ieprhJnLN1oAiY5JNXLH/Un/eqketXrH/Unn+KgDDm/wBdJ/vGkVipyKWb/XSf7xplAF6J1dOPy9KlU4rORijZU4NXYZFkHHB7igDrfAXiu68J65Hf2yiaFh5dxbMflnjPVT79wex/GvZ7uD7MbbxN4YczaNefOVVvuHujDswPFfOCkg13vw18czeFLySG5iN5ot1xdWhPXtvX0Yfr0PbAB9A6TrNtqkCIy5lcYKnoa4fxBodxoWpf2ppS5tWb99GByv4VevbVbJYNf0CX7folwd6NHklP9lvQjpzXUaVrFrqyMilRKVGUbGSD7UAQeGtKn8RXUEdpMUjlTcec4+tVPH3wk1K7t54EjM4VTJbzqPuN3U+xrqvCmzw3rqXYU/YXyJAByme/0r117pTZi5tyJo2UOChzlfUUAfnBqumTWN5NbXMTRXETFHRhyCKzHjwea+3fiX8M9B+I8ct3pk0dh4ijX7+Plk9BIv8A7MP1r5I8W+GNT8M6vNpmtWj213Eejchh2ZT3B9RQByxWkxViSMiothoAjx6U8LT1jPpUgjx1oAjUZOACT2xX0X8J/CH9h6Itzdxf8TC6AaT1ReyVx/wk8ASX0sWtarEy2qndbxsPvn+8fb0r3JIXUbV4HQ8UAWFHyAgbMjJ2joK0IiiwpGo/djk8dD71ny3cVlGGuWQBRwD1JrC8Qa2fsTbitpE2QWJG9/YCgCz4m8QRLJJZafIrT42yMp+VfbNUvD+oabZWn2m6uka73nO7ncR6V5Zqd1eajMLPRoZgGbGAuWPuSK9W8DfDpY7eC61hnubkEN5f8Cf40Ad18Obi81PxNqmrxwyQ6ZdW0QfcMCScHGV/4D1NaHxY1t9I8OpFCSst6/k7gcYUDJrotMvbRGhsLZlyicBBwMdqi8V+HLPxNpZs77cpB3RSr96NvUf4UAeCwmPb+7IddvVucV1Xwn1ybTvEzaNIzGyuydinnbJjIx7EVgz+A/Fen6pNaRWUlxAxASeAjy2XPU5PH0NekeA/AZ0W5i1DV7hZdQXJjijPyR5GM57nH4UAdrq73UelXj6ege8WFzCp6F8cfrXzY3imJLSTS7+GVrtgzTSSDB3nr+tfR2tagLC1LKQJm+5npn1rzXxN4ds/FMzvNHHFfbfluEXhj7jvQB8z+MLW21OMzWjB7qMcgD76/wCIrzmZCrEEGvcPEnhDU9EvGNxCqr97zFHyn3Brz7U9IS/Z3t3T7VklkHAf3HvQBxlJVma2eKQo6kMOCDUZiNAEVHOetPKEU0qaACijBpQKAEpyqTShamiXvQAqRcc11nw88Dax471xdN0SH5Vw09w+RHAvqx/kOprS+F3w31n4g6n5Vght9NiYC5vXHyRj0H95vYfjX1XHo9r4R0q18JeDYTBuAa5uMZkfPVmb+8f06CgCj4V+HWi+DLS30zSkkvNQkH7+8YD5m+nb6dqq/FzVrDwtplrYxlXvnUysmefY13WrajZeB/CjXt+TLLEuEQcvNIeirXgMel6l4r1ybXPEasjTncsHt2GOwAoAoeDtGudYuvtuo4SItvxyS1elXdzbaZZsZCAAuAqis281C10i3CYClVyIwMY9K5zRjqvie7lmb/RrOM7pZpT8sajufwoAkWC+8YaiA2610qM5dnOAqjqTXnvxR8Y298E0TQP3eh2h4I4Nw4/jPt6fnWh8TfiHbyWTeH/DLldNU4uLkcNdH0/3P5/SvHbi4Mh60AJcSlmNViaVjmkPSgBtXbEt5R4/i/pVOrtiP3TdfvUAYc3+uk/3jTKfN/rpP940ygApQSDkcGkooAuw3Ab5XwG9fWrKMQayanhuGThvmX+VAHofw/8AHN/4SvHMKrc6fOMXNlKfklHqPRvevX1tbHxFpo13wTOSEIM1qeJbdv7pHp+hr5qjlDDKHP8ASt3wv4k1Lw1qsWo6RctBcpwe6uvdWXoR7UAfTfhzXPtFusV4FS4PykMeprs/DHihdCuEstQyNOlbCSdrcn1/2T+leRaLq+k/EaAHTJRpPiZRuktCwCTHuYz3+nUfrUh1250rdYeII2Lj5cuvNAH0C+gLbeI49ZsmHlMP3iKex7j2rK8f+HND+IOh3Gn3cS/b4VZraRxskjb2Poe4rmvA/i2bTbGNY3fUNMAz5f8Ay0hH+z7e1dhLJomuRre2tyyTDqoO1xn1U0AfHGufD7UrQzfZ9szREh4tw3jH6GuLlhMLlJVZXHBDDBFfU/ifQF0zXZXDLNbzHergcjPUGqOn+GLXWdUW1/s6G5MvAaSPJQetAHzPBBJcyiO2ieWRuAqjJr1z4ffC1HaHUfEk0JUEMtmrA/8AfZ/pX0TpPwj8N2EIUxSM/wDEYyIx+lbdt4T8PaEhmttIEsi8gkGVifxoA46zsnngWLTrSV1UYVYhhcDtnoK1LfwZqt2FNzcRWSHJIH7xx/Su6sZ5ZoCRamAYyitx+GKhv72OxgJvbqON8cAf4UAeaeJNKs9HDR2CSXd7tx59w2cH2HQV5hJpV1JqIm1fzJxu556fhXqXih3uH821khjVyckknmuVuNLupFZluyScAEUAeq+D/Cmi6VpUM8NvG0s8YZpW5Jz2Fb0lrHNbCO0CxIepC9q5X4bazCmiR6ZqVwkd9blh+8OAyk8FSa39Y8RWenoywkXFxjhIyCB9TQBSkttK8Ms+o3twVcjhQMk/Qd6hs/H2lXEwWSK7t4jj99Ig2D64ORXDahfyahcNcXMm6YnBX+77UyElSSQ2OhUjrQB7RHLHJHvjlRkPO4MCKwNU8a+GtMvTZ3er2n20Dd9njbfJ+QrxnxRpWs3Wj3R0S8uLeOYKXVWIGAecYrB8P+HbbTYlmEKm8Y5M0gyw9c0Ae7xazoHjJVtrO92Xagskci7X+oB61p6PoiaVau0x+0uB6fyrxzTbdbe4imj2pcI27zs7cH616ZoPjO2miaDV5UhdRxcH7jf/AF6AL2o3WiarGbW+Q8ow2Mo6Y5r5m1nwRZwatIunuWt3cmNyCSvPSvoHU20dllurW/huJXBCCI55I/SvLLiw1G2O1vKePJIwORQBwWs+AJLpBtzMP+eigB1/xFc1rPwt8R2GntqNraPf6ev3pLcbmj/3k6ivW7e6uoT5d3aSEHI3xnge5r1X4ZP9phZrW5AMZxIh6kfSgD4YeLYxV1IYdQRyKjMantX6E+JPAnhjxKrf21ollcSN1mWPy5P++1wf1rzjWP2cfCN0zPp95qWn/wCyJFlUf99DP60AfHZgFMMOK+ltS/ZjusbtK8S28q/9N4Cv6qTWRH8A7rTXEurXSXcQPPkPhT/WgDwO1tZrq4SC1ikmmc4WONSzE/QV6p4A+E99e65ZjxNC9tZZ3SQhsOV9Cf4f516Xa+GLTw0mzTEjtZnXIcKA359a3vDNvbR3C3Oq3sjoP4Q/86APXPDtvp2nadDp+g2kdtYW64VIlwo/xPqaqazqGmeGIJNR1Jt9zKcRxqMySt2VR/Wse88cW62a2/h6ATzAbVeTiNPc+tcTfzC3ml1LXLv7Vdt1kbog9FHYUAJfTX+v6n/auu4AU/6NaA/JAvue59TWL4j8R22mQyKkyS3TcLt7Vkar4outWm+x6LASWO1So5Y1Bf22j+C7dLvxk63mpEb4tOibLE+r+g+v4UAQ6boj6ikmu+JbwWOlxnc0khxuHoo75riviL8RTqlu2j6CjWOhIceWOHnPq/t7Vz3jnxxqXim7D3biO2i4gtYuI4h7DufeuPdyxyTQA6aUuxJNQk0HmigBKDzSsQBknAqrLc54j/OgCSWVYxjq3pUlk7NExJ/irOJz161esP8AUn/e/wAKAKc3+uk/3jTKfN/rpP8AeNMoAKKKKACiiigBysVOVODVmK57PwfUVUooA2bW5kgljmt5WjkQhkkRiCpHQgjkGvX/AA18WrbUbVNO+IFqbyMcJqMKjzl/3x/F9Rz7GvCUdkOVOKsx3Q/jGPcUAfUGn6Ib9GvPAut219ag5MSvhx6gjr+daOnX8sVwItZjNjKgwHYEFvxr5d0+/uLK4W5sLmWCdfuyQuUYfiK9B0T4w+IbNVh1cW+s2oGNl2g3/wDfY5/PNAHv8bWmpR/LerIE6Kzc1r+GZW0rUBcZdiOCTyNvpXjum/EbwLqm0X1lf6Hcn+OM+bHn8Of0rqdOuFv8Hwz4ksb9ccRGUK59tpoA9W1H4ix2KM39ntMR/CsgBP5isi3+MdpNH/yCZ4Zc42ySjj36VwOpza9ANt/pDuq/xqmR9cisRtVt5X8u90tAW4IL4P60Aen6n4+1PUY5IbWWOwLLlfJG58Hvk1kiTz0LXk1xO5ADO7EkmuV0y902C9D+RLCWGwMzbk+ntXUxguECPlTzkHigDQtzGLZI9pA7cZxUTxyDDZBB6KB0pBnGArHaOxpSQzZEZXHcmgCv5R8zPlk46HufWr0BCjCqRjnII4qqVkUsNoI7Vn6iNSNsy6dAhlJxnOOKANOWWSIyKyphhxIBlh60xpy0RHmndjtxTLYTNaq1zB5cuBvXrzSMsshISLAI6kdaAPT/AATpyjwvGl0oY3IZmyOoPArzW80uCwu7qOFi48z+NunOK9F8P+JdNttEtk1K6gtJ4U2tG7YJA7j1rzW8vWvLqWZVkMcjsVJGOM8UAUgHPmCf5kU444pl9EkkKhN4HbDcCroRpdxfcmRgjAqjJMYbhYpEYqwPzKmcY+lABp8Ihy0bP5jjqBwa0G3NERkhuv1qpZyo4bBfaDgFhtq0CnYguO2P1oAqTQuxBUKDjt1xUumT3umziSwm8qUdCo5+hqcgMMqck9cDBpyK2chcjqQeKAO00fxxd7VXU7MSKR/rYjg/iK2/t+ian1uWt5CNuGJQ4/ka87EZUbkAC9yT0qojyxzMwMToTgZcD+dAHrukWFrY5NrfNJGeqGQFaLu60fTYXknlgVV+YgHcfyry9LlV4Zo1x97DdKytU1bS7c7Jbgb8/dTkmgBvjDX11fVXmsLYwwqcIHXBYeuO1Uo5C1u0moFEi7ryOKgXVLu8fGjaPdTjGFlcYA/OoLnRby3b+0PGOpw2dlGN/lbwG+gHc/SgAufF0Sj7No8Bml+7vC/yqumiatqanUNfuo9P0yPlmnbaMfjXJ678XotPL2/hTSba1i6Cedd8h98dB+teZ+I/F+teIZd+q381wB91GOFX6KOBQB6x4h+JGieGraSz8EQ+benhtTlTp/uKev1PH1rxfVdVutSupLi8nknnkOXkkYszH3NZ7OzHJOaTrQApbNJ9aOnNQPcKvT5j7dKAJ6gluFXIXk/pVeSZ36nA9BUVAD5JGkPzH8KZRRQAVfsP9Sf97/CqFX7D/Un/AHv8KAKc3+uk/wB40yrk1nJ5r8p949zTPscnqn50AVqKs/Y5PVPzo+xyeqfnQBWoqz9jk9U/Oj7HJ6p+dAFairP2OT1T86Pscnqn50AVqKs/Y5PVPzo+xyeqfnQBXBKnIJFTJcMPvDcKd9jk9U/Oj7HJ6p+dAD0mQ98H3qZJGVgysVYcgg4Iqt9jk9U/OnLazL0dR+JoA6vSfHnifSQq2WuXqIOiPJvX8myK6m0+MuslVXVdP0vUVHUyQ7GP4g/0ry8RSjqUP51NHbu/Qr+dAHsNt8R/B15Iran4evbJ/wC/azBxn1xxXRaT4n8Iz5Fl4puLLPRL2IjH44xXz+LWQ91/Ol+ySZ+8v50AfVWm3Et0udP8QaTf/wBzZKua0hHrsIy1nHNx9+MjmvkUWsoOQy5+prRstS1qwI+xapdQY6eXO60AfUTX2pKzGXSpRx05xT7W51S53GGxZQOTuQ/lnivni0+IHjS1AEfiC6ZR2kYOP1FGp+PvGOojbc67chf7sTeWP/HQKAPoa6u9Ts8vNZnaBnJU4qKy1LUNTLR2igSZ+8iEhfYk18+6N488W6XdJNFrM1wq9YbpzKjD0INbXiP4p+JNZsxa2/2bS4Dy4siyM5926/gKAPS/E2natBdJc3RmIHV2G5QO/A6U/RtVuLbzHk3z2zsdq7vmX8PSvGvCfjjxD4d1FbhLtry1J/e2txIzJIPx6H3Fd+fi3pBXK+FUDNywE4A/9BoA7+PWdNZiTK0Tf7QIxTzqlgTj7XGvvXnJ+LOlbty+EoS3qbn/AOxqs/xWsgxaHwnaDnJ3XB5/8doA9LOr6cHDC6jbj09KhPiXTlbahY+4XivNm+LsiriHwxpagdNzsf6VE/xf1kH/AEPSNFtgOn7pmx+ZoA9Kk8RKwZbG0nebOP8AVkjNZE+meKNUl82IXgOchABGo9ua87ufix4xlBEV5a24P/PGBR/SsS98c+L7zd52vXmD1CSlR+gFAHuUHhbXTZCK+uUgiB3HzZ8n8apXNn4c07d/afiizibukUm5h+WTXz3d3epXbFrq8lmJ7ySM386pNDMerr+ZoA+gpfG3gDS4zGs2oagR/wA81IB/EkVhXnxi0m1UjQ/DMCOOFkuZN2PwA/rXjBtpfVfzNN+ySf3l/M0Ad9rHxd8UX6lIb1bKI/wWiCMfn1/WuIv9Wvb+Uy3l1NPIf4pHLH8zUH2ST1WhrV1GSVoAiLE9abQySfw7PxNRNBO3V1/A0ASNIi9WxUDXX90fiaT7HJ/eT8zR9jk9U/OgCF5Gf7zE0yrP2OT1T86Pscnqn50AVqKs/Y5PVPzo+xyeqfnQBWoqz9jk9U/Oj7HJ6p+dAFar9h/qT/vf4VD9jk9U/Or9jaSeSeU+96n/AAoA/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    His CT shows the mass with collapse of the lower lobe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_26_5541=[""].join("\n");
var outline_f5_26_5541=null;
var title_f5_26_5542="Chloral hydrate: Drug information";
var content_f5_26_5542=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chloral hydrate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/59/33716?source=see_link\">",
"    see \"Chloral hydrate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/38/2662?source=see_link\">",
"    see \"Chloral hydrate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F149264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Somnote&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F149265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      PMS-Chloral Hydrate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F149287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Hypnotic, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F149267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sedation, anxiety:",
"     </b>",
"     Oral: 250 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypnotic:",
"     </b>",
"     Oral: 500-1000 mg at bedtime or 30 minutes prior to procedure, not to exceed 2 g/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Discontinuation:",
"     </b>",
"     Withdraw gradually over 2 weeks if patient has been maintained on high doses for prolonged period of time. Do not stop drug abruptly; sudden withdrawal may result in delirium.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F149279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/38/2662?source=see_link\">",
"      see \"Chloral hydrate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sedation, anxiety:",
"     </b>",
"     Oral, rectal: 5-15 mg/kg/dose every 8 hours, maximum: 500 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prior to EEG:",
"     </b>",
"     Oral, rectal: 20-25 mg/kg/dose, 30-60 minutes prior to EEG; may repeat in 30 minutes to maximum of 100 mg/kg or 2 g total",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypnotic:",
"     </b>",
"     Oral, rectal: 20-40 mg/kg/dose up to a maximum of 50 mg/kg/24 hours or 1 g/dose or 2 g/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Conscious sedation:",
"     </b>",
"     Oral: 50-75 mg/kg/dose 30-60 minutes prior to procedure; may repeat 30 minutes after initial dose if needed, to a total maximum dose of 120 mg/kg or 1 g total",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Discontinuation:",
"     </b>",
"     Withdraw gradually over 2 weeks if patient has been maintained on high doses for prolonged period of time. Do not stop drug abruptly; sudden withdrawal may result in delirium.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F149268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypnotic: Initial: Oral: 250 mg at bedtime; adjust for renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F149269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Avoid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis effects: Supplemental dose is not necessary; dialyzable (50% to 100%).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F149270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid use in patients with severe hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F149241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Somnote&reg;: 500 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral: 500 mg/5 mL (5 mL [DSC], 473 mL [DSC])",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F149224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F149289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F149245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chilling the syrup may help to mask unpleasant taste. Do not crush capsule (contains drug in liquid form). Gastric irritation may be minimized by diluting dose in water or other oral liquid.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rectal administration: May administer chloral hydrate syrup rectally.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F149244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term sedative and hypnotic (&lt;2 weeks); sedative/hypnotic for diagnostic procedures; sedative prior to EEG evaluations",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5174520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - low; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F149285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, disorientation, sedation, excitement (paradoxical), dizziness, fever, headache, confusion, lightheadedness, nightmares, hallucinations, drowsiness, &ldquo;hangover&rdquo; effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Gastric irritation, nausea, vomiting, diarrhea, flatulence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukopenia, eosinophilia, acute intermittent porphyria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Physical and psychological dependence may occur with prolonged use of large doses",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F149248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to chloral hydrate or any component of the formulation; hepatic or renal impairment; gastritis or ulcers; severe cardiac disease",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F149228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Use with caution in patients with porphyria.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use in older adults, potential risks exceed benefits; doses only 3 times the recommended dose are associated with overdosage potential; in addition, tolerance develops within 10 days of use (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Long-term care facility residents: Recent interpretive guidelines from the Centers for Medicare and Medicaid Services (CMS) discourage the use of chloral hydrate in residents of long-term care facilities.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neonates: Use with caution in neonates; drug may accumulate with repeated use and  prolonged use in neonates associated with hyperbilirubinemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Duration of therapy: Tolerance to hypnotic effect develops, therefore, not recommended for use &gt;2 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Metabolite: Trichloroethanol (TCE), a metabolite of chloral hydrate, is a carcinogen in mice; there is no data in humans.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Abrupt discontinuance may lead to withdrawal symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F149233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flumazenil: May diminish the sedative effect of Hypnotics (Nonbenzodiazepine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Furosemide: May enhance the adverse/toxic effect of Chloral Hydrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Hypnotics (Nonbenzodiazepine) may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Chloral Hydrate may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F149260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F149236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13447510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Chloral hydrate crosses the placenta and has been found in amniotic fluid and fetal blood.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F149273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F149238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs, O",
"     <sub>",
"      2",
"     </sub>",
"     saturation and blood pressure with doses used for conscious sedation",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Chloradorm (AU);",
"     </li>",
"     <li>",
"      Chloraldurat (CH, DE, NL);",
"     </li>",
"     <li>",
"      Chloralhydrat 500 (ID);",
"     </li>",
"     <li>",
"      Escre (JP);",
"     </li>",
"     <li>",
"      Kloral (DK);",
"     </li>",
"     <li>",
"      Pocral (KP);",
"     </li>",
"     <li>",
"      Suppojuvent Sedante (ES);",
"     </li>",
"     <li>",
"      Welldorm (GB)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F149227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Central nervous system depressant effects are due to its active metabolite trichloroethanol, mechanism unknown",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F149247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Time to sleep: 0.5-1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 4-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral, rectal: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Rapidly hepatic to trichloroethanol (active metabolite); variable amounts hepatically and renally to trichloroacetic acid (inactive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Active metabolite: 8-11 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as metabolites); feces (small amounts)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, Committee on Drugs and Committee on Environmental Health, &ldquo;Use of Chloral Hydrate for Sedation in Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1993, 92(3):471-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/26/5542/abstract-text/8361811/pubmed\" id=\"8361811\" target=\"_blank\">",
"        8361811",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/26/5542/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buck ML, &ldquo;Chloral Hydrate Use During Infancy,&rdquo;",
"      <i>",
"       Neonatal Pharmacology Quarterly",
"      </i>",
"      , 1992, 1(1):31-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buur T, Larsson R, and Norlander B, &ldquo;Pharmacokinetics of Chloral Hydrate Poisoning Treated With Hemodialysis and Hemoperfusion,&rdquo;",
"      <i>",
"       Acta Med Scand",
"      </i>",
"      , 1988, 223(3):269-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/26/5542/abstract-text/3354353/pubmed\" id=\"3354353\" target=\"_blank\">",
"        3354353",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donovan KL and Fisher DJ, &ldquo;Reversal of Chloral Hydrate Overdose With Flumazenil,&rdquo;",
"      <i>",
"       Br Med J (Clin Res Ed)",
"      </i>",
"      , 1989, 298(6682):1253.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kauffman RE, &ldquo;Chloral Hydrate - Is It a Carcinogenic Hazard?&rdquo;",
"      <i>",
"       Pediatr Alert",
"      </i>",
"      , 1991, 16(6):21-2.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Laptook AR and Rosenfeld CR, &ldquo;Chloral Hydrate Toxicity in a Preterm Infant,&rdquo;",
"      <i>",
"       Pediatr Pharmacol (New York)",
"      </i>",
"      , 1984, 4(3):161-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mayers DJ, Hindmarsh KW, Gorecki DK, et al, &ldquo;Sedative/Hypnotic Effects of Chloral Hydrate in the Neonate: Trichloroethanol or Parent Drug?&rdquo;",
"      <i>",
"       Dev Pharmacol Ther",
"      </i>",
"      , 1992, 19(2-3):141-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/26/5542/abstract-text/1340434/pubmed\" id=\"1340434\" target=\"_blank\">",
"        1340434",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mayers DJ, Hindmarsh KW, Sankaran K, et al, &ldquo;Chloral Hydrate Disposition Following Single-Dose Administration to Critically Ill Neonates and Children,&rdquo;",
"      <i>",
"       Dev Pharmacol Ther",
"      </i>",
"      , 1991, 16(2):71-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/26/5542/abstract-text/1914781/pubmed\" id=\"1914781\" target=\"_blank\">",
"        1914781",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meyer E, Van Bocxlaer JF, Lambert WE, et al, &ldquo;Determination of Chloral Hydrate and Metabolites in a Fatal Intoxication,&rdquo;",
"      <i>",
"       J Anal Toxicol",
"      </i>",
"      , 1995, 19(2):124-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/26/5542/abstract-text/7769782/pubmed\" id=\"7769782\" target=\"_blank\">",
"        7769782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mowry JB, Wilson GA, and Schreiner R, &ldquo;Effect of Exchange Transfusion in Chloral Hydrate Overdose,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1983, 25:15-21.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Salmon AG, Kizer KW, Zeise L, et al, &ldquo;Potential Carcinogenicity of Chloral Hydrate - A Review,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1995, 33(2):115-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/26/5542/abstract-text/7897749/pubmed\" id=\"7897749\" target=\"_blank\">",
"        7897749",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seger D and Schwartz G, &ldquo;Chloral Hydrate: A Dangerous Sedative for Overdose Patients?&rdquo;",
"      <i>",
"       Pediatr Emerg Care",
"      </i>",
"      , 1994, 10(6):349-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/26/5542/abstract-text/7899123/pubmed\" id=\"7899123\" target=\"_blank\">",
"        7899123",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sing K, Erickson T, Amitai Y, et al, &ldquo;Case Series of Chloral Hydrate Toxicity From Oral and Intravenous Administration,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1993, 35:339.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steinberg AD, &ldquo;Should Chloral Hydrate be Banned?&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1993, 92(3)442-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/26/5542/abstract-text/10835095/pubmed\" id=\"10835095\" target=\"_blank\">",
"        10835095",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zeltzer LK, Altman A, Cohen D, et al, &ldquo;American Academy of Pediatrics Report of the Subcommittee on the Management of Pain Associated With Procedures in Children With Cancer,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1990, 86(5 Pt 2):826-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/26/5542/abstract-text/2216645/pubmed\" id=\"2216645\" target=\"_blank\">",
"        2216645",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9239 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-C2E244C14E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_26_5542=[""].join("\n");
var outline_f5_26_5542=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149264\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149265\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149287\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149267\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149279\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149268\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149269\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149270\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149241\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149224\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149289\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149245\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149244\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174520\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149285\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149248\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149228\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299013\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149233\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149260\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149236\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13447510\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149273\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149238\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038557\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149227\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149247\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9239\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9239|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/59/33716?source=related_link\">",
"      Chloral hydrate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/38/2662?source=related_link\">",
"      Chloral hydrate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_26_5543="Clinical manifestations of malaria";
var content_f5_26_5543=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations of malaria",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/26/5543/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/26/5543/contributors\">",
"     Joel G Breman, MD, DTPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/26/5543/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/26/5543/contributors\">",
"     Johanna Daily, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/26/5543/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/26/5543/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/26/5543/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of malaria vary with geography, epidemiology, immunity, and age. In areas where malaria is highly endemic, groups at highest risk include young children (6 to 36 months), who can develop severe illness, and pregnant women, who are at risk for delivering low birth weight newborns. In areas where malaria is transmitted throughout the year, older children and adults develop partial immunity after repeated infections and are at relatively low risk for severe disease.",
"   </p>",
"   <p>",
"    Travelers to malarious areas generally have had no previous exposure to malaria parasites or have lost their immunity if they left the endemic area; they are at very high risk for severe disease if infected with Plasmodium falciparum [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5543/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. For this reason, it is important to consider malaria in all febrile patients with history of travel to malarious areas.",
"   </p>",
"   <p>",
"    The clinical manifestations of malaria will be reviewed here. The epidemiology, pathogenesis, diagnosis and treatment of malaria are discussed in detail separately. (See related topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCUBATION PERIOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the bite of an infected female Anopheles mosquito, the inoculated sporozoites go to the liver within 1 to 2 hours. Individuals are asymptomatic for 12 to 35 days (depending on parasite species), until the erythrocytic stage of the parasite life cycle (",
"    <a class=\"graphic graphic_figure graphicRef58397 \" href=\"UTD.htm?35/50/36647\">",
"     figure 1",
"    </a>",
"    ). Release of merozoites from infected red cells when they rupture causes fever and the other manifestations of malaria. The relapsing species Plasmodium vivax and P. ovale can present as a new infection weeks or months after the initial illness due to activation of residual hypnozoites in the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5543/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incubation period for P. falciparum infection is about 12 to 14 days. Longer incubation periods are more likely in semi-immune individuals and individuals taking ineffective malaria prophylaxis. The incubation period for P. vivax and P. ovale is also about two weeks; most relapses due to these species occur within three months. The incubation period for P. malariae is about 18 days; however, low grade asymptomatic infections can persist for years (",
"    <a class=\"graphic graphic_table graphicRef53291 \" href=\"UTD.htm?15/38/15981\">",
"     table 1",
"    </a>",
"    ). P. falciparum and malariae have no dormant (hypnozoite) phase, hence do not relapse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4394?source=see_link\">",
"     \"Overview of non-falciparum malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Uncomplicated malaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malaria should be suspected in patients with any febrile illness if they have had exposure to a region where malaria is endemic [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5543/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The initial symptoms of malaria are nonspecific and may also include tachycardia, tachypnea, chills, malaise, fatigue, diaphoresis, headache, cough, anorexia, nausea, vomiting, abdominal pain, diarrhea, arthralgias, and myalgias [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5543/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In general, patients who are not obtunded and can take medicines orally have \"uncomplicated\" disease.",
"   </p>",
"   <p>",
"    Physical findings may include mild anemia and a palpable spleen. Anemia is common among young children in endemic areas and is often due to multiple causes in addition to malaria (including iron and other nutritional deficiencies as well as intestinal geohelminth infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5543/abstract/4\">",
"     4",
"    </a>",
"    ]. Mild jaundice may also develop in patients with otherwise uncomplicated falciparum malaria. Splenic enlargement is a frequent finding among otherwise healthy individuals in endemic areas; this condition may reflect repeated malaria infections or infection due to other causes. The spleen often shrinks due to infarctions after multiple malaria exposures, such that it is not palpable. In nonimmune individuals with acute malaria, the spleen may become palpable after several days.",
"   </p>",
"   <p>",
"    Laboratory evaluation may demonstrate: parasitemia (usually &lt;5000",
"    <span class=\"nowrap\">",
"     parasites/microL",
"    </span>",
"    of blood, &lt;0.1 percent parasitized RBCs), anemia, thrombocytopenia, elevated transaminases, mild coagulopathy, and elevated BUN and creatinine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10248?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis of malaria\", section on 'Parasite density'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Uncomplicated malaria can occur with any Plasmodium species. Although falciparum malaria is the most virulent, it is often not possible to determine the species of malaria infection on clinical grounds alone; there are some unique characteristics associated with each species, and P. vivax, P. ovale, P. malariae, and P. knowlesi are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4394?source=see_link\">",
"     \"Overview of non-falciparum malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Complicated malaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with complicated or severe malaria may have hyperparasitemia [&ge;100,000",
"    <span class=\"nowrap\">",
"     parasites/microL",
"    </span>",
"    of blood (&ge;5 to 10 percent of parasitized RBCs)]. The WHO uses cutoffs of 5 percent (in low transmission areas) and 10 percent (in high transmission areas) to define hyperparasitemia for diagnosis of severe disease diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5543/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many of the clinical findings are the result of the parasitized (and non-parasitized) RBCs adhering to small blood vessels (\"cytoadherence\") causing small infarcts, capillary leakage, and organ dysfunction; these include the following&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5543/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Altered consciousness with or without seizures",
"     </li>",
"     <li>",
"      Respiratory distress or acute respiratory distress syndrome (ARDS)",
"     </li>",
"     <li>",
"      Circulatory collapse",
"     </li>",
"     <li>",
"      Metabolic acidosis",
"     </li>",
"     <li>",
"      Renal failure, hemoglobinuria (\"blackwater fever\")",
"     </li>",
"     <li>",
"      Hepatic failure",
"     </li>",
"     <li>",
"      Coagulopathy with or without disseminated intravascular coagulation",
"     </li>",
"     <li>",
"      Severe anemia or massive intravascular hemolysis",
"     </li>",
"     <li>",
"      Hypoglycemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Physical findings may include pallor, petechiae, jaundice, hepatomegaly",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    splenomegaly. Splenic rupture has been described. Diagnostic evaluation may demonstrate the following: parasitemia &ge;5 to 10 percent, anemia, thrombocytopenia, coagulopathy, elevated transaminases, elevated",
"    <span class=\"nowrap\">",
"     BUN/creatinine,",
"    </span>",
"    acidosis, and hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5543/abstract/3,7,8\">",
"     3,7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although most severe and complicated malaria is usually due to P. falciparum, patients with complicated infection due to P. vivax have also been described. Those at greatest risk for severe disease include nonimmune individuals, immunocompromised patients (including asplenic individuals), children 6 to 36 months of age, and pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5543/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. Increasing parasitemia is associated with increasing disease severity. Semi-immune individuals may have substantial parasitemia with few or no clinical manifestations. However, some severely ill or inadequately treated patients may have a low but rising parasitemia when first seen by a clinician. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10248?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis of malaria\", section on 'Parasite density'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Manifestations of complicated malaria can portend a grave prognosis; such patients should receive a prompt and thorough evaluation and immediate treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5543/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13338?source=see_link\">",
"     \"Treatment of severe falciparum malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cerebral malaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral malaria is an encephalopathy that presents with impaired consciousness, delirium,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    seizures; focal neurologic signs are unusual. The onset may be gradual or sudden following a convulsion. The severity depends on a combination of factors including parasite virulence, host immune response, and time between onset of symptoms and initiation of therapy. Signs of cerebral malaria should be evaluated and managed promptly, as cerebral malaria can progress rapidly to coma and death. If untreated, cerebral malaria is almost universally fatal; with treatment, mortality is 15 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5543/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with cerebral malaria the mean opening pressure is about 16 cm of CSF. Laboratory examination may be normal or may demonstrate slightly elevated total protein level and cell count. In a study comparing CSF findings from 12 children with cerebral malaria and 14 children with presumed viral encephalitis, patients with cerebral malaria had lower white cell count, glucose and protein levels [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5543/abstract/13\">",
"     13",
"    </a>",
"    ]. Children with malaria had mean white cell count of 0",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    (range 0 to 4",
"    <span class=\"nowrap\">",
"     cells/microL);",
"    </span>",
"    children with viral encephalitis had mean white cell count of 4",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    (range 0 to 9",
"    <span class=\"nowrap\">",
"     cells/",
"    </span>",
"    microL). A CSF glucose concentration below 3.4",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    (61",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    was the best discriminator of cerebral malaria from presumed viral encephalitis.",
"   </p>",
"   <p>",
"    Among survivors of cerebral malaria, neurologic sequelae are more common among children than adults (about 15 versus 3 percent, respectively). Residual deficits may include hemiplegia, cerebral palsy, cortical blindness, deafness, epilepsy, language deficit, and impaired cognition [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5543/abstract/12\">",
"     12",
"    </a>",
"    ]. Such sequelae are more likely among patients with other grave prognostic indicators including hypoglycemia, acidosis, severe anemia, repeated seizures, and deep coma.",
"   </p>",
"   <p>",
"    Risk factors for cerebral malaria include age (children and elderly), pregnancy, poor nutritional status, HIV infection, host genetic susceptibility, and history of splenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5543/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Among adults, cerebral malaria occurs more commonly in nonimmune individuals than in those living in highly endemic areas (where cerebral malaria is more common in children). In a study of 19,560 Kenyan children with malaria, neurologic involvement was observed in 48 percent of cases; presentation included seizures, prostration, impaired consciousness and agitation (38, 21, 13, and 3 percent of cases, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5543/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retinal hemorrhages may be observed in 30 to 40 percent of cases via pupillary dilation and indirect ophthalmoscopy; without pupillary dilation, this finding may be seen in approximately 15 percent of cases. Other funduscopic abnormalities include discrete spots of retinal opacification (30 to 60 percent), papilledema (8 percent among children, rare among adults), cotton wool spots (&lt;5 percent), and decolorization of a retinal vessel or segment of vessel (",
"    <a class=\"graphic graphic_picture graphicRef65241 \" href=\"UTD.htm?39/55/40820\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef64492 \" href=\"UTD.htm?29/19/30001\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef50690 \" href=\"UTD.htm?39/51/40753\">",
"     picture 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5543/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia is a common complication of severe malaria, although the usual signs (sweating, tachycardia, neurologic impairment) are difficult to distinguish from systemic symptoms due to severe malaria. Hypoglycemia occurs as a result of the following factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diminished hepatic gluconeogenesis",
"     </li>",
"     <li>",
"      Depletion of liver glycogen stores",
"     </li>",
"     <li>",
"      Increase in the consumption of glucose by the host (and, to a much lesser extent, the parasite)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       Quinine",
"      </a>",
"      induced hyperinsulinemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hypoglycemia is associated with a poor prognosis, particularly in children and pregnant women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acidosis is an important cause of death from severe malaria; it is caused by several factors, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anaerobic glycolysis in host tissues where sequestered parasites interfere with microcirculatory flow",
"     </li>",
"     <li>",
"      Parasite lactate production",
"     </li>",
"     <li>",
"      Hypovolemia",
"     </li>",
"     <li>",
"      Insufficient hepatic and renal lactate clearance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prognosis of severe acidosis is poor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Renal impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal impairment is common among adults with severe falciparum malaria; it is relatively rare among children. The pathogenesis of renal failure is uncertain but may be related to erythrocyte sequestration interfering with renal microcirculatory flow and metabolism. Other potential factors include hypovolemia and hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5543/abstract/18\">",
"     18",
"    </a>",
"    ]. Large amounts of hemoglobin and malarial pigments may be present in the urine secondary to intravascular hemolysis. This uncommon syndrome known as \"blackwater fever\" manifests in very dark urine following several attacks of falciparum malaria; mortality is high. Renal impairment can manifest as acute tubular necrosis (both clinically and pathologically), although renal cortical necrosis does not occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Noncardiogenic pulmonary edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noncardiogenic pulmonary edema (eg, adult respiratory distress syndrome) may be observed in adults with severe falciparum malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5543/abstract/19\">",
"     19",
"    </a>",
"    ]. The pathogenesis is uncertain but may be related to sequestration of parasitized red cells in the lungs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cytokine induced leakage from the pulmonary vasculature. This complication may develop even after several days of antimalarial therapy, and can be aggravated by overly vigorous administration of intravenous fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5543/abstract/10\">",
"     10",
"    </a>",
"    ]. Noncardiogenic pulmonary edema can also develop in otherwise uncomplicated vivax malaria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with severe anemia may present with deep, labored respirations. This is usually due to metabolic acidosis (often compounded by hypovolemia), although previously it has been attributed to \"anemic congestive cardiac failure.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hematologic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children in endemic areas with serial episodes of malaria infection may develop severe chronic anemia. In nonimmune individuals and in areas with unstable transmission, anemia can develop acutely. Anemia in the setting of malaria occurs as a result of the following factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemolysis of parasitized red cells",
"     </li>",
"     <li>",
"      Increased splenic sequestration and clearance of erythrocytes with diminished deformability",
"     </li>",
"     <li>",
"      Cytokine suppression of hematopoiesis",
"     </li>",
"     <li>",
"      Shortened erythrocyte survival",
"     </li>",
"     <li>",
"      Repeated infections and ineffective treatments",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mild thrombocytopenia and coagulopathy are common in the setting of falciparum malaria. Bleeding with evidence of disseminated intravascular coagulation occurs in &lt;5 percent of patients with severe malaria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Liver dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild jaundice due to hemolysis in malaria is common. Severe jaundice due to hemolysis, hepatocyte injury, and cholestasis may occur in the setting of P. falciparum infection; this manifestation is more common among adults than children. Liver dysfunction together with renal impairment and other organ dysfunction portends a poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5543/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Concomitant infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Septicemia may complicate severe malaria, particularly in children [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5543/abstract/20\">",
"     20",
"    </a>",
"    ]. In endemic areas, Salmonella bacteremia has been associated with P. falciparum infections [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5543/abstract/21\">",
"     21",
"    </a>",
"    ]. Chest infections and catheter-induced urinary tract infections are common among patients who are unconscious for &ge;3 days. Aspiration pneumonia may follow generalized seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     FEVER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early in the course of malaria infection, febrile paroxysms occur at irregular intervals each day. The temperature of nonimmune individuals and children may rise above 40&ordm;C and may occur in conjunction with tachycardia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    delirium. Febrile convulsions may occur among children in the setting of malaria due to any species. However, generalized seizures are associated with falciparum and may herald the development of cerebral malaria. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Cerebral malaria'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Later in the course of infection, rupture of infected red cells can become synchronous following concurrent schizont rupture and release of merozoites from erythrocytes (",
"    <a class=\"graphic graphic_figure graphicRef58397 \" href=\"UTD.htm?35/50/36647\">",
"     figure 1",
"    </a>",
"    ). Febrile paroxysms may occur every other day for P. vivax, P. ovale, and P. falciparum and every third day for P. malariae. Paroxysms occurring at regular intervals are more common in the setting of infection due to P. vivax or P. ovale than P. falciparum. With improvements in early diagnosis and treatment, this traditional description of cyclic fever is seen infrequently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CHILDREN VERSUS ADULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations of malaria vary between children and adults. Children with severe malaria often experience convulsions, coma, hypoglycemia, metabolic acidosis, severe anemia, and defects in cognition and other neurodevelopmental capacities. Findings observed more frequently among adults include severe jaundice, acute renal failure, and acute pulmonary edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women with falciparum malaria in areas of highly endemic, stable transmission tend to be asymptomatic, despite intense accumulation of parasitized erythrocytes in the placental microcirculation; anemia is common in these patients. Pregnant women with falciparum malaria in areas of low unstable transmission are prone to severe infection; they are vulnerable to high-level parasitemia with anemia, hypoglycemia, and acute pulmonary edema.",
"   </p>",
"   <p>",
"    Primigravid and secundigravid women and their fetuses are particularly vulnerable to falciparum malaria; fetal distress, premature labor, stillbirth, and low birth weight (average reduction 170 g) are common [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5543/abstract/9\">",
"     9",
"    </a>",
"    ]. P. vivax malaria in pregnancy is also associated with a reduction in birth weight (average reduction 110 g); this effect is more pronounced in multigravid than primigravid women.",
"   </p>",
"   <p>",
"    HIV infection in the setting of malaria and pregnancy increases the likelihood of congenital malaria infection and exacerbates the reduction in birth weight associated with malaria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/8/3209?source=see_link&amp;anchor=H14#H14\">",
"     \"HIV and malaria\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Malaria and pregnancy is discussed in further detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/33/16921?source=see_link\">",
"     \"Overview of malaria in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     RECRUDESCENCE OR RELAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both recrudescent and relapsing infections manifest as return of disease after its apparent cessation. Recrudescence occurs most often within days or weeks; relapse occurs within weeks or months. In recrudescence, parasites remain in the bloodstream undetected due to ineffective treatment or host immunological response (or both). In relapse, new hypnozoites are released from liver cells causing another parasitemia. P. falciparum is the usual cause of recrudescent infections, although P. malariae can remain dormant for years; P. vivax and P. ovale may cause relapse months after the primary blood stage infection is cured, as these species have hypnozoite forms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     COEXISITING CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There appears to be a biological association between malaria, HIV, malnutrition, and invasive bacterial infections. These conditions occur often in malarious areas as do geohelminths; the latter contribute greatly to anemia and malnutrition, especially in children [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5543/abstract/4,20\">",
"     4,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malaise, headache, fatigue, abdominal discomfort, and muscle aches followed by fever can resemble the symptoms of a viral illness. The headache of malaria may be severe, although there is no neck stiffness or photophobia as seen with bacterial or viral meningitis. Myalgia may be prominent but it is not usually as severe as in dengue fever, and the muscles are not tender as in leptospirosis or typhus. Patients with pneumonia may have intercostal retractions and other signs of labored breathing. Bacteremia may present with septic shock; confirmation requires culture equipment.",
"   </p>",
"   <p>",
"    Malaria is not associated with a rash (unlike meningococcal septicemia, typhus, enteric fever, viral exanthems, or drug reactions). Petechial hemorrhages in the skin or mucous membranes (features of viral hemorrhagic fevers and leptospirosis) occur only rarely in severe falciparum malaria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    Basics topics (see",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?3/47/3826?source=see_link\">",
"     \"Patient information: Malaria (The Basics)\"",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In areas where malaria is endemic, groups at high risk for severe malaria and its consequences include young children (6 to 36 months) and pregnant women. Older children and adults develop partial immunity after repeated infection and are at relatively low risk for severe disease. As disease incidence wanes, older age groups will become more susceptible due to decreasing immunity. Travelers to areas where malaria is endemic generally have no previous exposure to malaria parasites and are at very high risk for severe disease if infected with P. falciparum. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incubation period for P. falciparum infection is usually 12 to 14 days. Longer incubation periods are more likely in semi-immune individuals and individuals taking inadequate malaria prophylaxis at the time of infection. The relapsing malarias (P. vivax and P. ovale) can cause clinical illness several weeks or months after the initial infection due to presence of hypnozoites in the liver [",
"      <a class=\"abstract\" href=\"UTD.htm?5/26/5543/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incubation period'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Malaria should be suspected in patients with any febrile illness after exposure to a region where malaria is endemic. The initial symptoms and signs of malaria are nonspecific and may also include tachycardia, tachypnea, chills, malaise, fatigue, diaphoresis, headache, cough, anorexia, nausea, vomiting, abdominal pain, diarrhea, arthralgias, and myalgias. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Uncomplicated malaria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complicated or severe malaria is generally defined as acute malaria with hyperparasitemia (&ge;5 to 10 percent of RBCs infected)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      major signs of organ dysfunction. Features of complicated malaria may include cerebral malaria, hypoglycemia, acidosis, renal impairment, noncardiogenic pulmonary edema, anemia and other hematologic abnormalities, liver dysfunction, and concomitant infection. These are discussed in detail above. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Complicated malaria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common manifestations among children with severe malaria include convulsions, coma, hypoglycemia, metabolic acidosis, severe anemia, and neurodevelopmental sequelae. Findings observed more frequently among adults than children include severe jaundice, acute renal failure, and acute pulmonary edema. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Children versus adults'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of malaria includes viral infection, meningitis, pneumonia, bacteremia, leptospirosis, typhus, and enteric fever. Malaria can coexist with these entities, and with HIV, malnutrition, and intestinal geohelminths. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5543/abstract/1\">",
"      Wilson ME, Weld LH, Boggild A, et al. Fever in returned travelers: results from the GeoSentinel Surveillance Network. Clin Infect Dis 2007; 44:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5543/abstract/2\">",
"      Svenson JE, MacLean JD, Gyorkos TW, Keystone J. Imported malaria. Clinical presentation and examination of symptomatic travelers. Arch Intern Med 1995; 155:861.",
"     </a>",
"    </li>",
"    <li>",
"     White NJ, Breman JG. Harrisons Principles of Internal Medicine, 17th ed., Kasper, E Braunwald, AS Fauci, et al (Eds), McGraw Hill, New York 2008. p.1280.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5543/abstract/4\">",
"      Brooker S, Akhwale W, Pullan R, et al. Epidemiology of plasmodium-helminth co-infection in Africa: populations at risk, potential impact on anemia, and prospects for combining control. Am J Trop Med Hyg 2007; 77:88.",
"     </a>",
"    </li>",
"    <li>",
"     WHO guidelines for the treatment of malaria. Geneva, World Health Organization, 2010. file://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf (Accessed on December 30, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5543/abstract/6\">",
"      White NJ. The treatment of malaria. N Engl J Med 1996; 335:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5543/abstract/7\">",
"      Devarbhavi H, Alvares JF, Kumar KS. Severe falciparum malaria simulating fulminant hepatic failure. Mayo Clin Proc 2005; 80:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5543/abstract/8\">",
"      FIELD JW. Blood examination and prognosis in acute falciparum malaria. Trans R Soc Trop Med Hyg 1949; 43:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5543/abstract/9\">",
"      Steketee RW, Nahlen BL, Parise ME, Menendez C. The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg 2001; 64:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5543/abstract/10\">",
"      World Health Organization. Severe and complicated malaria. Trans R Soc Trop Med Hyg 2000; 94 Suppl:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5543/abstract/11\">",
"      Stanley J. Malaria. Emerg Med Clin North Am 1997; 15:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5543/abstract/12\">",
"      Mung'Ala-Odera V, Snow RW, Newton CR. The burden of the neurocognitive impairment associated with Plasmodium falciparum malaria in sub-saharan Africa. Am J Trop Med Hyg 2004; 71:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5543/abstract/13\">",
"      Jakka SR, Veena S, Atmakuri RM, Eisenhut M. Characteristic abnormalities in cerebrospinal fluid biochemistry in children with cerebral malaria compared to viral encephalitis. Cerebrospinal Fluid Res 2006; 3:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5543/abstract/14\">",
"      Reyburn H, Mbatia R, Drakeley C, et al. Association of transmission intensity and age with clinical manifestations and case fatality of severe Plasmodium falciparum malaria. JAMA 2005; 293:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5543/abstract/15\">",
"      Ranque S, Safeukui I, Poudiougou B, et al. Familial aggregation of cerebral malaria and severe malarial anemia. J Infect Dis 2005; 191:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5543/abstract/16\">",
"      Idro R, Ndiritu M, Ogutu B, et al. Burden, features, and outcome of neurological involvement in acute falciparum malaria in Kenyan children. JAMA 2007; 297:2232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5543/abstract/17\">",
"      Lewallen S, Bronzan RN, Beare NA, et al. Using malarial retinopathy to improve the classification of children with cerebral malaria. Trans R Soc Trop Med Hyg 2008; 102:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5543/abstract/18\">",
"      Barsoum RS. Malarial acute renal failure. J Am Soc Nephrol 2000; 11:2147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5543/abstract/19\">",
"      Taylor WR, Hanson J, Turner GD, et al. Respiratory manifestations of malaria. Chest 2012; 142:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5543/abstract/20\">",
"      Berkley JA, Bejon P, Mwangi T, et al. HIV infection, malnutrition, and invasive bacterial infection among children with severe malaria. Clin Infect Dis 2009; 49:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5543/abstract/21\">",
"      Morpeth SC, Ramadhani HO, Crump JA. Invasive non-Typhi Salmonella disease in Africa. Clin Infect Dis 2009; 49:606.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5709 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-F708DC0240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_26_5543=[""].join("\n");
var outline_f5_26_5543=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCUBATION PERIOD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Uncomplicated malaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Complicated malaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cerebral malaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Renal impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Noncardiogenic pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hematologic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Liver dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Concomitant infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      FEVER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CHILDREN VERSUS ADULTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      RECRUDESCENCE OR RELAPSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      COEXISITING CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5709\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5709|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/50/36647\" title=\"figure 1\">",
"      Malaria life cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5709|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/55/40820\" title=\"picture 1\">",
"      White-centered hemorrhages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/19/30001\" title=\"picture 2\">",
"      Vessel changes in optic fundi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/51/40753\" title=\"picture 3\">",
"      Retinal whitening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5709|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/38/15981\" title=\"table 1\">",
"      Features of malaria spp",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10248?source=related_link\">",
"      Diagnosis of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/8/3209?source=related_link\">",
"      HIV and malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/33/16921?source=related_link\">",
"      Overview of malaria in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4394?source=related_link\">",
"      Overview of non-falciparum malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/47/3826?source=related_link\">",
"      Patient information: Malaria (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13338?source=related_link\">",
"      Treatment of severe falciparum malaria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_26_5544="Furosemide: Pediatric drug information";
var content_f5_26_5544=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Furosemide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"    see \"Furosemide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/14/12518?source=see_link\">",
"    see \"Furosemide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F7305944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F174841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lasix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F174842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Furosemide&reg;;",
"     </li>",
"     <li>",
"      AVA-Furosemide;",
"     </li>",
"     <li>",
"      Bio-Furosemide;",
"     </li>",
"     <li>",
"      Dom-Furosemide;",
"     </li>",
"     <li>",
"      Furosemide Injection Sandoz Standard;",
"     </li>",
"     <li>",
"      Furosemide Injection, USP;",
"     </li>",
"     <li>",
"      Furosemide Special;",
"     </li>",
"     <li>",
"      Furosemide Special Injection;",
"     </li>",
"     <li>",
"      Lasix&reg;;",
"     </li>",
"     <li>",
"      Lasix&reg; Special;",
"     </li>",
"     <li>",
"      Novo-Semide;",
"     </li>",
"     <li>",
"      NTP-Furosemide;",
"     </li>",
"     <li>",
"      Nu-Furosemide;",
"     </li>",
"     <li>",
"      PMS-Furosemide;",
"     </li>",
"     <li>",
"      Teva-Furosemide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1058876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Diuretic, Loop",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Edema:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Doses of 1 mg/kg/dose 1-2 times/day have been used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Significant absorption within ECMO circuit; avoid administration directly into circuit; high doses may be required for adequate diuretic effect (Buck, 2003):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     GA &lt;31 weeks: 1 mg/kg/dose every 24 hours; accumulation and increased risk of toxicity may be observed with doses &gt;2 mg/kg or doses of 1 mg/kg given more frequently than every 24 hours (Mirochnick, 1988)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     GA &ge;31 weeks: 1-2 mg/kg/dose every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous I.V. infusion: 0.2 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     , increase in 0.1 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     increments every 12-24 hours to a maximum infusion rate of 0.4 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     (Luciani, 1997; Schoemaker, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pulmonary edema: Inhalation: 1-2 mg/kg/dose diluted in 2 mL NS as a single dose (Brion, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1058869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"      see \"Furosemide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 2 mg/kg once daily; if ineffective, may increase in increments of 1-2 mg/kg/dose every 6-8 hours; not to exceed 6 mg/kg/dose. In most cases, it is not necessary to exceed individual doses of 4 mg/kg or a dosing frequency of once or twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., I.V.: 1-2 mg/kg/dose every 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous infusion: 0.05 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ; titrate dosage to clinical effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Edema, heart failure:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: Initial: 20-80 mg/dose with the same dose repeated or increased in increments of 20-40 mg/dose at intervals of 6-8 hours; usual maintenance dose interval is once or twice daily; may be titrated up to 600 mg/day with severe edematous states.",
"     <b>",
"      Note:",
"     </b>",
"     May also be given on 2-4 consecutive days every week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M., I.V.: 20-40 mg/dose; repeat in 1-2 hours as needed and increase by 20 mg/dose until the desired effect has been obtained; usual dosing interval: 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous I.V. infusion: Initial I.V. bolus dose of 20-40 mg over 1-2 minutes, followed by continuous I.V. infusion doses of 10-40 mg/",
"     <b>",
"      hour",
"     </b>",
"     . If urine output is &lt;1 mL/kg/",
"     <b>",
"      hour",
"     </b>",
"     , increase as necessary to a maximum of 80-160 mg/",
"     <b>",
"      hour",
"     </b>",
"     . The risk associated with higher infusion rates (80-160 mg/",
"     <b>",
"      hour",
"     </b>",
"     ) must be weighed against alternative strategies.",
"     <b>",
"      Note:",
"     </b>",
"     ACC/AHA 2005 guidelines for chronic HF recommend 40 mg I.V. dose followed by 10-40 mg/",
"     <b>",
"      hour",
"     </b>",
"     infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acute pulmonary edema: I.V.: 40 mg over 1-2 minutes; if response not adequate within 1 hour, may increase dose to 80 mg;",
"     <b>",
"      Note:",
"     </b>",
"     ACC/AHA 2005 guidelines for chronic HF recommend a maximum single dose of 160-200 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hypertension, resistant (JNC 7): Oral: 20-80 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Refractory CHF: Oral, I.V.: Doses up to 8 g/day have been used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Adults: Acute renal failure: High doses (up to 1-3 g/day - oral/I.V.) have been used to initiate desired response; avoid use in oliguric states",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not removed by hemo- or peritoneal dialysis; supplemental dose is not necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic disease:",
"     </b>",
"     Diminished natriuretic effect with increased sensitivity to hypokalemia and volume depletion in cirrhosis; monitor effects, particularly with high doses",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F174813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 10 mg/mL (2 mL, 4 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 40 mg/5 mL (5 mL, 500 mL); 10 mg/mL (4 mL, 60 mL, 120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 20 mg, 40 mg, 80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lasix&reg;: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lasix&reg;: 40 mg, 80 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F174798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1058880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May administer with food or milk to decrease GI distress",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: I.V.: May be administered undiluted direct I.V. at a maximum rate of 0.5 mg/kg/minute (not to exceed 4 mg/minute); may also be diluted for infusion 1-2 mg/mL (maximum concentration: 10 mg/mL) over 10-15 minutes (following maximum rate as above); in adults, 20-40 mg undiluted solution may be administered over 1-2 minutes",
"    </p>",
"   </div>",
"   <div class=\"block uicn drugH1Div\" id=\"F14472641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     2 mg/mL",
"     <b>",
"      or",
"     </b>",
"     undiluted as 10 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14472640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     1 mg/mL",
"     <b>",
"      or",
"     </b>",
"     2 mg/mL",
"     <b>",
"      or",
"     </b>",
"     undiluted as 10 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F174900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      20",
"     </sub>",
"     W, mannitol 20%, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, alprostadil, amifostine, amphotericin B cholesteryl sulfate complex, anidulafungin, argatroban, aztreonam, bivalirudin, bleomycin, calcium gluconate, cefepime, ceftazidime, cefuroxime, cisplatin, cladribine, cyclophosphamide, cytarabine, dexmedetomidine, docetaxel, doripenem, doxorubicin liposome, epinephrine, etoposide phosphate, fentanyl, fludarabine, fluorouracil, foscarnet, gallium nitrate, granisetron, heparin, hetastarch in lactated electrolyte (Hextend&reg;), hydrocortisone sodium succinate, hydromorphone, indomethacin, insulin (regular), leucovorin calcium, linezolid, lorazepam, magnesium sulfate, melphalan, meropenem, methotrexate, micafungin, mitomycin, nitroprusside, norepinephrine, oxaliplatin, paclitaxel, piperacillin/tazobactam, potassium chloride, procainamide, propofol, ranitidine, remifentanil, sargramostim, sodium bicarbonate, tacrolimus, teniposide, thiopental, thiotepa, tirofiban, tobramycin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amsacrine, azithromycin, caffeine citrate, caspofungin, chlorpromazine, ciprofloxacin, diltiazem, droperidol, eptifibatide, esmolol, fenoldopam, filgrastim, fluconazole, gemcitabine, gentamicin, haloperidol, hydralazine, idarubicin, labetalol, levofloxacin, methocarbamol, metoclopramide, midazolam, milrinone, nesiritide, nicardipine, ondansetron, phenylephrine, promethazine, quinidine gluconate, telavancin, vecuronium, vinblastine, vincristine, vinorelbine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Amikacin, amiodarone, cisatracurium, dobutamine, dopamine, doxorubicin HCl, drotrecogin alfa, famotidine, kanamycin, meperidine, metoprolol, morphine, nitroglycerin, pantoprazole, vasopressin, vitamin B complex with C.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Bleomycin, cisplatin, cyclophosphamide, dexamethasone sodium phosphate, fluorouracil, heparin, leucovorin calcium, methotrexate, mitomycin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Caffeine citrate, diphenhydramine, dimenhydrinate, doxapram, doxorubicin HCl, droperidol, meperidine, metoclopramide, milrinone, pantoprazole, protamine, thiamine, vinblastine, vincristine.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1058872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Furosemide injection should be stored at controlled room temperature and protected from light; exposure to light may cause discoloration; do not use furosemide solutions if they have a yellow color; refrigeration may result in precipitation or crystallization, however, resolubilization at room temperature or warming may be performed without affecting the stability; furosemide solutions are unstable in acidic media but very stable in basic media; I.V. infusion solution mixed in NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W solution is stable for 24 hours at room temperature",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Tablets: Store at 25&ordm;C (77&ordm;F); excursions permitted to 15&ordm;C to 30&ordm;C (59&ordm;F to 89&ordm;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1058879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of edema associated with heart failure and hepatic or renal disease; used alone or in combination with antihypertensives in treatment of hypertension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F174902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Furosemide may be confused with famotidine, finasteride, fluconazole, FLUoxetine, fosinopril, loperamide, torsemide",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lasix&reg; may be confused with Lanoxin&reg;, Lidex&reg;, Lomotil&reg;, Lovenox&reg;, Luvox&reg;, Luxiq&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lasix [U.S., Canada, and multiple international markets] may be confused with Esidrex brand name for hydrochlorothiazide [multiple international markets]; Esidrix brand name for hydrochlorothiazide [Germany]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Urex [Australia, Hong Kong, Turkey] may be confused with Eurax brand name for crotamiton [U.S., Canada, and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F174899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Acute hypotension, chronic aortitis, necrotizing angiitis, orthostatic hypotension, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fever, headache, hepatic encephalopathy, lightheadedness,  restlessness, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Bullous pemphigoid, cutaneous vasculitis, drug rash with eosinophilia and systemic symptoms (DRESS), erythema multiforme, exanthematous pustulosis (generalized), exfoliative dermatitis, photosensitivity, pruritus, purpura, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Cholesterol and triglycerides increased, glucose tolerance test altered, gout, hyperglycemia, hyperuricemia, hypocalcemia, hypochloremia, hypokalemia, hypomagnesemia, hyponatremia, metabolic alkalosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, cramping, diarrhea, nausea, oral and gastric irritation, pancreatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary bladder spasm, urinary frequency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematological: Agranulocytosis (rare), anemia, aplastic anemia (rare), eosinophilia, hemolytic anemia, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Intrahepatic cholestatic jaundice, ischemic hepatitis, liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site pain (following I.M. injection), thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle spasm, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, xanthopsia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hearing impairment (reversible or permanent with rapid I.V. or I.M. administration), tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Allergic interstitial nephritis, fall in glomerular filtration rate and renal blood flow (due to overdiuresis), glycosuria, transient rise in BUN",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis (rare), exacerbate or activate systemic lupus erythematosus",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1058884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to furosemide or any component of the formulation; anuria",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1058868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with cirrhosis; avoid sudden changes in fluid and electrolyte balance and acid/base status which may lead to hepatic encephalopathy. Administration with an aldosterone antagonist or potassium-sparing diuretic may provide additional diuretic efficacy and maintain normokalemia. Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonylurea allergy is specifically contraindicated in product labeling; a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted. Oral solution may contain sorbital which can cause diarrhea.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1058867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Loop diuretics are potent diuretics; excess amounts can lead to profound diuresis with fluid and electrolyte loss",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; monitor for and correct electrolyte disturbances; adjust dose to avoid dehydration. Potassium supplementation and/or use of potassium-sparing diuretics may be necessary to prevent hypokalemia. Monitor fluid status and renal function in an attempt to prevent oliguria, azotemia, and reversible increases in BUN and creatinine; close medical supervision of aggressive diuresis required. Coadministration of antihypertensives may increase the risk of hypotension.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Ototoxicity has been demonstrated following administration of furosemide and other loop diuretics. Other possible risk factors may include use in renal impairment, excessive doses, rapid injection, and concurrent use of other ototoxins (eg, aminoglycosides).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Oral solution may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; use oral solutions containing propylene glycol with caution in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F174807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Loop Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May decrease the serum concentration of Furosemide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Loop Diuretics may enhance the adverse/toxic effect of Allopurinol. Loop Diuretics may increase the serum concentration of Allopurinol. Specifically, Loop Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Loop Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Loop Diuretics may enhance the adverse/toxic effect of Cardiac Glycosides. This by increasing the risk of hypokalemia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloral Hydrate: Furosemide may enhance the adverse/toxic effect of Chloral Hydrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CISplatin: Loop Diuretics may enhance the nephrotoxic effect of CISplatin. Loop Diuretics may enhance the ototoxic effect of CISplatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May enhance the adverse/toxic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Loop Diuretics may enhance the QTc-prolonging effect of Dofetilide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethacrynic Acid: Furosemide may enhance the ototoxic effect of Ethacrynic Acid.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the diuretic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: Loop Diuretics may diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Loop Diuretics may decrease the serum concentration of Lithium. Loop Diuretics may increase the serum concentration of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: May diminish the therapeutic effect of Loop Diuretics. Methotrexate may increase the serum concentration of Loop Diuretics. Loop Diuretics may increase the serum concentration of Methotrexate. Management: Monitor for increased methotrexate and/or loop diuretic levels/toxicity with concomitant use of these agents and monitor for decreased therapeutic effects of loop diuretics. Methotrexate and/or loop diuretic dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Loop Diuretics may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the diuretic effect of Loop Diuretics. Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the diuretic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May enhance the adverse/toxic effect of Loop Diuretics. Probenecid may diminish the diuretic effect of Loop Diuretics. Probenecid may increase the serum concentration of Loop Diuretics. Management: Monitor for decreased diuretic effects or increased adverse effects of loop diuretics with concomitant use of probenecid. Bumetanide prescribing information recommends against concomitant use of probenecid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RisperiDONE: Loop Diuretics may enhance the adverse/toxic effect of RisperiDONE.  Management: Consider alternative diuretic therapy (e.g., thiazides) to more potent diuretics (e.g., furosemide) in elderly patients receiving risperidone. Patients who require use of more potent diuretic therapy should be closely monitored and adequately hydrated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the serum concentration of Furosemide. Sucralfate may impair the absorption of furosemide. Management: Avoid concomitant oral administration of furosemide and sucralfate. Separate administration by at least 2 hours. Does not apply to parenterally administered furosemide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Loop Diuretics may enhance the hypokalemic effect of Topiramate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1058887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not mix with acidic solutions; limit intake of natural licorice (causes sodium and water retention and increases potassium loss)",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F174809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F174823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated maternal death, fetal toxicity, and fetal loss. There are no adequate and well-controlled studies in pregnant women. Crosses the placenta. Increased fetal urine production, electrolyte disturbances reported. Generally, use of diuretics during pregnancy is avoided due to risk of decreased placental perfusion. Monitor fetal growth if used during pregnancy; may increase birth weight.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1058875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum electrolytes, renal function, blood pressure, hearing (if high dosages used)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1058866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits reabsorption of sodium and chloride in the ascending loop of Henle and distal renal tubule, interfering with the chloride-binding cotransport system, thus causing increased excretion of water, potassium, sodium, chloride, magnesium, and calcium",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1058882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Within 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Oral: Within 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 2 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1058883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: 65% in patients with normal renal function, decreases to 45% in patients with renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Normal renal function: 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal failure: 9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 50% of oral dose and 80% of I.V. dose excreted unchanged in the urine within 24 hours; the remainder is eliminated by other nonrenal pathways including liver metabolism and excretion of unchanged drug in feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1058874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/14/12518?source=see_link\">",
"      see \"Furosemide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1058885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Single dose studies utilizing nebulized furosemide at 1-2 mg/kg/dose (diluted to a final volume of 2 mL with NS) have been shown to be effective in improving pulmonary function in preterm infants with bronchopulmonary dysplasia undergoing mechanical ventilation; no diuresis or systemic side effects were noted",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"'Inactive' Ingredients in Pharmaceutical Products: Update (Subject Review),\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1997, 99(2):268-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/26/5544/abstract-text/9024461/pubmed\" id=\"9024461\" target=\"_blank\">",
"        9024461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aufricht C, Votava F, Marx M, et al, \"Intratracheal Furosemide in Infants After Cardiac Surgery: Its Effects on Lung Mechanics and Urinary Output, and Its Levels in Plasma and Tracheal Aspirate,\"",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 1997, 23(9):992-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/26/5544/abstract-text/9347373/pubmed\" id=\"9347373\" target=\"_blank\">",
"        9347373",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brion LP, Primhak RA, and Yong W, \"Aerosolized Diuretics for Preterm Infants With (or Developing) Chronic Lung Disease,\"",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2006, 3:CD001694.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/26/5544/abstract-text/16855973/pubmed\" id=\"16855973\" target=\"_blank\">",
"        16855973",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buck ML, \"Pharmacokinetic Changes During Extracorporeal Membrane Oxygenation: Implications for Drug Therapy of Neonates,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2003, 42(5):403-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/26/5544/abstract-text/12739981/pubmed\" id=\"12739981\" target=\"_blank\">",
"        12739981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/26/5544/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Copeland JG, Campbell DW, Plachetka JR, et al, &ldquo;Diuresis With Continuous Infusion of Furosemide After Cardiac Surgery,&rdquo;",
"      <i>",
"       Am J Surg",
"      </i>",
"      , 1983, 146(6):796-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/26/5544/abstract-text/6650766/pubmed\" id=\"6650766\" target=\"_blank\">",
"        6650766",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Engle MA, Lewy JE, Lewy PR, et al, \"The Use of Furosemide in the Treatment of Edema in Infants and Children,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1978, 62(5):811-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/26/5544/abstract-text/724325/pubmed\" id=\"724325\" target=\"_blank\">",
"        724325",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, \"ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult-Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure),\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 46(6):1116-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/26/5544/abstract-text/16168273 /pubmed\" id=\"16168273 \" target=\"_blank\">",
"        16168273",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute for Safe Medication Practices (ISMP), \"Standard Concentrations of Neonatal Drug Infusions,\"",
"      <i>",
"       ISMP",
"      </i>",
"      , 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Luciani GB, Nichani S, Chang AC, et al, \"Continuous Versus Intermittent Furosemide Infusion in Critically Ill Infants After Open Heart Operations,\"",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 1997, 64(4):1133-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/26/5544/abstract-text/9354540/pubmed\" id=\"9354540\" target=\"_blank\">",
"        9354540",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mirochnick MH, Miceli JJ, Kramer PA, et al, \"Furosemide Pharmacokinetics in Very Low Birth Weight Infants,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1988, 112(4):653-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/26/5544/abstract-text/3351693/pubmed\" id=\"3351693\" target=\"_blank\">",
"        3351693",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pai VB and Nahata MC, &ldquo;Aerosolized Furosemide in the Treatment of Acute Respiratory Distress and Possible Bronchopulmonary Dysplasia in Preterm Neonates,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2000, 34(3):386-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/26/5544/abstract-text/ 10917388 /pubmed\" id=\" 10917388 \" target=\"_blank\">",
"        10917388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prandota J, \"Clinical Pharmacology of Furosemide in Children: A Supplement,\"",
"      <i>",
"       Am J Ther",
"      </i>",
"      , 2001, 8(4):275-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/26/5544/abstract-text/11441327/pubmed\" id=\"11441327\" target=\"_blank\">",
"        11441327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rastogi A, Luayon M, Ajayi OA, et al, &ldquo;Nebulized Furosemide in Infants With Bronchopulmonary Dysplasia,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1994, 125(6 Pt 1):976-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/26/5544/abstract-text/ 7996373 /pubmed\" id=\" 7996373 \" target=\"_blank\">",
"        7996373",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rudy DW, Voelker JR, Greene PK, et al, &ldquo;Loop Diuretics for Chronic Renal Insufficiency: A Continuous Infusion Is More Efficacious Than Bolus Therapy,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1991, 115(5):360-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/26/5544/abstract-text/1863026/pubmed\" id=\"1863026\" target=\"_blank\">",
"        1863026",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schoemaker RC, van dDer Vorst MM, van Heel IR, et al, \"Development of an Optimal Furosemide Infusion Strategy in Infants With Modeling and Simulation,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2002, 72(4):383-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/26/5544/abstract-text/12386640/pubmed\" id=\"12386640\" target=\"_blank\">",
"        12386640",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13329 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-1420615FBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_26_5544=[""].join("\n");
var outline_f5_26_5544=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7305944\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174841\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174842\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058876\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442564\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058869\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174813\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174798\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058880\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472641\">",
"      Usual Infusion Concentrations: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472640\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174900\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058872\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058879\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174902\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174899\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058884\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058868\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058867\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299370\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174807\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058887\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174809\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174823\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058875\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058866\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058882\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058883\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058874\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058885\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13329\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13329|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=related_link\">",
"      Furosemide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/14/12518?source=related_link\">",
"      Furosemide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_26_5545="Diagnosis and differential diagnosis of primary hyperparathyroidism";
var content_f5_26_5545=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and differential diagnosis of primary hyperparathyroidism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/26/5545/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/26/5545/contributors\">",
"     Ghada El-Hajj Fuleihan, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/26/5545/contributors\">",
"     Shonni J Silverberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/26/5545/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/26/5545/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/26/5545/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/26/5545/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/26/5545/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of hyperparathyroidism is usually first suspected because of the finding of an elevated serum calcium concentration. If hypercalcemia is confirmed on a repeat sample, all of its causes should be considered (",
"    <a class=\"graphic graphic_table graphicRef66865 \" href=\"UTD.htm?28/40/29324\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=see_link\">",
"     \"Etiology of hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The serum parathyroid hormone (PTH) concentration should then be measured using a two-site immunoradiometric sandwich assay. The diagnosis of primary hyperparathyroidism is usually made by finding a frankly elevated PTH concentration or one that is within the normal range but inappropriately elevated given the patient's hypercalcemia (",
"    <a class=\"graphic graphic_figure graphicRef50252 \" href=\"UTD.htm?33/8/33935\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The diagnosis and differential diagnosis of primary hyperparathyroidism will be discussed here. Other aspects of primary hyperparathyroidism are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=see_link\">",
"     \"Clinical manifestations of primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30361?source=see_link\">",
"     \"Pathogenesis and etiology of primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link\">",
"     \"Management of primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18377?source=see_link\">",
"     \"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/0/35850?source=see_link\">",
"     \"Parathyroid exploration for primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common clinical presentation of primary hyperparathyroidism is asymptomatic hypercalcemia. The diagnosis of primary hyperparathyroidism is usually made by finding a frankly elevated PTH concentration or one that is within the normal range but inappropriately elevated given the patient's hypercalcemia (",
"    <a class=\"graphic graphic_figure graphicRef50252 \" href=\"UTD.htm?33/8/33935\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef62624 \" href=\"UTD.htm?42/48/43791\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Measurement of serum calcium",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single elevated serum calcium concentration should be repeated to confirm the presence of hypercalcemia. The total serum calcium concentration should be used for both the initial and the repeat serum calcium measurements. If a laboratory known to measure ionized calcium reliably is available, some authorities prefer to measure the ionized calcium, although this usually adds little in patients with normal serum albumin concentrations and no abnormalities in acid base balance [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5545/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20934?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnostic approach to hypercalcemia\", section on 'Interpretation of serum calcium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One circumstance in which ionized calcium measurements may be a useful adjunct to diagnosis is in patients with normocalcemic primary hyperparathyroidism. In one series, 12 of 60 patients had a raised serum concentration of ionized calcium in the presence of a normal total serum calcium concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5545/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Normocalcemic primary hyperparathyroidism versus secondary hyperparathyroidism'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If available, previous values for serum calcium should be reviewed. The presence of longstanding asymptomatic hypercalcemia is more suggestive of primary hyperparathyroidism and also raises the possibility of familial hypocalciuric hypercalcemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Measurement of PTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The accurate measurement of serum PTH has been greatly simplified by the use of immunoradiometric (IRMA) and immunochemiluminescent assays [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5545/abstract/3\">",
"     3",
"    </a>",
"    ]. These tests measure intact PTH by using antibodies directed simultaneously at both the N&ndash; and the C&ndash;terminal regions of the PTH molecule. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/58/21416?source=see_link\">",
"     \"Parathyroid hormone assays and their clinical use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 80 to 90 percent of patients with primary hyperparathyroidism have high serum PTH concentrations (normal range 10 to 60",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef50252 \" href=\"UTD.htm?33/8/33935\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5545/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In one report, as an example, the average serum calcium and PTH concentrations in patients with asymptomatic hyperparathyroidism were 11",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and 120",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5545/abstract/5\">",
"     5",
"    </a>",
"    ]. However, 10 to 20 percent of patients have serum PTH values that are only minimally elevated or normal, ranging from 35 to 65",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5545/abstract/4\">",
"     4",
"    </a>",
"    ]. These \"normal\" values in the presence of hypercalcemia are inappropriately high; normal subjects given calcium intravenously have suppressed serum PTH concentrations (below 10",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    and patients with nonparathyroid hypercalcemia virtually always have values below 20 to 25",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef50252 \" href=\"UTD.htm?33/8/33935\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5545/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Rarely, a patient with proven primary hyperparathyroidism has a serum intact PTH concentration in the lower half of the normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5545/abstract/8\">",
"     8",
"    </a>",
"    ] or one that is undetectable [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5545/abstract/9\">",
"     9",
"    </a>",
"    ]. In the latter report, the patient had a biologically active PTH fragment, which was undetectable with the intact PTH assay. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/58/21416?source=see_link&amp;anchor=H7#H7\">",
"     \"Parathyroid hormone assays and their clinical use\", section on 'PTH fragments'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The immunoradiometric assays (second generation PTH assays) that replaced older radioimmunoassays (first generation PTH assays) for PTH were touted as measuring \"intact\" PTH molecule. It is now recognized that second-generation PTH assays detect not only intact 1-84 PTH, but also large carboxyterminal fragments (such as 7-84) of PTH. Some of these fragments may be biologically inactive, while others may inhibit osteoclastic bone resorption, inhibit the formation of mature osteoclasts, and have hypocalcemic properties. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/58/21416?source=see_link&amp;anchor=H7#H7\">",
"     \"Parathyroid hormone assays and their clinical use\", section on 'PTH fragments'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Newer third-generation assays that detect exclusively the biologically active PTH 1-84 (whole PTH or bioactive PTH) require both the extreme amino-terminal and carboxy-terminal ends of the molecule for detection. Some data suggest these assays may be superior in patients with renal failure, for intraoperative PTH monitoring, and for initial diagnosis in patients with primary hyperparathyroidism and inappropriately \"normal\" serum PTH concentrations in second generation IRMA assays. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/58/21416?source=see_link&amp;anchor=H10#H10\">",
"     \"Parathyroid hormone assays and their clinical use\", section on 'Clinical use of PTH assays'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although limited data [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5545/abstract/10\">",
"     10",
"    </a>",
"    ] suggest that PTH is increased in a higher proportion of patients with primary hyperparathyroidism using the PTH (1-84) assay, several other studies have found no increase in diagnostic utility [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5545/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Thus, either intact PTH (second-generation PTH assay) or PTH (1-84) assays (third generation PTH assays) can be used for diagnosis of hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5545/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the most common clinical presentation of primary hyperparathyroidism is asymptomatic hypercalcemia with an elevated or high-normal intact PTH concentration, the presentation may be atypical. Atypical presentations include a spectrum of disturbances in calcium homeostasis, ranging from symptomatic severe hypercalcemia (parathyroid crisis) to normocalcemic primary hyperparathyroidism. Laboratory testing often can distinguish atypical presentations of primary hyperparathyroidism from other diseases, such as malignancy, familial hypocalciuric hypercalcemia (FHH), and secondary hyperparathyroidism (",
"    <a class=\"graphic graphic_table graphicRef71910 \" href=\"UTD.htm?22/17/22812\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In primary hyperparathyroidism and FHH, the calcium and PTH levels are usually simultaneously elevated. Other less common causes of hypercalcemia, including milk-alkali syndrome, granulomatous disease, and hypervitaminosis D, are associated with suppressed rather than elevated PTH concentrations. They are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=see_link\">",
"     \"Etiology of hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20934?source=see_link\">",
"     \"Diagnostic approach to hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary hyperparathyroidism and malignancy are the most common causes of hypercalcemia, accounting for more than 90 percent of cases (",
"    <a class=\"graphic graphic_table graphicRef66865 \" href=\"UTD.htm?28/40/29324\">",
"     table 1",
"    </a>",
"    ). It is usually not difficult to differentiate between them. Malignancy is often evident clinically by the time it causes hypercalcemia, and patients with hypercalcemia of malignancy have higher calcium concentrations and are more symptomatic from hypercalcemia than individuals with primary hyperparathyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=see_link\">",
"     \"Hypercalcemia of malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, it may be difficult to differentiate the two problems clinically when the presentation is less typical. As an example, some patients with occult malignancy may present with mild hypercalcemia. Alternatively, patients with hyperparathyroidism can occasionally have acute onset of severe, symptomatic hypercalcemia (parathyroid crisis). In these cases, measurement of intact PTH will usually distinguish the two diseases. Intact PTH concentrations are generally undetectable or very low in hypercalcemia of malignancy and are elevated or high-normal in primary hyperparathyroidism (",
"    <a class=\"graphic graphic_table graphicRef71910 \" href=\"UTD.htm?22/17/22812\">",
"     table 2",
"    </a>",
"    ). It is uncommon for patients with hypercalcemia of malignancy to have elevated PTH levels, but this finding may occur rarely in individuals with hypercalcemia of malignancy and concomitant primary hyperparathyroidism or in individuals with PTH secreting tumors, which are also rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=see_link&amp;anchor=H8#H8\">",
"     \"Hypercalcemia of malignancy\", section on 'Ectopic PTH secretion'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=see_link&amp;anchor=H9#H9\">",
"     \"Hypercalcemia of malignancy\", section on 'Coexisting primary hyperparathyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Familial hypocalciuric hypercalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial hypocalciuric hypercalcemia (FHH) is due to an inactivating mutation in the calcium-sensing receptor in the parathyroid glands and the kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5545/abstract/14\">",
"     14",
"    </a>",
"    ]. A family history of hypercalcemia, especially in young children, and the absence of symptoms and signs of hypercalcemia (such as anorexia, neuromuscular symptoms, and polyuria) are characteristic of this disorder.",
"   </p>",
"   <p>",
"    Fifteen to 20 percent of patients with FHH may have a mildly elevated PTH concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5545/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. In these individuals, it may be difficult to distinguish asymptomatic primary hyperparathyroidism from FHH. It is important to make this distinction, however, because FHH is a benign inherited condition that typically does not require parathyroidectomy, nor will it be cured by it.",
"   </p>",
"   <p>",
"    The major feature that distinguishes FHH from primary hyperparathyroidism is a low urine calcium excretion and",
"    <span class=\"nowrap\">",
"     Ca/Cr",
"    </span>",
"    clearance ratio (",
"    <a class=\"graphic graphic_table graphicRef71910 \" href=\"UTD.htm?22/17/22812\">",
"     table 2",
"    </a>",
"    ). In contrast, most patients with primary hyperparathyroidism have either normal or elevated urinary calcium excretion. Because the calcium-sensing receptor is a cation receptor, urinary magnesium excretion parallels calcium excretion and is therefore low in FHH in contrast to primary hyperparathyroidism. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Measurement of urinary calcium excretion'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=see_link&amp;anchor=H11#H11\">",
"     \"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia\", section on 'Distinction from primary hyperparathyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two drugs deserve special consideration when evaluating a patient for hyperparathyroidism: thiazide diuretics and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Thiazide diuretics reduce urinary calcium excretion and therefore can cause mild hypercalcemia (up to 11.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.9",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=see_link\">",
"     \"Etiology of hypercalcemia\"",
"    </a>",
"    .) In addition, some patients with hyperparathyroidism may be prescribed thiazides, which may elevate the serum calcium further and thereby unmask the hyperparathyroidism. Following discontinuation of the drug, these individuals remain hypercalcemic, although perhaps less so, and are found to have surgically proven hyperparathyroidism. Thus, if a patient taking a thiazide is found to be hypercalcemic, the drug should be withdrawn, if possible, and calcium and PTH assessed three months later. Persistent hypercalcemia (with elevated or high-normal PTH) after drug withdrawal suggests that the thiazide has unmasked primary hyperparathyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30361?source=see_link&amp;anchor=H22#H22\">",
"     \"Pathogenesis and etiology of primary hyperparathyroidism\", section on 'Thiazide therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    decreases parathyroid gland sensitivity to calcium, shifting the calcium-PTH curve to the right (",
"    <a class=\"graphic graphic_figure graphicRef66597 \" href=\"UTD.htm?12/41/12958\">",
"     figure 2",
"    </a>",
"    ). Lithium may also reduce urinary calcium excretion. Lithium is thought to affect calcium-PTH dynamics through an action downstream of the calcium-sensing receptor, but the exact locus is still unknown. Some patients taking lithium develop hypercalcemia and hypocalciuria, and a subset of these individuals has high serum PTH concentrations. If the lithium can be stopped without exacerbating the psychiatric condition, the hypercalcemia may resolve. Following discontinuation, the serum calcium concentration is more likely to normalize if the duration of lithium use had been relatively short, eg, less than a few years, but less likely if it had been longer, eg, more than 10 years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30361?source=see_link&amp;anchor=H23#H23\">",
"     \"Pathogenesis and etiology of primary hyperparathyroidism\", section on 'Lithium therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36744?source=see_link&amp;anchor=H12#H12\">",
"     \"Parathyroid hormone secretion and action\", section on 'Lithium and PTH secretion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Normocalcemic primary hyperparathyroidism versus secondary hyperparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally, patients with primary hyperparathyroidism have normal total and ionized calcium concentrations (normocalcemic primary hyperparathyroidism). These patients typically come to medical attention in the setting of an evaluation for low bone mineral density. In these cases, it may be difficult to distinguish secondary hyperparathyroidism from early primary hyperparathyroidism because the biochemical findings may be similar.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Secondary hyperparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary hyperparathyroidism occurs when the parathyroid gland appropriately responds to a reduced level of extracellular calcium. PTH concentrations rise, and calcium is mobilized by increasing intestinal absorption (via increase in calcitriol) and by increasing bone resorption. Thus, it is characterized biochemically by elevated PTH and normal or low serum calcium concentrations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link&amp;anchor=H2#H2\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\", section on 'Overview of secondary hyperparathyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Secondary hyperparathyroidism may occur in patients with renal failure and impaired calcitriol (1,25 dihydroxyvitamin D) production, as well as in individuals with inadequate calcium intake or absorption, as can occur with vitamin D deficiency or with gastrointestinal diseases causing malabsorption (",
"    <a class=\"graphic graphic_table graphicRef73157 \" href=\"UTD.htm?22/29/23003\">",
"     table 3",
"    </a>",
"    ). Assessment of renal function (serum creatinine), vitamin D status (25-hydroxyvitamin D, 25OHD), and calcium sufficiency (urinary calcium excretion) may help differentiate normocalcemic primary and secondary hyperparathyroidism. Further assessment and work-up for specific gastrointestinal disorders is generally undertaken only when the clinical suspicion is high.",
"   </p>",
"   <p>",
"    Some patients may have more than one condition leading to increased PTH secretion. Co-existing primary hyperparathyroidism and vitamin D deficiency is not uncommon. When this occurs, the serum calcium level in the primary hyperparathyroid patient may be reduced (into the normal range in some cases) due to vitamin D deficiency. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Vitamin D metabolites'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Normocalcemic primary hyperparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasingly, patients undergoing evaluation for low bone density or other conditions may have PTH levels drawn in the absence of hypercalcemia. An international panel of experts recognized a new phenotype of primary hyperparathyroidism in which PTH levels are elevated but serum calcium is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5545/abstract/18\">",
"     18",
"    </a>",
"    ]. In order to make this diagnosis, certain conditions must be met. In particular, all secondary causes for hyperparathyroidism (",
"    <a class=\"graphic graphic_table graphicRef73157 \" href=\"UTD.htm?22/29/23003\">",
"     table 3",
"    </a>",
"    ) must be ruled out, and ionized calcium levels should be normal. The most common explanation for the finding of an elevated PTH and normal serum calcium remains concomitant hypercalcemic primary hyperparathyroidism and vitamin D deficiency.",
"   </p>",
"   <p>",
"    Patients without an apparent secondary cause may have a \"forme fruste\" of primary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5545/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. It might be expected that early in the natural history of primary hyperparathyroidism, elevated PTH levels would precede the development of overt hypercalcemia. In these patients, the serum calcium concentration would be expected to rise above the upper limit of normal when followed over time.",
"   </p>",
"   <p>",
"    In one prospective study of 37 patients with normocalcemic hyperparathyroidism, 41 percent developed evidence for progressive hyperparathyroid disease during a median of three years (range 1 to 8) of observation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5545/abstract/21\">",
"     21",
"    </a>",
"    ]. However, less than 20 percent of patients became hypercalcemic during the observation period. Instead, some persistently normocalcemic patients developed other indications of progressive disease, such as kidney stones, hypercalciuria, bone loss, and fracture. Furthermore, four individuals with normal serum calcium levels had successful parathyroid surgery.",
"   </p>",
"   <p>",
"    There are no data to suggest that these patients will ultimately become hypercalcemic, and over what time period. In addition, since most of these patients were identified in the course of an evaluation for osteoporosis, fracture, or low bone density, they may not represent an early form of asymptomatic primary hyperparathyroidism, but could instead represent a unique phenotype of the disease.",
"   </p>",
"   <p>",
"    Identification of the normocalcemic patients who represent the true clinical precursor of hypercalcemic asymptomatic primary hyperparathyroidism would probably require population screening, which we do not recommend.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TESTS TO CONFIRM PRIMARY HYPERPARATHYROIDISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary hyperparathyroidism is suspected when the intact PTH or PTH (1-84) concentration is elevated or high-normal in the setting of hypercalcemia. Additional tests that can distinguish primary hyperparathyroidism from the diseases described above include measurement of urinary calcium excretion and 25-hydroxyvitamin D (",
"    <a class=\"graphic graphic_table graphicRef71910 \" href=\"UTD.htm?22/17/22812\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef62624 \" href=\"UTD.htm?42/48/43791\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Measurement of urinary calcium excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of 24-hour urine calcium excretion is required for distinguishing primary hyperparathyroidism from familial hypocalciuric hypercalcemia (FHH). (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Familial hypocalciuric hypercalcemia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Approximately 40 percent of patients with primary hyperparathyroidism are hypercalciuric, and most of the remaining patients have normal values [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5545/abstract/22\">",
"     22",
"    </a>",
"    ]. An elevated urinary calcium concentration essentially excludes FHH. If calcium excretion is low, eg, less than 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (5.0",
"    <span class=\"nowrap\">",
"     mmol/day),",
"    </span>",
"    familial hypocalciuric hypercalcemia (FHH, see above) or hyperparathyroidism with concomitant vitamin D deficiency are possibilities; about 75 percent of affected persons with FHH excrete less than 100 mg of calcium in urine daily (",
"    <a class=\"graphic graphic_algorithm graphicRef62624 \" href=\"UTD.htm?42/48/43791\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5545/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A",
"    <span class=\"nowrap\">",
"     Ca/Cr",
"    </span>",
"    clearance ratio, which is equivalent to the fractional excretion of calcium, also may be helpful. This ratio is calculated from 24-hour urinary calcium and creatinine and total serum calcium and creatinine concentrations using the following formula:",
"   </p>",
"   <p>",
"    &nbsp;",
"    <span class=\"nowrap\">",
"     Ca/Cr",
"    </span>",
"    clearance ratio &nbsp;= &nbsp;[24 hour Urine Ca &nbsp;x &nbsp;serum Cr] &nbsp;&divide; &nbsp;[serum Ca &nbsp;x &nbsp;24 hour Urine Cr]",
"   </p>",
"   <p>",
"    The data establishing the value of the calcium to creatinine clearance ratio in differentiating FHH from primary hyperparathyroidism are based primarily on 24 hour urine collections. While there are insufficient data available to prove that",
"    <span class=\"nowrap\">",
"     Ca/Cr",
"    </span>",
"    ratios calculated from spot urines are equivalent to those determined from 24-hour urines, in principle the two should reflect renal calcium handling similarly.",
"   </p>",
"   <p>",
"    A value below 0.01 in a vitamin D replete individual is highly suggestive of FHH rather than hyperparathyroidism (ratio usually &gt;0.02). In an analysis of five large studies combining 165 patients with FHH and 197 patients with primary hyperparathyroidism, a",
"    <span class=\"nowrap\">",
"     Ca/Cr",
"    </span>",
"    clearance ratio &lt;0.01 had a sensitivity for FHH of 85 percent, a specificity of 88 percent, and a positive predictive value of 85 percent; a value &gt;0.02 essentially excluded FHH [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5545/abstract/14,16\">",
"     14,16",
"    </a>",
"    ]. Due to the difficulty of differentiating FHH from primary hyperparathyroidism when the",
"    <span class=\"nowrap\">",
"     Ca/Cr",
"    </span>",
"    clearance ratio is &lt;0.02, some have suggested CaSR mutation analysis for such individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5545/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=see_link&amp;anchor=H11#H11\">",
"     \"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia\", section on 'Distinction from primary hyperparathyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Vitamin D metabolites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with primary hyperparathyroidism convert more 25OHD (calcidiol) to 1,25 dihydroxyvitamin D (calcitriol) than normal individuals. Serum concentrations of 1,25 dihydroxyvitamin D may therefore be at upper limits of normal or elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5545/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. An elevated value is not specific for diagnosis, and measurement of 1,25-dihydroxyvitamin D is not generally needed to confirm the diagnosis.",
"   </p>",
"   <p>",
"    However, due to the significant prevalence of vitamin D insufficiency in individuals with primary hyperparathyroidism, the Third International Workshop on Asymptomatic Primary Hyperparathyroidism recommends measuring 25OHD in all patients with the disease and repleting those with low levels (defined as &le;20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [50",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    prior to making any management decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5545/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link&amp;anchor=H22#H22\">",
"     \"Management of primary hyperparathyroidism\", section on 'Treatment of concomitant vitamin D deficiency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of vitamin D deficiency in adults\", section on 'Coexisting primary hyperparathyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measurement of vitamin D metabolites is also useful in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To differentiate hypervitaminosis D from primary hyperparathyroidism, we typically measure both 1,25-dihydroxyvitamin D and 25OHD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20934?source=see_link\">",
"       \"Diagnostic approach to hypercalcemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      To differentiate FHH from mild primary hyperparathyroidism with concomitant vitamin D deficiency in individuals with elevated serum PTH and calcium and normal or low 24-hour urinary calcium excretion, we typically measure 25OHD. In the latter patients, urinary calcium excretion increases with vitamin D repletion, thereby distinguishing it from FHH.",
"     </li>",
"     <li>",
"      To differentiate secondary hyperparathyroidism due to vitamin D deficiency from normocalcemic primary hyperparathyroidism in patients with elevated PTH and normal serum calcium concentrations, we typically measure 25OHD, which is low in the former and normal in the latter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sometimes patients with presumed secondary hyperparathyroidism have primary hyperparathyroidism with concomitant vitamin D deficiency. In these patients, the diagnosis of mild primary hyperparathyroidism is obscured by vitamin D deficiency (due to poor dietary intake of vitamin D or sunlight exposure) and may not be recognized until vitamin D is repleted and hypercalcemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypercalciuria develop. Primary hyperparathyroidism with coexisting vitamin D deficiency may be suspected when serum calcium concentrations are in the upper half of the normal range and urinary calcium concentration is normal, despite vitamin D deficiency.",
"   </p>",
"   <p>",
"    Individuals with normocalcemic hyperparathyroidism and low 25OHD concentrations may be repleted with vitamin D. However, vitamin D replacement should be provided cautiously in those with suspected concurrent primary hyperparathyroidism, in particular in those with hypercalciuria, as worsening hypercalcemia and hypercalciuria may develop. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link&amp;anchor=H22#H22\">",
"     \"Management of primary hyperparathyroidism\", section on 'Treatment of concomitant vitamin D deficiency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of vitamin D deficiency in adults\", section on 'Coexisting primary hyperparathyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, serum and urinary calcium remain normal and PTH normalizes after vitamin D repletion in individuals with vitamin D deficiency-induced secondary hyperparathyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     OTHER TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other tests that follow are less helpful in confirming the diagnosis of primary hyperparathyroidism but may provide useful clinical information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Serum phosphorus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum phosphorus concentration may be decreased but typically is in the lower range of normal. Some patients have mild hyperchloremic acidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=see_link\">",
"     \"Clinical manifestations of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Serum creatinine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum creatinine concentration provides information about renal function, which can be diminished by hypercalcemia. Rather than using serum creatinine alone, the GFR can be estimated in patients with a stable serum creatinine concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=see_link\">",
"     \"Clinical manifestations of hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link&amp;anchor=H20659769#H20659769\">",
"     \"Assessment of kidney function\", section on 'Estimation equations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An estimated GFR of 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    is the threshold of chronic kidney disease for deciding which asymptomatic individuals with primary hyperparathyroidism may benefit from early surgical treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5545/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of primary hyperparathyroidism\", section on 'Guidelines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Markers of bone turnover",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biochemical markers of bone turnover (collagen crosslinks, osteocalcin, bone-specific alkaline phosphatase) are often at the upper end of normal or mildly elevated in asymptomatic primary hyperparathyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42519?source=see_link\">",
"     \"Bone physiology and biochemical markers of bone turnover\"",
"    </a>",
"    .) In those with more severe disease, they are typically high. They are only occasionally helpful in the management of hyperparathyroidism and should not be routinely measured [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5545/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Bone mineral density",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hyperparathyroidism may have decreased bone mineral density (BMD), in particular at more cortical sites (forearm and hip) as compared to more cancellous sites (spine). Although measurement of BMD is not required for the diagnosis of primary hyperparathyroidism, it is an essential part of the management of the disease, and BMD must be measured at the spine, hip, and distal one-third forearm sites. The degree of bone loss is reflective of the severity of hyperparathyroidism and is useful for making recommendations for parathyroid surgery or observation with monitoring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of primary hyperparathyroidism\", section on 'Bone disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Renal imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with undiagnosed nephrocalcinosis or calcium kidney stones are regarded as having symptomatic disease, regardless of the absence of symptoms. Thus, these patients meet criteria for surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5545/abstract/26\">",
"     26",
"    </a>",
"    ]. Although routine renal imaging at the time of the original evaluation for primary hyperparathyroidism is no longer recommended, renal imaging should be performed if kidney stones are suspected or if there is a history of kidney stones [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5545/abstract/13\">",
"     13",
"    </a>",
"    ]. Ultrasound is typically the imaging modality used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Localization studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of primary hyperparathyroidism is established by appropriate biochemical testing. Localization studies with ultrasonography, technetium-99m sestamibi, CT, or MRI scanning should not be used to establish the diagnosis of primary hyperparathyroidism. Their utility is questionable when bilateral neck exploration is planned. However, they are commonly used now, along with intraoperative PTH monitoring, to facilitate unilateral exploration and minimally invasive surgery in those with probable single gland disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18377?source=see_link\">",
"     \"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/6/2147?source=see_link\">",
"       \"Patient information: Primary hyperparathyroidism (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/52/29507?source=see_link\">",
"       \"Patient information: Primary hyperparathyroidism (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     PTH versus non-PTH mediated hypercalcemia",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of hyperparathyroidism is usually first suspected by the finding of an elevated serum calcium concentration. Measuring intact serum PTH will help distinguish primary hyperparathyroidism from PTH-independent causes of hypercalcemia, such as malignancy. A frankly elevated PTH concentration or a PTH value in the upper half of the normal range in the setting of hypercalcemia is likely the result of primary hyperparathyroidism (",
"      <a class=\"graphic graphic_algorithm graphicRef62624 \" href=\"UTD.htm?42/48/43791\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PTH concentrations below 20 to 25",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      in the setting of hypercalcemia are possible but rare in primary hyperparathyroidism and indicate the need for evaluation for other causes of hypercalcemia (",
"      <a class=\"graphic graphic_table graphicRef66865 \" href=\"UTD.htm?28/40/29324\">",
"       table 1",
"      </a>",
"      ). It is uncommon for patients with hypercalcemia of malignancy to have elevated PTH levels, but this finding may occur rarely in individuals with hypercalcemia of malignancy and concomitant primary hyperparathyroidism or in individuals with PTH secreting tumors, which are also rare. If the elevated PTH is exclusively drug-induced, as opposed to unmasked abnormal PTH dynamics by the drug, the hyperparathyroidism and hypercalcemia should reverse with discontinuation of the offending medication, especially in instances of short duration of therapy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20934?source=see_link\">",
"       \"Diagnostic approach to hypercalcemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     FHH versus primary hyperparathyroidism",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In some individuals with mildly elevated calcium and PTH concentrations, it may be difficult to distinguish primary hyperparathyroidism from FHH (",
"      <a class=\"graphic graphic_table graphicRef71910 \" href=\"UTD.htm?22/17/22812\">",
"       table 2",
"      </a>",
"      ). In these cases, urinary calcium excretion should be measured. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Tests to confirm primary hyperparathyroidism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An elevated urinary calcium concentration or a",
"      <span class=\"nowrap\">",
"       Ca/Cr",
"      </span>",
"      clearance ratio &gt;0.02 essentially excludes FHH. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Measurement of urinary calcium excretion'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Familial hypocalciuric hypercalcemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with normal or low urinary calcium concentrations, 25OHD concentrations should be measured to distinguish primary hyperparathyroidism with vitamin D deficiency from FHH (",
"      <a class=\"graphic graphic_algorithm graphicRef62624 \" href=\"UTD.htm?42/48/43791\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Vitamin D metabolites'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with primary hyperparathyroidism and vitamin D deficiency, urinary calcium will increase after vitamin D repletion, thereby differentiating it from FHH. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Vitamin D metabolites'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Normocalcemic hyperparathyroidism",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with normocalcemic hyperparathyroidism (elevated PTH, normal serum calcium) typically come to medical attention in the setting of an evaluation for low bone mineral density. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Normocalcemic primary hyperparathyroidism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis also includes secondary hyperparathyroidism (",
"      <a class=\"graphic graphic_table graphicRef73157 \" href=\"UTD.htm?22/29/23003\">",
"       table 3",
"      </a>",
"      ) and primary hyperparathyroidism with concomitant vitamin D deficiency (",
"      <a class=\"graphic graphic_table graphicRef71910 \" href=\"UTD.htm?22/17/22812\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Evaluation to rule out causes of secondary hyperparathyroidism, especially vitamin D deficiency or insufficiency, is essential. Patients with true normocalcemic primary hyperparathyroidism may develop symptomatic disease, and therefore require monitoring. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Normocalcemic primary hyperparathyroidism versus secondary hyperparathyroidism'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5545/abstract/1\">",
"      Silverberg SJ, Bilezikian JP. Evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81:2036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5545/abstract/2\">",
"      Glendenning P, Gutteridge DH, Retallack RW, et al. High prevalence of normal total calcium and intact PTH in 60 patients with proven primary hyperparathyroidism: a challenge to current diagnostic criteria. Aust N Z J Med 1998; 28:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5545/abstract/3\">",
"      Endres DB, Villanueva R, Sharp CF Jr, Singer FR. Immunochemiluminometric and immunoradiometric determinations of intact and total immunoreactive parathyrin: performance in the differential diagnosis of hypercalcemia and hypoparathyroidism. Clin Chem 1991; 37:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5545/abstract/4\">",
"      Nussbaum SR, Zahradnik RJ, Lavigne JR, et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987; 33:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5545/abstract/5\">",
"      Silverberg SJ, Shane E, de la Cruz L, et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 1989; 4:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5545/abstract/6\">",
"      Fuleihan GE, Gundberg CM, Gleason R, et al. Racial differences in parathyroid hormone dynamics. J Clin Endocrinol Metab 1994; 79:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5545/abstract/7\">",
"      Grant FD, Conlin PR, Brown EM. Rate and concentration dependence of parathyroid hormone dynamics during stepwise changes in serum ionized calcium in normal humans. J Clin Endocrinol Metab 1990; 71:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5545/abstract/8\">",
"      Hollenberg AN, Arnold A. Hypercalcemia with low-normal serum intact PTH: a novel presentation of primary hyperparathyroidism. Am J Med 1991; 91:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5545/abstract/9\">",
"      Au AY, McDonald K, Gill A, et al. PTH mutation with primary hyperparathyroidism and undetectable intact PTH. N Engl J Med 2008; 359:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5545/abstract/10\">",
"      Silverberg SJ, Gao P, Brown I, et al. Clinical utility of an immunoradiometric assay for parathyroid hormone (1-84) in primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88:4725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5545/abstract/11\">",
"      Boudou P, Ibrahim F, Cormier C, et al. Third- or second-generation parathyroid hormone assays: a remaining debate in the diagnosis of primary hyperparathyroidism. J Clin Endocrinol Metab 2005; 90:6370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5545/abstract/12\">",
"      Carnevale V, Dionisi S, Nofroni I, et al. Potential clinical utility of a new IRMA for parathyroid hormone in postmenopausal patients with primary hyperparathyroidism. Clin Chem 2004; 50:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5545/abstract/13\">",
"      Eastell R, Arnold A, Brandi ML, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009; 94:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5545/abstract/14\">",
"      Fuleihan Gel-H. Familial benign hypocalciuric hypercalcemia. J Bone Miner Res 2002; 17 Suppl 2:N51.",
"     </a>",
"    </li>",
"    <li>",
"     El-Hajj Fuleihan G, Heath H III. Familial benign hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. In: The Parathyroids: Basic and Clinical Concepts, 2nd, Bilezikian JP, Marcus R, Levine MA (Eds), Academic Press, San Diego 2001. p.607.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5545/abstract/16\">",
"      Marx SJ, Stock JL, Attie MF, et al. Familial hypocalciuric hypercalcemia: recognition among patients referred after unsuccessful parathyroid exploration. Ann Intern Med 1980; 92:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5545/abstract/17\">",
"      Nissen PH, Christensen SE, Heickendorff L, et al. Molecular genetic analysis of the calcium sensing receptor gene in patients clinically suspected to have familial hypocalciuric hypercalcemia: phenotypic variation and mutation spectrum in a Danish population. J Clin Endocrinol Metab 2007; 92:4373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5545/abstract/18\">",
"      Silverberg SJ, Lewiecki EM, Mosekilde L, et al. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009; 94:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5545/abstract/19\">",
"      Silverberg SJ, Bilezikian JP. \"Incipient\" primary hyperparathyroidism: a \"forme fruste\" of an old disease. J Clin Endocrinol Metab 2003; 88:5348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5545/abstract/20\">",
"      Tordjman KM, Greenman Y, Osher E, et al. Characterization of normocalcemic primary hyperparathyroidism. Am J Med 2004; 117:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5545/abstract/21\">",
"      Lowe H, McMahon DJ, Rubin MR, et al. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 2007; 92:3001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5545/abstract/22\">",
"      Silverberg SJ, Shane E, Jacobs TP, et al. Nephrolithiasis and bone involvement in primary hyperparathyroidism. Am J Med 1990; 89:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5545/abstract/23\">",
"      Christensen SE, Nissen PH, Vestergaard P, et al. Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow-up study on methods. Clin Endocrinol (Oxf) 2008; 69:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5545/abstract/24\">",
"      Broadus AE, Horst RL, Lang R, et al. The importance of circulating 1,25-dihydroxyvitamin D in the pathogenesis of hypercalciuria and renal-stone formation in primary hyperparathyroidism. N Engl J Med 1980; 302:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5545/abstract/25\">",
"      Silverberg SJ, Shane E, Jacobs TP, et al. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 1999; 341:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5545/abstract/26\">",
"      Bilezikian JP, Khan AA, Potts JT Jr, Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009; 94:335.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2029 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-F8E45503D2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_26_5545=[""].join("\n");
var outline_f5_26_5545=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Measurement of serum calcium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Measurement of PTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Familial hypocalciuric hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Normocalcemic primary hyperparathyroidism versus secondary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Secondary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Normocalcemic primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TESTS TO CONFIRM PRIMARY HYPERPARATHYROIDISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Measurement of urinary calcium excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Vitamin D metabolites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      OTHER TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Serum phosphorus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Serum creatinine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Markers of bone turnover",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Bone mineral density",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Renal imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Localization studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PTH versus non-PTH mediated hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      FHH versus primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Normocalcemic hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2029\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2029|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?42/48/43791\" title=\"algorithm 1\">",
"      Diag primary hyperpara",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2029|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/8/33935\" title=\"figure 1\">",
"      PTH and calcium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/41/12958\" title=\"figure 2\">",
"      Ca-PTH dynamics lithium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2029|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/40/29324\" title=\"table 1\">",
"      Causes hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/17/22812\" title=\"table 2\">",
"      DDX PHPT lab result",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/29/23003\" title=\"table 3\">",
"      Secondary hyperpara",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42519?source=related_link\">",
"      Bone physiology and biochemical markers of bone turnover",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=related_link\">",
"      Clinical manifestations of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=related_link\">",
"      Clinical manifestations of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20934?source=related_link\">",
"      Diagnostic approach to hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=related_link\">",
"      Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=related_link\">",
"      Etiology of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=related_link\">",
"      Hypercalcemia of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=related_link\">",
"      Management of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/0/35850?source=related_link\">",
"      Parathyroid exploration for primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/58/21416?source=related_link\">",
"      Parathyroid hormone assays and their clinical use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36744?source=related_link\">",
"      Parathyroid hormone secretion and action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30361?source=related_link\">",
"      Pathogenesis and etiology of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/52/29507?source=related_link\">",
"      Patient information: Primary hyperparathyroidism (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/6/2147?source=related_link\">",
"      Patient information: Primary hyperparathyroidism (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18377?source=related_link\">",
"      Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_26_5546="Surgical management of localized renal cell carcinoma";
var content_f5_26_5546=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgical management of localized renal cell carcinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/26/5546/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/26/5546/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/26/5546/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/26/5546/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/26/5546/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/26/5546/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/26/5546/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal cell carcinomas (RCCs), which originate within the renal cortex, are responsible for 80 to 85 percent of all primary renal neoplasms. Transitional cell carcinomas of the renal pelvis are the next most common (approximately 8 percent). Other parenchymal epithelial tumors, such as oncocytomas, collecting duct tumors, and renal sarcomas, occur infrequently. Nephroblastoma or Wilms' tumor is common in children (5 to 6 percent of all primary renal tumors).",
"   </p>",
"   <p>",
"    The role of surgery in the management of localized RCC will be reviewed here. The use of thermal ablation (radiofrequency ablation [RFA] and cryoablation) as definitive therapy is discussed separately, as is the use of surgery in patients with metastatic RCC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26310?source=see_link\">",
"     \"Radiofrequency ablation and cryoablation for renal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22630?source=see_link\">",
"     \"Role of surgery in patients with metastatic renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A presumptive diagnosis of RCC generally is made based upon the finding of a solid renal mass on imaging studies. This tentative diagnosis requires histologic confirmation, which can be obtained by either biopsy or surgical resection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2200?source=see_link\">",
"     \"Diagnostic approach, differential diagnosis, and treatment of a small renal mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal approach to management strategy is determined by the stage of disease, while taking into account the patient's overall medical condition and renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Renal function'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Stage I and II disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients in whom preoperative staging indicates that the tumor is either stage I or stage II (",
"    <a class=\"graphic graphic_table graphicRef54563 \" href=\"UTD.htm?14/54/15213\">",
"     table 1",
"    </a>",
"    ), surgery is usually curative. Surgical resection, with either a radical nephrectomy or a partial nephrectomy, is the standard of care for patients with a T1 (&le;7 cm) lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/2\">",
"     2",
"    </a>",
"    ]. Other nephron-sparing approaches (radiofrequency ablation [RFA], cryoablation) or active surveillance may be acceptable alternatives to radical nephrectomy for carefully selected patients. Patients with T2 (&gt;7 cm) primary lesions are generally managed with radical nephrectomy. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Radical nephrectomy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H20\">",
"     'Nephron-sparing approaches'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H29\">",
"     'Active surveillance'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Factors that are important in determining whether a partial or radical nephrectomy is preferred include the location of the tumor within the kidney, whether multiple tumors exist, and the presence of either a solitary kidney or a concurrent disorder associated with multiple RCCs (eg, von Hippel-Lindau disease). In addition, particular attention should be paid to the underlying renal function and the risk of chronic kidney disease. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Renal function'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Stage III disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radical nephrectomy is the preferred approach for patients with stage III disease (",
"    <a class=\"graphic graphic_table graphicRef54563 \" href=\"UTD.htm?14/54/15213\">",
"     table 1",
"    </a>",
"    ). Stage III disease includes patients with tumor invasion into the adrenal gland or perinephric tissues (but not extending beyond Gerota's fascia), those with enlarged abdominal lymph nodes, and those with invasion of the renal vein",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inferior vena cava (IVC).",
"   </p>",
"   <p>",
"    Specific surgical considerations for patients with stage III disease include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among those with radiologic evidence of abdominal lymph node involvement, a standard radical nephrectomy should be considered, since many nodes initially suspected of harboring tumor radiologically are enlarged only because of reactive inflammation [",
"      <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Lymph node dissection'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Involvement of the renal vein",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      IVC does not preclude a successful surgical resection. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Cavoatrial tumor involvement'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Stage IV disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with stage IV RCC are defined as those with large tumors extending beyond Gerota's fascia, obvious evidence of extensive disease in regional lymph nodes,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    distant metastases (",
"    <a class=\"graphic graphic_table graphicRef54563 \" href=\"UTD.htm?14/54/15213\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Nephrectomy may be indicated for palliation of local symptoms or in advance of systemic immunotherapy, or when tumor extends into an adjacent organ (T4) without other evidence of metastatic spread [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/3\">",
"     3",
"    </a>",
"    ]. Surgical resection of metastases may also be indicated in selected situations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22630?source=see_link\">",
"     \"Role of surgery in patients with metastatic renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to surgery, the glomerular filtration rate should be estimated from a stable serum creatinine concentration using the Modification in Diet and Renal Disease (MDRD) equation (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/61/10194?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Nephron-sparing approaches'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with primary tumor less than 4 cm, partial nephrectomy rather than radical nephrectomy is generally preferred to maximize the preservation of renal parenchyma and thus decrease the risk of chronic kidney disease. For patients with larger lesions (4 to 7 cm), the surgical approach should be individualized. Factors that need to be considered include the size of the lesion, its location within the kidney, and the function of the contralateral kidney.",
"   </p>",
"   <p>",
"    Even nephron-sparing surgery can be associated with a clinically significant decrease in renal function. In a multi-institutional series of 1228 patients who underwent partial nephrectomy, the presurgery GFR decreased from 74 to 67",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/4\">",
"     4",
"    </a>",
"    ]. Among patients with a GFR greater than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    , 29 percent had a GFR less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    at follow-up between 3 and 18 months. Factors associated with a decrease in GFR included increasing age, female gender, larger tumor size, a lower GFR prior to surgery, and clamping of the renal artery and vein during surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Partial versus radical nephrectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of partial versus radical nephrectomy on subsequent renal function was evaluated in a retrospective cohort study of 662 patients with small (&lt;4 cm) solitary cortical lesions, an apparently healthy contralateral kidney, and a serum creatinine less than 1.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (124",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/5\">",
"     5",
"    </a>",
"    ]. Prior to surgery, 24 percent of patients had an estimated GFR between 45 and 59",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 and 2 percent had an estimated GFR between 30 and 44",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2. Three years after surgery, patients undergoing partial nephrectomy had a significantly lower likelihood of having a glomerular filtration rate below 45",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 than those undergoing radical nephrectomy (5 versus 36 percent).",
"   </p>",
"   <p>",
"    Preservation of renal function may be associated with improved survival. This was suggested in a retrospective single institution study of 510 patients managed with either partial or radical nephrectomy for localized primary renal cell carcinoma between 4 and 7 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/6\">",
"     6",
"    </a>",
"    ]. In this nonrandomized study, the five-year cancer-specific survival rate was at least equivalent for partial nephrectomy after correcting for T stage and nuclear grade. However, loss of renal function with radical nephrectomy was associated with a significantly increased risk of cardiac death and a decrease in overall survival (five-year overall survival 78 versus 85 percent for patients treated with radical and partial nephrectomy, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Solitary kidney",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with a solitary kidney, ablative techniques may be especially useful for preservation of renal function. This was illustrated in a retrospective series of 89 patients with 98 tumors in a solitary kidney, in which decline in glomerular filtration rate was significantly less in those treated with radiofrequency ablation compared with those managed with open partial nephrectomy (10 versus 25 percent at 12 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/7\">",
"     7",
"    </a>",
"    ]. A possible mechanism is avoidance of cold ischemia during surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RADICAL NEPHRECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radical nephrectomy consists of ligation of the renal artery and vein, and excision of the kidney, Gerota's fascia, and ipsilateral adrenal gland. This became the procedure of choice in the 1960s when a study reported a superior five-year survival rate compared with simple nephrectomy (66 versus 48 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/8\">",
"     8",
"    </a>",
"    ]. As with other urologic malignancies, hospitals and surgeons doing a higher volume of nephrectomies have lower mortality rates than those with lower volumes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several surgical approaches are available for the satisfactory performance of radical nephrectomy. The thoracoabdominal approach offers the ability to palpate the ipsilateral lung cavity and mediastinum, and to resect a solitary pulmonary metastasis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/8,10,11\">",
"     8,10,11",
"    </a>",
"    ]. An extrapleural supracostal incision or an anterior transabdominal incision may also be performed. Independent of the surgical approach, early ligation of the vascular pedicle is important to prevent tumor dissemination at surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Laparoscopic nephrectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic nephrectomy represents a reasonable alternative to open radical nephrectomy for T1 and T2 RCCs &lt;10 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. Although technically demanding, the oncologic outcome appears to be equivalent to open nephrectomy in series with long-term outcome. Seeding at the operative sites has been described only rarely [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/16\">",
"     16",
"    </a>",
"    ]. Intact specimen removal is preferred to piecemeal removal [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Management of the adrenal gland",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for prophylactic ipsilateral adrenalectomy is controversial. Involvement of the ipsilateral adrenal gland is uncommon (5 percent or less) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Adrenal gland involvement is usually due to direct extension from a large upper pole lesion; adrenal involvement in association with extraadrenal metastases is also seen. Although some series suggest that a negative staging CT scan effectively excludes adrenal involvement by tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/19\">",
"     19",
"    </a>",
"    ], others report a false negative rate as high as 23 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adrenalectomy is typically reserved for patients with large (&gt;4 cm) upper pole lesions, non-organ confined tumor stage (T3 or greater), or solitary ipsilateral adrenal metastases identified by preoperative imaging studies (",
"    <a class=\"graphic graphic_table graphicRef54563 \" href=\"UTD.htm?14/54/15213\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Lymph node dissection",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     No suspected nodal metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of routine extended lymphadenectomy in conjunction with radical nephrectomy is controversial when there is no preoperative evidence of lymph node involvement. The rationale for this approach is that lymphadenectomy adds little morbidity, allows better evaluation of the extent of disease, decreases local recurrence rates, and potentially improves survival [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/21-27\">",
"     21-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized phase 3 trial conducted by the European Organization for Research and Treatment of Cancer (EORTC 30881) randomly assigned 772 patients to radical nephrectomy alone or with lymph node dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/28\">",
"     28",
"    </a>",
"    ]. At a median follow-up of over 12 years, there were no differences in overall survival or deaths due to cancer in the two treatment arms.",
"   </p>",
"   <p>",
"    However, only 4 percent of patients assigned to lymph node dissection had positive nodes, probably due to earlier diagnosis and more effective preoperative evaluation. As a result, the study included a large proportion of patients in whom lymph node dissection may not have been indicated and was significantly underpowered to demonstrate any benefit in those patients who would be most likely to benefit from lymphadenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A lymph node dissection may remain important for patients who are at increased risk of having lymph node involvement. We suggest performing a lymph node dissection limited to the renal hilum for patients who are undergoing radical nephrectomy in whom nodal metastases are not suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Suspected nodal metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extended lymphadenectomy is indicated when nodal metastases are suspected on a preoperative CT scan and there is no evidence of distant metastases. In such patients, extended lymphadenectomy can be curative, and systemic treatment options are generally not curative for regional nodal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cavoatrial tumor involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;RCC is complicated by tumor thrombus involving the inferior vena cava (IVC) or right atrium in 5 to 10 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/30\">",
"     30",
"    </a>",
"    ]. The extent of involvement is important for staging (",
"    <a class=\"graphic graphic_table graphicRef54563 \" href=\"UTD.htm?14/54/15213\">",
"     table 1",
"    </a>",
"    ) and surgical planning (",
"    <a class=\"graphic graphic_figure graphicRef78193 \" href=\"UTD.htm?7/12/7375\">",
"     figure 1",
"    </a>",
"    ). Preoperative magnetic resonance imaging (MRI) is generally the best test to determine the presence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extent of cavoatrial thrombus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extension of tumor into the IVC does not necessarily preclude a favorable long-term outcome. Radical nephrectomy with thrombectomy can provide immediate palliation of symptoms and five-year survival rates up to 72 percent, if there are no nodal or distant metastases and tumor does not invade perinephric fat [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Patients with mobile tumor thrombus rather than tumor directly invading the IVC wall may have a better outcome after extraction of the thrombus (five year survival 69 versus 26 percent in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Simple thrombectomy may suffice for patients with thrombus extending below the major hepatic veins. For thrombi located above the major hepatic veins, cardiopulmonary bypass and hypothermic circulatory arrest may be required for complete resection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/33,36,37\">",
"     33,36,37",
"    </a>",
"    ]. Because of its greater morbidity, this approach should generally be reserved for patients without evidence of distant or nodal metastases. Five-year survival is dismal in patients with distant metastases, and thrombectomy should only be considered in these cases as part of a trial evaluating systemic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/38\">",
"     38",
"    </a>",
"    ]. Limited evidence suggests that aggressive therapy (radical nephrectomy, thrombectomy, postoperative immunotherapy) may produce long-term survival in some patients with advanced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/34,39\">",
"     34,39",
"    </a>",
"    ]. A minimally invasive technique for thrombus removal above the hepatic veins has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/40\">",
"     40",
"    </a>",
"    ]. This may reduce perioperative morbidity and mortality, thereby expanding the utility of nephrectomy in this patient population [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two potentially fatal complications of cavoatrial thrombus are thrombus migration and embolization [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/41\">",
"     41",
"    </a>",
"    ]. Intraoperative transesophageal echocardiography may be useful to detect tumor thrombus migration [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/30\">",
"     30",
"    </a>",
"    ]. Preoperative embolization is rare because the tumor thrombus tends to have a \"capsule\" and does not readily break off small pieces. IVC filters are generally avoided as they need to be placed above the renal veins and if they become blocked, can impair function of the remaining kidney.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    has been used in cases where embolization has occurred preoperatively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23270?source=see_link\">",
"     \"Pulmonary tumor embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Preoperative angioinfarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angioinfarction has been used to reduce vascularity and lower the risk of hemorrhage during nephrectomy with large, marginally resectable tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/42\">",
"     42",
"    </a>",
"    ]. The technique has also been used to control symptoms (bleeding, pain) in patients with unresectable or symptomatic metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several techniques have been developed for embolizing the renal artery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/44\">",
"     44",
"    </a>",
"    ]. Most patients experience pain, fever, and nausea, which may last for several days following the procedure.",
"   </p>",
"   <p>",
"    Spontaneous regression of metastases is rare following sequential angioinfarction and nephrectomy; in addition, no survival benefit has been observed compared with patients undergoing nephrectomy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Adjuvant therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability of immunotherapy to induce responses in some patients with advanced RCCs has led to the evaluation of various immunotherapeutic strategies as an adjuvant following complete surgical resection. However, multiple randomized trials have",
"    <strong>",
"     not",
"    </strong>",
"    demonstrated a survival benefit in this setting with any form of immunotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=see_link&amp;anchor=H34#H34\">",
"     \"Immunotherapy of renal cell carcinoma\", section on 'Adjuvant immunotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Molecularly targeted therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progress in the treatment of advanced RCC using molecularly targeted agents has led to the initiation of clinical trials to test these approaches for patients at high risk following surgery. Although preliminary studies have demonstrated the feasibility of neoadjuvant treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/48,49\">",
"     48,49",
"    </a>",
"    ], the use of such agents is not indicated outside the context of a clinical trial [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28170?source=see_link\">",
"     \"Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1135590744\">",
"    <span class=\"h3\">",
"     Postoperative radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis based upon five retrospective studies and two randomized trials failed to provide any evidence that postoperative radiation therapy improved either disease-free survival or overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     NEPHRON-SPARING APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with RCCs, particularly those in whom the removal of large amounts of renal tissue would result in the significant loss of renal function, should be managed with nephron-sparing approaches when possible. Options for appropriately selected patients include partial nephrectomy, thermal ablation (radiofrequency ablation [RFA] and cryotherapy), and active surveillance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Partial nephrectomy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Oncologic outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized clinical trial was conducted by the EORTC in 541 patients with presumed clinical stage T1 or T2 RCC to compare the oncologic outcome after nephron-sparing surgery or radical nephrectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/51\">",
"     51",
"    </a>",
"    ]. Both approaches appeared to provide excellent oncologic control in this patient population, with recurrences (local, regional, or distant) in 12 of 268 (4.5 percent) of those treated with nephron-sparing surgery versus 9 of 273 (3.3 percent) managed with radical nephrectomy. There were 8 and 4 RCC-related deaths in the two groups, respectively. At a median follow-up of 9.3 years, the five-year overall survival was significantly better for patients who had undergone radical nephrectomy (81 versus 76 percent). The reason for this mortality difference is unclear but could not be attributed to complications of surgery. Retrospective analyses suggest a higher rate of renal insufficiency and associated complications (hypertension, cardiovascular disease) with radical nephrectomy rather than nephron-sparing surgery. However, such differences did not appear to influence mortality in this prospective, randomized trial. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Partial versus radical nephrectomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Observational data also indicate that the oncologic outcomes are similar to radical nephrectomy, at least for patients with T1 tumors (",
"    <a class=\"graphic graphic_table graphicRef54563 \" href=\"UTD.htm?14/54/15213\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/52-56\">",
"     52-56",
"    </a>",
"    ]. This was illustrated by the composite experience in 1454 patients from seven centers [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/52\">",
"     52",
"    </a>",
"    ]. With a mean follow-up of over five years, there were no significant differences in local or distant recurrence rates with T1N0M0 tumors treated with either partial (n = 379) or radical (n = 1075) nephrectomy. Approximately 85 percent of the partial nephrectomies were performed for tumors &le; 4 cm (ie, T1a), but results in this [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/52\">",
"     52",
"    </a>",
"    ] and other series [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/54-56\">",
"     54-56",
"    </a>",
"    ] support the use of partial nephrectomy in patients with T1b tumors.",
"   </p>",
"   <p>",
"    In contrast, the oncologic outcomes in patients with T2 or greater disease are uncertain, with some series reporting inferior outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/57,58\">",
"     57,58",
"    </a>",
"    ], while one center has observed comparable outcomes in carefully selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, partial nephrectomy has become the standard of care for patients with T1a (&le;4 cm) primary tumor. For those with T1b (&gt;4 to &lt;7 cm) tumors, the choice of partial nephrectomy versus radical nephrectomy should be individualized. Factors that should be considered in addition to the size of the lesion include the location of the tumor within the kidney as well as the function of the contralateral kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/2,52,60\">",
"     2,52,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If nephron-sparing surgery is attempted, intraoperative findings may preclude the completion of such surgery. Most urologists, for example, recommend converting the surgery to radical nephrectomy in cases with renal vein invasion or sarcomatoid histology on frozen section.",
"   </p>",
"   <p>",
"    Up to 15 percent of patients with papillary tumors and 8 percent of those with other histologic subtypes have multicentric tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/61\">",
"     61",
"    </a>",
"    ], which would not be detected with a partial nephrectomy and could lead to recurrent disease. However, reported rates of local recurrence are low (0 to 10 percent) in appropriately selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/52,57,60,62-67\">",
"     52,57,60,62-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications of nephron-sparing surgery are similar to nephrectomy and include urinary fistulae, acute renal failure, the need for temporary or permanent dialysis, and bleeding (7, 6, 5, and 2 percent of cases, respectively, in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Positive surgical margins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical significance of positive surgical margins is unclear, and positive margins do not necessarily imply an ominous prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Every effort should be made to ensure negative margins at the time of surgery, but an incidental finding on the final pathology specimen can be managed with careful surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The result of this conservative approach to a positive surgical margin is illustrated by a series of 1390 patients who underwent partial nephrectomy at one of two high volume institutions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/68\">",
"     68",
"    </a>",
"    ]. If margins were positive at frozen section, reresection or completion nephrectomy was undertaken. Overall, 77 patients (6 percent) had margins that were positive only on the final pathology examination and not by frozen section. These patients were managed with surveillance only. In this series, there was no difference in the five- and ten-year probabilities of local recurrence-free survival compared to those patients with negative margins (98 versus 97 and 91 versus 93 percent, respectively). There also was no difference in the incidence of distant metastases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Adrenalectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients undergoing partial nephrectomy, concomitant adrenalectomy should be restricted to those with a suspicious lesion identified on preoperative imaging or to those in whom adrenal invasion is suspected based upon intraoperative findings.",
"   </p>",
"   <p>",
"    The limited role of adrenalectomy in conjunction with partial nephrectomy was illustrated by a series of 2065 patients undergoing partial nephrectomy at a single institution, in which concomitant adrenalectomy was performed in 48 cases (2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/70\">",
"     70",
"    </a>",
"    ]. Of these, one patient had RCC directly invading the adrenal, two patients had adrenal metastases, and three had other adrenal tumors. Benign lesions were found in 42 cases (87 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Small multiple and/or bilateral tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although bilateral tumors are more common with inherited conditions (eg, von Hippel-Lindau disease, familial papillary RCC), between 1 and 4 percent of patients with apparently sporadic tumors also have bilateral RCCs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients who have multiple",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bilateral tumors, some clinicians advocate waiting until the largest lesion is greater than 3 cm before performing a partial nephrectomy in order to preserve renal parenchyma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/72\">",
"     72",
"    </a>",
"    ]. Allowing such tumors to grow beyond 3 cm before resection may be detrimental. This size criterion was derived from studies in patients with von Hippel-Lindau disease, in whom preservation of renal parenchyma is critically important because of the high likelihood of additional subsequent renal lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\", section on 'Renal cell carcinomas'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During nephron-sparing surgery, the kidney should be carefully examined to exclude a second malignancy. The importance of this approach was illustrated by a series of 112 patients with sporadic renal masses that included 25 with presumed simple cysts identified preoperatively by imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/73\">",
"     73",
"    </a>",
"    ]. Overall, a second lesion was identified and resected in 37 cases. Eight of the 37 second lesions (22 percent) were malignant, including 4 of the 25 (16 percent) with presumed benign cysts. The authors concluded that a partial nephrectomy was still appropriate therapy for these patients, based upon the small size of the additional malignant lesions and the favorable prognosis.",
"   </p>",
"   <p>",
"    Simple enucleation rather than partial nephrectomy has been used as a treatment for T1a RCC (",
"    <a class=\"graphic graphic_table graphicRef54563 \" href=\"UTD.htm?14/54/15213\">",
"     table 1",
"    </a>",
"    ). This approach has been reported to yield comparable results in patients with small tumors, but experience is more limited than with other forms of partial nephrectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/74\">",
"     74",
"    </a>",
"    ]. Although enucleation is reasonable for selected lesions in some patients with von Hippel-Lindau disease, partial nephrectomy with a rim of normal renal parenchyma is preferable. In one series, more than 50 percent of patients with renal cell carcinoma who underwent enucleation ex vivo after radical nephrectomy still had residual carcinoma adjacent to the pseudocapsule [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with an inherited disorder resulting in the presence of multiple small tumors, partial nephrectomy may involve the resection of numerous, small lesions at a single operation with the goal of maintaining as much renal function as possible [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35910?source=see_link\">",
"     \"Hereditary kidney cancer syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Continued surveillance is required after partial nephrectomy, since patients are at risk for recurrence of the original lesion as well as additional tumors. However, the risk of developing metastatic disease appears to be relatively low as long as the patient is followed carefully. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/38/32360?source=see_link\">",
"     \"Surveillance for metastatic disease after nephrectomy for renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Bench dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of techniques such as \"bench dissection\" in patients with larger or centrally located tumors is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/60,77\">",
"     60,77",
"    </a>",
"    ]. One study found that only 6 of 16 patients who underwent initially successful \"bench surgery\" and renal autotransplantation were eventually free of both malignancy and the need for dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/77\">",
"     77",
"    </a>",
"    ]. In addition, in patients with tumors invading the adrenal gland or perinephric tissue, partial nephrectomy should be restricted to clinical studies since the incidence of multifocality may be as high as 50 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic techniques have been used to perform partial nephrectomy for both peripheral and central lesions and in patients with a solitary kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/78-80\">",
"     78-80",
"    </a>",
"    ]. Seven-year follow-up data suggest that this approach gives results that are comparable to open partial nephrectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. This procedure is technically difficult and should be restricted to physicians with extensive experience using this approach. In patients with a solitary kidney, an open approach may be preferred, because laparoscopic surgery has been associated with a longer warm ischemia time and a higher incidence of complications [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Superselective embolization of the tumor may reduce the risk of bleeding, thus facilitating a laparoscopic approach [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. This approach is experimental.",
"   </p>",
"   <p>",
"    Positive margins have been identified in 2 to 3 percent of patients on the final pathology following laparoscopic partial nephrectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. The significance of this finding and whether or not additional treatment is required remains uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Thermal ablation techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;For elderly patients and those with significant comorbidities that increase the risks of surgery, thermal ablation (ie, cryotherapy or radiofrequency ablation) are appropriate alternatives to surgical resection. A decision regarding treatment depends upon the assessment of the overall patient's condition. However, the long-term risk of local recurrence after cryotherapy or radiofrequency ablation has not been fully defined.",
"   </p>",
"   <p>",
"    Thermal ablation techniques permit percutaneous tumor treatment without open surgical intervention. Both approaches are limited by the absence of pathologic confirmation of the diagnosis or the diagnostic accuracy possible with a small sample from a needle biopsy. A nondiagnostic biopsy at the time of ablation does not exclude the possibility of RCC, and careful follow-up is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. There are no randomized trials comparing these approaches with surgery. RFA cryoablation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26310?source=see_link\">",
"     \"Radiofrequency ablation and cryoablation for renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     ACTIVE SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development and widespread use of improved imaging modalities (MRI, CT) has led to an increased detection of small lesions. For individuals with small lesions and significant comorbidity or a short life expectancy, active surveillance may be an appropriate alternative to immediate treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/2\">",
"     2",
"    </a>",
"    ]. A discussion on the evaluation of the incidentally detected renal mass is covered elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2200?source=see_link\">",
"     \"Diagnostic approach, differential diagnosis, and treatment of a small renal mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of individualizing treatment planning and considering the impact of age and comorbidity was illustrated by a retrospective analysis of 537 patients, aged 75 years or older, who had suspected primary tumors less than 7 cm in size [",
"    <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/88\">",
"     88",
"    </a>",
"    ]. Patients were managed with a variety of approaches, including radical nephrectomy, nephron-sparing approaches (RFA, cryoablation), or with active surveillance. The five-year cancer specific mortality rates for surgery, nephron-sparing approaches, and active surveillance were 9, 4, and 6 percent, respectively; cardiovascular disease was the primary cause of mortality. Multivariate analysis found that the Charlson comorbidity index and increasing age were significantly associated with all-cause mortality; the initial management approach was a statistically significant factor.",
"   </p>",
"   <p>",
"    There are no clinical trials that define the optimal follow-up for a patient who is managed with active surveillance. Periodic imaging is indicated for these patients. Important factors to consider in determining the intensity of follow-up include the age and overall health of the patient, which must be balanced against the risk of progression of the lesion as well as exposure to radiation from repeated imaging. In older patients and those with significant comorbidity, our approach is to use ultrasound annually for several years until it is established that the lesion is not progressing. For younger patients, we will use an ultrasound at six months and one year and a CT (pre and post contrast) at two years to rule out lesion progression. Other approaches would be reasonable depending on the size and features of the lesion and anxiety of the patient. For patients without significant competing morbidities who have lesions that exhibit progression over the observation interval, local treatment is indicated. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal surveillance strategy after potentially curative treatment for RCC has not been well studied. Follow-up should be based upon the most likely sites and timing of metastases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/38/32360?source=see_link\">",
"     \"Surveillance for metastatic disease after nephrectomy for renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/53/30546?source=see_link\">",
"       \"Patient information: Renal cell carcinoma (kidney cancer) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical resection remains the preferred approach for patients with stage I, II, or III renal cell carcinoma (RCC) (",
"      <a class=\"graphic graphic_table graphicRef54563 \" href=\"UTD.htm?14/54/15213\">",
"       table 1",
"      </a>",
"      ). The choice of radical or partial nephrectomy is based upon multiple factors, including the stage and location of the tumor, whether multiple tumors exist, the presence of either a solitary kidney or a concurrent disorder associated with multiple RCCs (eg, von Hippel-Lindau disease), and underlying renal function [",
"      <a class=\"abstract\" href=\"UTD.htm?5/26/5546/abstract/2\">",
"       2",
"      </a>",
"      ]. Both open and laparoscopic approaches can be used for either radical or partial nephrectomy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with stage I, II, or III RCC without comorbidity precluding resection, we recommend definitive therapy rather than active surveillance or a lesser approach (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Surgical resection is the standard approach for definitive therapy. This approach has been shown to offer a high-probability of long-term disease-free survival. There are insufficient long-term follow-up data from ablative procedures to establish the equivalence of these approaches. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Stage I and II disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Stage III disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with a T1a (&le;4 cm) primary tumor, we suggest partial nephrectomy rather than radical nephrectomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This approach maximizes the preservation of renal parenchyma and thus decreases the risk of chronic kidney disease. Radical nephrectomy is an appropriate alternative when partial nephrectomy is not technically feasible. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Stage I and II disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Partial nephrectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a T1b (&gt;4 and &lt;7 cm) lesion, important factors in determining the surgical approach (ie, radical versus partial nephrectomy) in addition to the size of the tumor include the location of the tumor within the kidney and the function of the contralateral kidney. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Stage I and II disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Radical nephrectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with large tumors and when there is evidence of invasion into the adrenal, renal vein, or perinephric fat, radical nephrectomy has been the most widely used approach and remains the preferred procedure. Involvement of the inferior vena cava with tumor is not a contraindication to radical nephrectomy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Radical nephrectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients undergoing radical nephrectomy but without preoperative evidence of lymph node involvement, we suggest limiting the surgery to resection of lymph nodes at the renal hilum (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'No suspected nodal metastases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with suspected involvement of abdominal lymph node involvement, we recommend a standard radical nephrectomy with retroperitoneal lymph node dissection rather than radical nephrectomy alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Many patients with suspected lymph node involvement may have only inflammation present in these nodes. Furthermore, lymph node dissection is curative in a significant number of these patients. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Suspected nodal metastases'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For elderly patients and those with significant comorbidities that increase the risks of surgery, thermal ablation (ie, cryotherapy or radiofrequency ablation) are appropriate alternatives to surgical resection. A decision regarding treatment depends upon the assessment of the overall patient's condition. However, the long-term risk of local recurrence after cryotherapy or radiofrequency ablation has not been fully defined. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General considerations'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26310?source=see_link\">",
"       \"Radiofrequency ablation and cryoablation for renal cell carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with a small renal lesion but limited life expectancy or those at a very high risk of complications with active intervention, active surveillance is a reasonable option. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Active surveillance'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2200?source=see_link\">",
"       \"Diagnostic approach, differential diagnosis, and treatment of a small renal mass\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/1\">",
"      Vogelzang NJ, Stadler WM. Kidney cancer. Lancet 1998; 352:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/2\">",
"      Campbell SC, Novick AC, Belldegrun A, et al. Guideline for management of the clinical T1 renal mass. J Urol 2009; 182:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/3\">",
"      Margulis V, S&aacute;nchez-Ortiz RF, Tamboli P, et al. Renal cell carcinoma clinically involving adjacent organs: experience with aggressive surgical management. Cancer 2007; 109:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/4\">",
"      Clark MA, Shikanov S, Raman JD, et al. Chronic kidney disease before and after partial nephrectomy. J Urol 2011; 185:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/5\">",
"      Huang WC, Levey AS, Serio AM, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006; 7:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/6\">",
"      Weight CJ, Larson BT, Fergany AF, et al. Nephrectomy induced chronic renal insufficiency is associated with increased risk of cardiovascular death and death from any cause in patients with localized cT1b renal masses. J Urol 2010; 183:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/7\">",
"      Raman JD, Raj GV, Lucas SM, et al. Renal functional outcomes for tumours in a solitary kidney managed by ablative or extirpative techniques. BJU Int 2010; 105:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/8\">",
"      ROBSON CJ. Radical nephrectomy for renal cell carcinoma. J Urol 1963; 89:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/9\">",
"      Mitchell RE, Lee BT, Cookson MS, et al. Radical nephrectomy surgical outcomes in the University HealthSystem Consortium Data Base: Impact of hospital case volume, hospital size, and geographic location on 40,000 patients. Cancer 2009; 115:2447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/10\">",
"      Waters WB, Richie JP. Aggressive surgical approach to renal cell carcinoma: review of 130 cases. J Urol 1979; 122:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/11\">",
"      CHUTE R, SOUTTER L, KERR WS Jr. The value of the thoracoabdominal incision in the removal of kidney tumors. N Engl J Med 1949; 241:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/12\">",
"      Gong EM, Lyon MB, Orvieto MA, et al. Laparoscopic radical nephrectomy: comparison of clinical Stage T1 and T2 renal tumors. Urology 2006; 68:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/13\">",
"      Burgess NA, Koo BC, Calvert RC, et al. Randomized trial of laparoscopic v open nephrectomy. J Endourol 2007; 21:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/14\">",
"      Colombo JR Jr, Haber GP, Jelovsek JE, et al. Seven years after laparoscopic radical nephrectomy: oncologic and renal functional outcomes. Urology 2008; 71:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/15\">",
"      Berger A, Brandina R, Atalla MA, et al. Laparoscopic radical nephrectomy for renal cell carcinoma: oncological outcomes at 10 years or more. J Urol 2009; 182:2172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/16\">",
"      Tsivian A, Sidi AA. Port site metastases in urological laparoscopic surgery. J Urol 2003; 169:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/17\">",
"      Cohen DD, Matin SF, Steinberg JR, et al. Evaluation of the intact specimen after laparoscopic radical nephrectomy for clinically localized renal cell carcinoma identifies a subset of patients at increased risk for recurrence. J Urol 2005; 173:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/18\">",
"      O'Malley RL, Godoy G, Kanofsky JA, Taneja SS. The necessity of adrenalectomy at the time of radical nephrectomy: a systematic review. J Urol 2009; 181:2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/19\">",
"      Gill IS, McClennan BL, Kerbl K, et al. Adrenal involvement from renal cell carcinoma: predictive value of computerized tomography. J Urol 1994; 152:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/20\">",
"      Siemer S, Lehmann J, Kamradt J, et al. Adrenal metastases in 1635 patients with renal cell carcinoma: outcome and indication for adrenalectomy. J Urol 2004; 171:2155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/21\">",
"      Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969; 101:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/22\">",
"      Phillips E, Messing EM. Role of lymphadenectomy in the treatment of renal cell carcinoma. Urology 1993; 41:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/23\">",
"      Herrlinger A, Schrott KM, Schott G, Sigel A. What are the benefits of extended dissection of the regional renal lymph nodes in the therapy of renal cell carcinoma. J Urol 1991; 146:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/24\">",
"      Giuliani L, Giberti C, Martorana G, Rovida S. Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol 1990; 143:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/25\">",
"      Blom JH, van Poppel H, Marechal JM, et al. Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. Eur Urol 1999; 36:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/26\">",
"      Terrone C, Guercio S, De Luca S, et al. The number of lymph nodes examined and staging accuracy in renal cell carcinoma. BJU Int 2003; 91:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/27\">",
"      Canfield SE, Kamat AM, S&aacute;nchez-Ortiz RF, et al. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome. J Urol 2006; 175:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/28\">",
"      Blom JH, van Poppel H, Mar&eacute;chal JM, et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 2009; 55:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/29\">",
"      Studer UE, Birkh&auml;user FD. Lymphadenectomy combined with radical nephrectomy: to do or not to do? Eur Urol 2009; 55:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/30\">",
"      Sigman DB, Hasnain JU, Del Pizzo JJ, Sklar GN. Real-time transesophageal echocardiography for intraoperative surveillance of patients with renal cell carcinoma and vena caval extension undergoing radical nephrectomy. J Urol 1999; 161:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/31\">",
"      Aslam Sohaib SA, Teh J, Nargund VH, et al. Assessment of tumor invasion of the vena caval wall in renal cell carcinoma cases by magnetic resonance imaging. J Urol 2002; 167:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/32\">",
"      Goldfarb DA, Novick AC, Lorig R, et al. Magnetic resonance imaging for assessment of vena caval tumor thrombi: a comparative study with venacavography and computerized tomography scanning. J Urol 1990; 144:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/33\">",
"      Welz A, Schmeller N, Schmitz C, et al. Resection of hypernephromas with vena caval or right atrial tumor extension using extracorporeal circulation and deep hypothermic circulatory arrest: a multidisciplinary approach. Eur J Cardiothorac Surg 1997; 12:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/34\">",
"      Zisman A, Wieder JA, Pantuck AJ, et al. Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. J Urol 2003; 169:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/35\">",
"      Hatcher PA, Anderson EE, Paulson DF, et al. Surgical management and prognosis of renal cell carcinoma invading the vena cava. J Urol 1991; 145:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/36\">",
"      Chiappini B, Savini C, Marinelli G, et al. Cavoatrial tumor thrombus: single-stage surgical approach with profound hypothermia and circulatory arrest, including a review of the literature. J Thorac Cardiovasc Surg 2002; 124:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/37\">",
"      Tsuji Y, Goto A, Hara I, et al. Renal cell carcinoma with extension of tumor thrombus into the vena cava: surgical strategy and prognosis. J Vasc Surg 2001; 33:789.",
"     </a>",
"    </li>",
"    <li>",
"     Libertino JA, Swierzewski DJ, Swierzewski MJ. Renal cell carcinoma with extension into the vena cava. In: Reconstructive Urologic Surgery, 3rd, Libertino JA (Ed), Mosby, St. Louis 1998. p.47.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/39\">",
"      Naitoh J, Kaplan A, Dorey F, et al. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy. J Urol 1999; 162:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/40\">",
"      Fitzgerald JM, Tripathy U, Svensson LG, Libertino JA. Radical nephrectomy with vena caval thrombectomy using a minimal access approach for cardiopulmonary bypass. J Urol 1998; 159:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/41\">",
"      Shuch B, Larochelle JC, Onyia T, et al. Intraoperative thrombus embolization during nephrectomy and tumor thrombectomy: critical analysis of the University of California-Los Angeles experience. J Urol 2009; 181:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/42\">",
"      deKernion JB. Treatment of advanced renal cell carcinoma--traditional methods and innovative approaches. J Urol 1983; 130:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/43\">",
"      Swanson DA, Wallace S, Johnson DE. The role of embolization and nephrectomy in the treatment of metastatic renal carcinoma. Urol Clin North Am 1980; 7:719.",
"     </a>",
"    </li>",
"    <li>",
"     Linehan WM, Shipley WU, Parkinson DR. Cancer of the Kidney and Ureter. In: Cancer: Principles &amp; Practice Oncology, 4th, DeVita VT Jr, Hellman S, Rosenberg SA (Eds), Lippincott, Philadelphia 1993. p.1023.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/45\">",
"      Flanigan RC. The failure of infarction and/or nephrectomy in stage IV renal cell cancer to influence survival or metastatic regression. Urol Clin North Am 1987; 14:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/46\">",
"      Swanson DA, Johnson DE, von Eschenbach AC, et al. Angioinfarction plus nephrectomy for metastatic renal cell carcinoma--an update. J Urol 1983; 130:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/47\">",
"      Scherr AJ, Lima JP, Sasse EC, et al. Adjuvant therapy for locally advanced renal cell cancer: a systematic review with meta-analysis. BMC Cancer 2011; 11:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/48\">",
"      Thomas AA, Rini BI, Lane BR, et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 2009; 181:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/49\">",
"      Thomas AA, Rini BI, Stephenson AJ, et al. Surgical resection of renal cell carcinoma after targeted therapy. J Urol 2009; 182:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/50\">",
"      Tunio MA, Hashmi A, Rafi M. Need for a new trial to evaluate postoperative radiotherapy in renal cell carcinoma: a meta-analysis of randomized controlled trials. Ann Oncol 2010; 21:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/51\">",
"      Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2011; 59:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/52\">",
"      Patard JJ, Shvarts O, Lam JS, et al. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol 2004; 171:2181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/53\">",
"      Pahernik S, Roos F, Hampel C, et al. Nephron sparing surgery for renal cell carcinoma with normal contralateral kidney: 25 years of experience. J Urol 2006; 175:2027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/54\">",
"      Cr&eacute;pel M, Jeldres C, Perrotte P, et al. Nephron-sparing surgery is equally effective to radical nephrectomy for T1BN0M0 renal cell carcinoma: a population-based assessment. Urology 2010; 75:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/55\">",
"      Pahernik S, Roos F, R&ouml;hrig B, et al. Elective nephron sparing surgery for renal cell carcinoma larger than 4 cm. J Urol 2008; 179:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/56\">",
"      Thompson RH, Siddiqui S, Lohse CM, et al. Partial versus radical nephrectomy for 4 to 7 cm renal cortical tumors. J Urol 2009; 182:2601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/57\">",
"      Belldegrun A, Tsui KH, deKernion JB, Smith RB. Efficacy of nephron-sparing surgery for renal cell carcinoma: analysis based on the new 1997 tumor-node-metastasis staging system. J Clin Oncol 1999; 17:2868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/58\">",
"      Jeldres C, Patard JJ, Capitanio U, et al. Partial versus radical nephrectomy in patients with adverse clinical or pathologic characteristics. Urology 2009; 73:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/59\">",
"      Breau RH, Crispen PL, Jimenez RE, et al. Outcome of stage T2 or greater renal cell cancer treated with partial nephrectomy. J Urol 2010; 183:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/60\">",
"      Moll V, Becht E, Ziegler M. Kidney preserving surgery in renal cell tumors: indications, techniques and results in 152 patients. J Urol 1993; 150:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/61\">",
"      McKiernan J, Yossepowitch O, Kattan MW, et al. Partial nephrectomy for renal cortical tumors: pathologic findings and impact on outcome. Urology 2002; 60:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/62\">",
"      Uzzo RG, Novick AC. Nephron sparing surgery for renal tumors: indications, techniques and outcomes. J Urol 2001; 166:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/63\">",
"      Morgan WR, Zincke H. Progression and survival after renal-conserving surgery for renal cell carcinoma: experience in 104 patients and extended followup. J Urol 1990; 144:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/64\">",
"      Steinbach F, St&ouml;ckle M, M&uuml;ller SC, et al. Conservative surgery of renal cell tumors in 140 patients: 21 years of experience. J Urol 1992; 148:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/65\">",
"      Licht MR, Novick AC, Goormastic M. Nephron sparing surgery in incidental versus suspected renal cell carcinoma. J Urol 1994; 152:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/66\">",
"      Marberger M, Pugh RC, Auvert J, et al. Conservation surgery of renal carcinoma: the EIRSS experience. Br J Urol 1981; 53:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/67\">",
"      Herr HW. Partial nephrectomy for unilateral renal carcinoma and a normal contralateral kidney: 10-year followup. J Urol 1999; 161:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/68\">",
"      Yossepowitch O, Thompson RH, Leibovich BC, et al. Positive surgical margins at partial nephrectomy: predictors and oncological outcomes. J Urol 2008; 179:2158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/69\">",
"      Bensalah K, Pantuck AJ, Rioux-Leclercq N, et al. Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol 2010; 57:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/70\">",
"      Lane BR, Tiong HY, Campbell SC, et al. Management of the adrenal gland during partial nephrectomy. J Urol 2009; 181:2430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/71\">",
"      Patel MI, Simmons R, Kattan MW, et al. Long-term follow-up of bilateral sporadic renal tumors. Urology 2003; 61:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/72\">",
"      Bazeed MA, Sch&auml;rfe T, Becht E, et al. Conservative surgery of renal cell carcinoma. Eur Urol 1986; 12:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/73\">",
"      Raz O, Mendlovic S, Leibovici D, et al. The prevalence of malignancy in satellite renal lesions and its surgical implication during nephron sparing surgery. J Urol 2007; 178:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/74\">",
"      Carini M, Minervini A, Masieri L, et al. Simple enucleation for the treatment of PT1a renal cell carcinoma: our 20-year experience. Eur Urol 2006; 50:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/75\">",
"      Marshall FF, Taxy JB, Fishman EK, Chang R. The feasibility of surgical enucleation for renal cell carcinoma. J Urol 1986; 135:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/76\">",
"      Fadahunsi AT, Sanford T, Linehan WM, et al. Feasibility and outcomes of partial nephrectomy for resection of at least 20 tumors in a single renal unit. J Urol 2011; 185:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/77\">",
"      Stormont TJ, Bilhartz DL, Zincke H. Pitfalls of \"bench surgery\" and autotransplantation for renal cell carcinoma. Mayo Clin Proc 1992; 67:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/78\">",
"      Lane BR, Gill IS. 7-year oncological outcomes after laparoscopic and open partial nephrectomy. J Urol 2010; 183:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/79\">",
"      Ono Y, Hattori R, Gotoh M, et al. Laparoscopic radical nephrectomy for renal cell carcinoma: the standard of care already? Curr Opin Urol 2005; 15:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/80\">",
"      Gill IS, Kavoussi LR, Lane BR, et al. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol 2007; 178:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/81\">",
"      Lane BR, Novick AC, Babineau D, et al. Comparison of laparoscopic and open partial nephrectomy for tumor in a solitary kidney. J Urol 2008; 179:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/82\">",
"      Gallucci M, Guaglianone S, Carpanese L, et al. Superselective embolization as first step of laparoscopic partial nephrectomy. Urology 2007; 69:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/83\">",
"      Simone G, Papalia R, Guaglianone S, et al. Preoperative superselective transarterial embolization in laparoscopic partial nephrectomy: technique, oncologic, and functional outcomes. J Endourol 2009; 23:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/84\">",
"      Permpongkosol S, Colombo JR Jr, Gill IS, Kavoussi LR. Positive surgical parenchymal margin after laparoscopic partial nephrectomy for renal cell carcinoma: oncological outcomes. J Urol 2006; 176:2401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/85\">",
"      Breda A, Stepanian SV, Liao J, et al. Positive margins in laparoscopic partial nephrectomy in 855 cases: a multi-institutional survey from the United States and Europe. J Urol 2007; 178:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/86\">",
"      Permpongkosol S, Link RE, Solomon SB, Kavoussi LR. Results of computerized tomography guided percutaneous ablation of renal masses with nondiagnostic pre-ablation pathological findings. J Urol 2006; 176:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/87\">",
"      Matin SF, Ahrar K, Cadeddu JA, et al. Residual and recurrent disease following renal energy ablative therapy: a multi-institutional study. J Urol 2006; 176:1973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/26/5546/abstract/88\">",
"      Lane BR, Abouassaly R, Gao T, et al. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer 2010; 116:3119.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2985 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-EF0CD76C64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_26_5546=[""].join("\n");
var outline_f5_26_5546=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Stage I and II disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Stage III disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Stage IV disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Renal function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Partial versus radical nephrectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Solitary kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RADICAL NEPHRECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Laparoscopic nephrectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Management of the adrenal gland",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Lymph node dissection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - No suspected nodal metastases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Suspected nodal metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cavoatrial tumor involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Preoperative angioinfarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Molecularly targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1135590744\">",
"      - Postoperative radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      NEPHRON-SPARING APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Partial nephrectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Oncologic outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Positive surgical margins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Adrenalectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Small multiple and/or bilateral tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Bench dissection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Thermal ablation techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      ACTIVE SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2985\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2985|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/12/7375\" title=\"figure 1\">",
"      Cavoatrial tumor thrombus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2985|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/54/15213\" title=\"table 1\">",
"      TNM staging RCC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/61/10194?source=related_link\" title=\"calculator 1\">",
"      Calculator: Glomerular filtration rate estimate by abbreviated MDRD study equation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28170?source=related_link\">",
"      Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=related_link\">",
"      Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2200?source=related_link\">",
"      Diagnostic approach, differential diagnosis, and treatment of a small renal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35910?source=related_link\">",
"      Hereditary kidney cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=related_link\">",
"      Immunotherapy of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/53/30546?source=related_link\">",
"      Patient information: Renal cell carcinoma (kidney cancer) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23270?source=related_link\">",
"      Pulmonary tumor embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26310?source=related_link\">",
"      Radiofrequency ablation and cryoablation for renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22630?source=related_link\">",
"      Role of surgery in patients with metastatic renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/38/32360?source=related_link\">",
"      Surveillance for metastatic disease after nephrectomy for renal cell carcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_26_5547="Factors to consider pre OFC";
var content_f5_26_5547=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F55879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F55879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Factors to consider before undertaking an oral food challenge",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Risk of continued allergy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Potential severity of a reaction (safety)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nutritional importance of the avoided food",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Quality of life associated with inclusion/exclusion of the avoided food",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ability to cooperate with challenge procedures (eg, age, temperament)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Personal motivation to add the food to the diet",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Psychological factors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chance of intentional ingestion of a food because the patient/family thinks the allergy has resolved (eg, reduce risk taking if the allergy persists)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_26_5547=[""].join("\n");
var outline_f5_26_5547=null;
var title_f5_26_5548="Ethanol content in beverages and other products";
var content_f5_26_5548=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ethanol content in beverages, medications, and household products",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Item",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ethanol content by volume, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Beverage*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nonalcoholic beer",
"       </td>",
"       <td>",
"        0.32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Beer",
"       </td>",
"       <td>",
"        3.2-14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Wine",
"       </td>",
"       <td>",
"        8-22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Liquor",
"       </td>",
"       <td>",
"        20-95",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Medication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cold/allergy",
"       </td>",
"       <td>",
"        5-16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cough medicine",
"       </td>",
"       <td>",
"        2-25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Household products",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aftershave lotion",
"       </td>",
"       <td>",
"        15-80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glass cleaners",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mouthwashes",
"       </td>",
"       <td>",
"        15-25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Perfumes or colognes",
"       </td>",
"       <td>",
"        25-95",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alcohol-based hand sanitizers&bull;",
"       </td>",
"       <td>",
"        &nbsp;60-95",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Typical content for beer, wine, and liquor is 5, 14, and 40 percent, respectively.",
"     <br>",
"      &bull; May also contain isopropyl alcohol (isopropanol).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kleinschmidt, KC. Ethanol. In: Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose, 4th ed, Shannon, MW, Borron, SW, Burns, MJ. Saunders Elsevier, Philadelphia, 2007. Illustration used with permission of Elsevier Inc. All rights reserved. Copyright &copy;2005 Elsevier Inc",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_26_5548=[""].join("\n");
var outline_f5_26_5548=null;
var title_f5_26_5549="Evaluation hearing loss";
var content_f5_26_5549=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation in childhood hearing loss",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Potential diagnosis",
"      </td>",
"      <td class=\"subtitle1\">",
"       Yield",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"       Laboratory evaluation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"1\" rowspan=\"3\">",
"       CBC",
"      </td>",
"      <td>",
"       Anemia",
"      </td>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       Low",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Leukemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fechner syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"       Antinuclear antibody, erythrocyte sedimentation rate, rheumatoid factor",
"      </td>",
"      <td>",
"       Systemic lupus erythematosus",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Low",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Autoimmune disorders",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"       Thyroid function studies",
"      </td>",
"      <td>",
"       Hypothyroidism",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Low",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pendred syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       BUN, creatinine, urinalysis",
"      </td>",
"      <td>",
"       Alport syndrome",
"      </td>",
"      <td>",
"       Low",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"       Serum glucose",
"      </td>",
"      <td>",
"       Diabetes mellitus",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Very low",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Alstrom syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Fluorescent treponemal antibody (FTA), rapid plasma reagin (RPR)",
"      </td>",
"      <td>",
"       Syphilis",
"      </td>",
"      <td>",
"       Low",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       TORCH titers*",
"      </td>",
"      <td>",
"       Congenital infection",
"      </td>",
"      <td>",
"       Depends upon timing",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Transaminases",
"      </td>",
"      <td>",
"       Liver abnormalities",
"      </td>",
"      <td>",
"       Very low",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Connexin 26",
"      </td>",
"      <td>",
"       Recessive SNHL",
"      </td>",
"      <td>",
"       High",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"       Radiologic evaluation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       High-resolution computed tomography of temporal bone",
"      </td>",
"      <td>",
"       Pathology of the temporal bone, inner-ear bony dysplasia, otosclerosis, erosive and destructive lesions",
"      </td>",
"      <td>",
"       High",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Magnetic resonance imaging",
"      </td>",
"      <td>",
"       Retrocochlear pathology including abnormalities of the membranous labyrinth, central auditory pathway, cerebellopontine angle, brainstem, or cerebral cortex",
"      </td>",
"      <td>",
"       Medium",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"       Other evaluation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       EKG",
"      </td>",
"      <td>",
"       Jervell and Lange-Nielsen syndrome",
"      </td>",
"      <td>",
"       Very low",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Genetics consultation",
"      </td>",
"      <td>",
"       Genetic SNHL",
"      </td>",
"      <td>",
"       Variable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Ophthalmology consultation",
"      </td>",
"      <td>",
"       Retinitis pigmentosa, congenital infection",
"      </td>",
"      <td>",
"       Low in infants unless they have congenital infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Neurology consultation",
"      </td>",
"      <td>",
"       Associated diseases",
"      </td>",
"      <td>",
"       Low",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * TORCH titers: toxoplasmosis, rubella, cytomegalovirus, and herpes simplex virus.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Billings, KR, Kenna, MA. Arch Otolaryngol Head Neck Surg 1999; 125:517 and Mafong, DD, Shin, EJ, Lalwani, AK. Laryngoscope 2002; 112:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_26_5549=[""].join("\n");
var outline_f5_26_5549=null;
var title_f5_26_5550="Assessment of airway pressures during mechanical ventilation";
var content_f5_26_5550=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Assessment of airway pressures during mechanical ventilation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 441px; height: 240px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ETT: Endotracheal tube; PE: Pulmonary embolism; PIP: Peak inspiratory pressure; Pplat: Plateau pressure; RMSB: Right main-stem bronchus",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fessler, MB, Welsh, CH. Mechanical Ventilation: Invasive and Noninvasive. In: Current Diagnosis and Treatment in Pulmonary Medicine, McPhee, SJ, Papadakis, MA, Tierney, LM (Eds), McGrawHill 2003. Copyright &copy; 2003 McGraw-Hill Companies, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_26_5550=[""].join("\n");
var outline_f5_26_5550=null;
var title_f5_26_5551="Knee extension exercise";
var content_f5_26_5551=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F78243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F78243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Leg extensions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 235px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient should gently push the affected leg back with the well-functioning leg until a stretch is felt.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_26_5551=[""].join("\n");
var outline_f5_26_5551=null;
